[
    {
        "path": [
            907040000,
            802000000
        ],
        "contexts": [
            " 9 Information to be included on the main label (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then: (d) if subsection 8(2) applies and the medicine: (i) includes one or more active ingredients, the name of which includes descriptors (for example chemical salts or hydration states) that are not therapeutically relevant; and (ii) the name and quantity or proportion of each of those active ingredients is displayed in accordance with subsection 8(2), then the name of the therapeutically active moiety(ies) of the active ingredient may be displayed on the main label on the primary pack, instead of the name of the active ingredient, if: (iii) this is in a text size of not less than 3.0 millimetres; and (iv) no quantity or proportion information is displayed for any of the active ingredients in the medicine.",
            " 8 Information to be included on the label (2) (f) The presentation of the critical health information, and any information mentioned in paragraphs 8(2)(c), 8(2)(d) or 8(2)(e) that is included, must be presented in black or other dark coloured texts, using only one colour, on a white or other contrasting background."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine contains an active ingredient with a therapeutically irrelevant descriptor in its name, and the name and quantity of this active ingredient is displayed in accordance with subsection 8(2), can the name of the therapeutically active moiety be displayed on the main label instead of the active ingredient name if it is in a text size of 2.5 millimetres and no quantity information is displayed?",
                    "Answer": "No",
                    "Answer Explanation": "According to subsection 9(7)(d), if a medicine contains an active ingredient whose name includes therapeutically irrelevant descriptors, and the name and quantity are displayed per subsection 8(2), the therapeutically active moiety name can only be displayed instead of the active ingredient name if the text size is at least 3.0 millimetres and no quantity information is displayed for any active ingredients. A 2.5 millimetre text size does not meet the minimum 3.0 millimetre requirement specified in 9(7)(d)(iii)."
                },
                {
                    "Question": "Assuming a medicine label includes critical health information and other information mentioned in 8(2)(c), (d) or (e), and this is all presented in red text on a white background, does this comply with the presentation requirements?",
                    "Answer": "No",
                    "Answer Explanation": "Subsection 8(2)(f) states that critical health information and any information from 8(2)(c), (d) or (e) must be presented in black or other dark coloured text, using only one colour, on a white or contrasting background. Using red text does not meet the requirement to use black or dark coloured text specified in 8(2)(f)."
                },
                {
                    "Question": "Assuming a medicine contains multiple active ingredients, some with therapeutically irrelevant descriptors in their names, and the names and quantities are displayed per 8(2), can the therapeutically active moiety names be displayed instead of the active ingredient names in 4.0 millimetre text if quantities are shown for some but not all active ingredients?",
                    "Answer": "No",
                    "Answer Explanation": "Subsection 9(7)(d) allows displaying therapeutically active moiety names instead of active ingredient names if the active ingredient names include irrelevant descriptors and are displayed with quantities per 8(2). However, this is only allowed if the moiety names are in at least 3.0 millimetre text and no quantities are displayed for any active ingredients, per 9(7)(d)(iii) and (iv). Displaying quantities for some ingredients violates the requirement in 9(7)(d)(iv) that no quantities be shown."
                },
                {
                    "Question": "Assuming a medicine label presents critical health information in blue text on a yellow background, and also includes other information from 8(2)(c) presented in black text on white, does the label comply with the presentation requirements?",
                    "Answer": "No",
                    "Answer Explanation": "Per 8(2)(f), critical health information and any 8(2)(c), (d) or (e) information included must be presented in black or dark coloured text, using only one colour, on a white or contrasting background. Using blue text on yellow for the critical information and a different black on white scheme for the 8(2)(c) information violates the 8(2)(f) requirement to use only one text colour for all of this information."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine contains an active ingredient with a therapeutically irrelevant descriptor in its name, and the name and quantity of this active ingredient is displayed in accordance with subsection 8(2), can the name of the therapeutically active moiety be displayed on the main label instead of the active ingredient name if it is in a text size of 2.5 millimetres and no quantity information is displayed?\", \"Answer\": \"No\", \"Answer Explanation\": \"According to subsection 9(7)(d), if a medicine contains an active ingredient whose name includes therapeutically irrelevant descriptors, and the name and quantity are displayed per subsection 8(2), the therapeutically active moiety name can only be displayed instead of the active ingredient name if the text size is at least 3.0 millimetres and no quantity information is displayed for any active ingredients. A 2.5 millimetre text size does not meet the minimum 3.0 millimetre requirement specified in 9(7)(d)(iii).\"}, {\"Question\": \"Assuming a medicine label includes critical health information and other information mentioned in 8(2)(c), (d) or (e), and this is all presented in red text on a white background, does this comply with the presentation requirements?\", \"Answer\": \"No\", \"Answer Explanation\": \"Subsection 8(2)(f) states that critical health information and any information from 8(2)(c), (d) or (e) must be presented in black or other dark coloured text, using only one colour, on a white or contrasting background. Using red text does not meet the requirement to use black or dark coloured text specified in 8(2)(f).\"}, {\"Question\": \"Assuming a medicine contains multiple active ingredients, some with therapeutically irrelevant descriptors in their names, and the names and quantities are displayed per 8(2), can the therapeutically active moiety names be displayed instead of the active ingredient names in 4.0 millimetre text if quantities are shown for some but not all active ingredients?\", \"Answer\": \"No\", \"Answer Explanation\": \"Subsection 9(7)(d) allows displaying therapeutically active moiety names instead of active ingredient names if the active ingredient names include irrelevant descriptors and are displayed with quantities per 8(2). However, this is only allowed if the moiety names are in at least 3.0 millimetre text and no quantities are displayed for any active ingredients, per 9(7)(d)(iii) and (iv). Displaying quantities for some ingredients violates the requirement in 9(7)(d)(iv) that no quantities be shown.\"}, {\"Question\": \"Assuming a medicine label presents critical health information in blue text on a yellow background, and also includes other information from 8(2)(c) presented in black text on white, does the label comply with the presentation requirements?\", \"Answer\": \"No\", \"Answer Explanation\": \"Per 8(2)(f), critical health information and any 8(2)(c), (d) or (e) information included must be presented in black or dark coloured text, using only one colour, on a white or contrasting background. Using blue text on yellow for the critical information and a different black on white scheme for the 8(2)(c) information violates the 8(2)(f) requirement to use only one text colour for all of this information.\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            908030000,
            907000000
        ],
        "contexts": [
            " 9 Information to be included on the main label (8) Where a medicine is: (c) (i) the total number of active ingredients in the different formulations in the composite pack or medicine kit are to be counted; and (ii) if the same active ingredient is contained in two or more formulations in the composite pack or medicine kit, each of those active ingredients is to be counted separately, for the purposes of determining if paragraph 9(6)(b) applies to the composite pack or medicine kit, or which paragraph in subsection 9(7) applies to the composite pack or medicine kit; and",
            " 9 Information to be included on the main label (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then: (d) if subsection 8(2) applies and the medicine: (i) includes one or more active ingredients, the name of which includes descriptors (for example chemical salts or hydration states) that are not therapeutically relevant; and (ii) the name and quantity or proportion of each of those active ingredients is displayed in accordance with subsection 8(2), then the name of the therapeutically active moiety(ies) of the active ingredient may be displayed on the main label on the primary pack, instead of the name of the active ingredient, if: (iii) this is in a text size of not less than 3.0 millimetres; and (iv) no quantity or proportion information is displayed for any of the active ingredients in the medicine."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is a composite pack or medicine kit containing two formulations with the same active ingredient, and the medicine is intended to be registered goods, how many times should that active ingredient be counted for the purposes of determining which paragraph in subsection 9(7) applies to the composite pack or medicine kit?",
                    "Answer": "The active ingredient should be counted twice.",
                    "Answer Explanation": "According to section 9(8)(c)(ii), if the same active ingredient is contained in two or more formulations in the composite pack or medicine kit, each of those active ingredients is to be counted separately for the purposes of determining which paragraph in subsection 9(7) applies to the composite pack or medicine kit. Therefore, if a composite pack or medicine kit contains two formulations with the same active ingredient, that active ingredient should be counted twice."
                },
                {
                    "Question": "Assuming a medicine is intended to be registered goods and includes an active ingredient whose name includes a non-therapeutically relevant descriptor, under what conditions can the name of the therapeutically active moiety be displayed on the main label instead of the active ingredient name?",
                    "Answer": "The name of the therapeutically active moiety can be displayed instead of the active ingredient name if the name and quantity or proportion of the active ingredient is displayed in accordance with subsection 8(2), the therapeutically active moiety name is in a text size of at least 3.0 millimetres, and no quantity or proportion information is displayed for any of the active ingredients.",
                    "Answer Explanation": "Section 9(7)(d) states that if subsection 8(2) applies and the medicine includes an active ingredient whose name includes a non-therapeutically relevant descriptor, and the name and quantity or proportion of that active ingredient is displayed per subsection 8(2), then the therapeutically active moiety name may be displayed instead of the active ingredient name if it is in a text size of at least 3.0 millimetres and no quantity or proportion information is displayed for any active ingredients."
                },
                {
                    "Question": "Assuming a medicine is a composite pack with three formulations each containing a different active ingredient, and the medicine is intended to be registered goods, which paragraph in subsection 9(7) would apply for determining the labelling requirements?",
                    "Answer": "Paragraph 9(7)(c) would apply for determining the labelling requirements.",
                    "Answer Explanation": "Section 9(8)(c)(i) states that for a composite pack or medicine kit, the total number of active ingredients in the different formulations are to be counted for the purposes of determining which paragraph in subsection 9(7) applies. With three formulations each containing a different active ingredient, the total count of active ingredients is three. Therefore, paragraph 9(7)(c), which covers medicines with 3 or more active ingredients, would apply in determining the labelling requirements for this composite pack."
                },
                {
                    "Question": "Assuming a medicine is intended to be registered goods and includes multiple active ingredients, one of which has a name that includes a non-therapeutically relevant chemical salt, under what conditions would displaying the therapeutically active moiety name instead of that active ingredient name on the main label be prohibited?",
                    "Answer": "Displaying the therapeutically active moiety name instead of the active ingredient name on the main label would be prohibited if the name and quantity or proportion of that active ingredient is not displayed in accordance with subsection 8(2), or if any quantity or proportion information is displayed for any of the active ingredients in the medicine.",
                    "Answer Explanation": "Section 9(7)(d) allows the therapeutically active moiety name to be displayed instead of an active ingredient name that includes a non-therapeutically relevant descriptor only if the name and quantity or proportion of that active ingredient is displayed per subsection 8(2), and no quantity or proportion information is displayed for any active ingredients. Therefore, if either of those conditions is not met, displaying the therapeutically active moiety name in place of the active ingredient name would be prohibited."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine is a composite pack or medicine kit containing two formulations with the same active ingredient, and the medicine is intended to be registered goods, how many times should that active ingredient be counted for the purposes of determining which paragraph in subsection 9(7) applies to the composite pack or medicine kit?\", \"Answer\": \"The active ingredient should be counted twice.\", \"Answer Explanation\": \"According to section 9(8)(c)(ii), if the same active ingredient is contained in two or more formulations in the composite pack or medicine kit, each of those active ingredients is to be counted separately for the purposes of determining which paragraph in subsection 9(7) applies to the composite pack or medicine kit. Therefore, if a composite pack or medicine kit contains two formulations with the same active ingredient, that active ingredient should be counted twice.\"}, {\"Question\": \"Assuming a medicine is intended to be registered goods and includes an active ingredient whose name includes a non-therapeutically relevant descriptor, under what conditions can the name of the therapeutically active moiety be displayed on the main label instead of the active ingredient name?\", \"Answer\": \"The name of the therapeutically active moiety can be displayed instead of the active ingredient name if the name and quantity or proportion of the active ingredient is displayed in accordance with subsection 8(2), the therapeutically active moiety name is in a text size of at least 3.0 millimetres, and no quantity or proportion information is displayed for any of the active ingredients.\", \"Answer Explanation\": \"Section 9(7)(d) states that if subsection 8(2) applies and the medicine includes an active ingredient whose name includes a non-therapeutically relevant descriptor, and the name and quantity or proportion of that active ingredient is displayed per subsection 8(2), then the therapeutically active moiety name may be displayed instead of the active ingredient name if it is in a text size of at least 3.0 millimetres and no quantity or proportion information is displayed for any active ingredients.\"}, {\"Question\": \"Assuming a medicine is a composite pack with three formulations each containing a different active ingredient, and the medicine is intended to be registered goods, which paragraph in subsection 9(7) would apply for determining the labelling requirements?\", \"Answer\": \"Paragraph 9(7)(c) would apply for determining the labelling requirements.\", \"Answer Explanation\": \"Section 9(8)(c)(i) states that for a composite pack or medicine kit, the total number of active ingredients in the different formulations are to be counted for the purposes of determining which paragraph in subsection 9(7) applies. With three formulations each containing a different active ingredient, the total count of active ingredients is three. Therefore, paragraph 9(7)(c), which covers medicines with 3 or more active ingredients, would apply in determining the labelling requirements for this composite pack.\"}, {\"Question\": \"Assuming a medicine is intended to be registered goods and includes multiple active ingredients, one of which has a name that includes a non-therapeutically relevant chemical salt, under what conditions would displaying the therapeutically active moiety name instead of that active ingredient name on the main label be prohibited?\", \"Answer\": \"Displaying the therapeutically active moiety name instead of the active ingredient name on the main label would be prohibited if the name and quantity or proportion of that active ingredient is not displayed in accordance with subsection 8(2), or if any quantity or proportion information is displayed for any of the active ingredients in the medicine.\", \"Answer Explanation\": \"Section 9(7)(d) allows the therapeutically active moiety name to be displayed instead of an active ingredient name that includes a non-therapeutically relevant descriptor only if the name and quantity or proportion of that active ingredient is displayed per subsection 8(2), and no quantity or proportion information is displayed for any active ingredients. Therefore, if either of those conditions is not met, displaying the therapeutically active moiety name in place of the active ingredient name would be prohibited.\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            802060000,
            802050000
        ],
        "contexts": [
            " 8 Information to be included on the label (2) (f) The presentation of the critical health information, and any information mentioned in paragraphs 8(2)(c), 8(2)(d) or 8(2)(e) that is included, must be presented in black or other dark coloured texts, using only one colour, on a white or other contrasting background.",
            " 8 Information to be included on the label (2) (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or distributor contact details."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine label includes critical health information and additional information about storage conditions, what color and background must the critical health information be presented on, and where must the storage conditions information be placed?",
                    "Answer": "The critical health information must be in black or dark colored text on a white or contrasting background. The storage conditions must be under an 'Other information' heading below the critical information.",
                    "Answer Explanation": "Section 8(2)(f) states that critical health information must be presented in black or dark text on a white or contrasting background. Section 8(2)(e) states that additional information like storage conditions must be under an 'Other information' heading that follows below the critical information headings mentioned in 8(2)(b)."
                },
                {
                    "Question": "Given a medicine label that contains critical health information, the names of inactive ingredients, and distributor contact details, what color must the critical information text be in, and under what heading must the ingredient and contact information be placed?",
                    "Answer": "The critical health information must be in black or another dark color. The inactive ingredients and distributor contact details must be under an 'Other information' heading or other appropriate heading below the critical information.",
                    "Answer Explanation": "Per 8(2)(f), critical health information must use black or dark colored text. 8(2)(e) states that information other than the critical health information, like excipient names and distributor details, must go under an 'Other information' or other appropriate heading that follows below the critical information headings from 8(2)(b)."
                },
                {
                    "Question": "Suppose a medicine label includes critical health information in blue text, along with a list of inactive ingredients. Assuming no other information is included, does this labeling comply with the regulations?",
                    "Answer": "No, this labeling does not comply. The critical health information must be in black or dark text, not blue. Additionally, the list of inactive ingredients must be under an 'Other information' or other appropriate heading below the critical information.",
                    "Answer Explanation": "8(2)(f) requires critical information to use black or dark text, so blue is not compliant. 8(2)(e) states inactive ingredients must be under a heading like 'Other information' below the critical information, which is also not satisfied here."
                },
                {
                    "Question": "Consider a medicine label containing critical health information, storage instructions, and sponsor contact details, with the storage and contact information under an 'Additional Details' heading below the critical information. Assuming the critical information uses red text on a white background, does the label meet the regulations?",
                    "Answer": "No, this label does not meet the regulations. While placing the storage instructions and sponsor contact under an appropriate 'Additional Details' heading below the critical information complies with 8(2)(e), using red text for the critical information violates 8(2)(f) which requires black or dark colored text.",
                    "Answer Explanation": "8(2)(e) is satisfied by having the storage and sponsor contact information under an appropriate heading below the critical information. However, 8(2)(f) specifies critical information must use black or dark text on a white or contrasting background, so red text is non-compliant."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine label includes critical health information and additional information about storage conditions, what color and background must the critical health information be presented on, and where must the storage conditions information be placed?\", \"Answer\": \"The critical health information must be in black or dark colored text on a white or contrasting background. The storage conditions must be under an 'Other information' heading below the critical information.\", \"Answer Explanation\": \"Section 8(2)(f) states that critical health information must be presented in black or dark text on a white or contrasting background. Section 8(2)(e) states that additional information like storage conditions must be under an 'Other information' heading that follows below the critical information headings mentioned in 8(2)(b).\"}, {\"Question\": \"Given a medicine label that contains critical health information, the names of inactive ingredients, and distributor contact details, what color must the critical information text be in, and under what heading must the ingredient and contact information be placed?\", \"Answer\": \"The critical health information must be in black or another dark color. The inactive ingredients and distributor contact details must be under an 'Other information' heading or other appropriate heading below the critical information.\", \"Answer Explanation\": \"Per 8(2)(f), critical health information must use black or dark colored text. 8(2)(e) states that information other than the critical health information, like excipient names and distributor details, must go under an 'Other information' or other appropriate heading that follows below the critical information headings from 8(2)(b).\"}, {\"Question\": \"Suppose a medicine label includes critical health information in blue text, along with a list of inactive ingredients. Assuming no other information is included, does this labeling comply with the regulations?\", \"Answer\": \"No, this labeling does not comply. The critical health information must be in black or dark text, not blue. Additionally, the list of inactive ingredients must be under an 'Other information' or other appropriate heading below the critical information.\", \"Answer Explanation\": \"8(2)(f) requires critical information to use black or dark text, so blue is not compliant. 8(2)(e) states inactive ingredients must be under a heading like 'Other information' below the critical information, which is also not satisfied here.\"}, {\"Question\": \"Consider a medicine label containing critical health information, storage instructions, and sponsor contact details, with the storage and contact information under an 'Additional Details' heading below the critical information. Assuming the critical information uses red text on a white background, does the label meet the regulations?\", \"Answer\": \"No, this label does not meet the regulations. While placing the storage instructions and sponsor contact under an appropriate 'Additional Details' heading below the critical information complies with 8(2)(e), using red text for the critical information violates 8(2)(f) which requires black or dark colored text.\", \"Answer Explanation\": \"8(2)(e) is satisfied by having the storage and sponsor contact information under an appropriate heading below the critical information. However, 8(2)(f) specifies critical information must use black or dark text on a white or contrasting background, so red text is non-compliant.\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            907030000,
            901030000
        ],
        "contexts": [
            " 9 Information to be included on the main label (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then: (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or",
            " 9 Information to be included on the main label (1) Subject to the qualifications and special requirements specified in this section and section 10 of this Order, the information on the main label of the medicine must include: (c) the quantity or proportion of all active ingredients in the medicine; and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine contains 5 active ingredients and is intended to be registered goods, is it required to include the quantity or proportion of all active ingredients on the main label?",
                    "Answer": "No",
                    "Answer Explanation": "According to section 9(7)(c), if the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. Paragraph 9(1)(c) states that the quantity or proportion of all active ingredients must be included on the main label. Therefore, since the medicine has 5 active ingredients, it is exempt from the requirement to include the quantity or proportion of all active ingredients on the main label, assuming subsection 8(2) applies."
                },
                {
                    "Question": "Assuming a medicine contains 3 active ingredients and is intended to be registered goods, is it required to include the quantity or proportion of all active ingredients on the main label?",
                    "Answer": "Yes",
                    "Answer Explanation": "Section 9(1)(c) states that the quantity or proportion of all active ingredients in the medicine must be included on the main label, subject to the qualifications in section 9. Section 9(7)(c) provides an exemption from 9(1)(c) if the medicine contains four or more active ingredients and subsection 8(2) applies. Since this medicine only contains 3 active ingredients, the exemption in 9(7)(c) does not apply, so the general requirement in 9(1)(c) to include the quantity or proportion of all active ingredients on the main label still applies."
                },
                {
                    "Question": "Assuming subsection 8(2) does not apply, if a medicine contains 6 active ingredients and is intended to be registered goods, is it required to include the quantity or proportion of all active ingredients on the main label?",
                    "Answer": "Yes",
                    "Answer Explanation": "Section 9(1)(c) requires the quantity or proportion of all active ingredients to be included on the main label, subject to the qualifications in section 9. Section 9(7)(c) provides an exemption from this requirement if the medicine contains four or more active ingredients and subsection 8(2) applies. However, this question states that subsection 8(2) does not apply. Therefore, even though the medicine contains more than four active ingredients, the exemption in 9(7)(c) does not apply, so the general requirement in 9(1)(c) to include the quantities or proportions on the label still applies."
                },
                {
                    "Question": "Assuming subsection 8(2) applies, if a medicine contains 2 active ingredients and is intended to be registered goods, is it required to include the quantity or proportion of all active ingredients on the main label?",
                    "Answer": "Yes",
                    "Answer Explanation": "Section 9(1)(c) states that the quantity or proportion of all active ingredients must be included on the main label of registered goods, subject to the qualifications in section 9. Section 9(7)(c) provides an exemption from this requirement if the medicine contains four or more active ingredients and subsection 8(2) applies. In this case, even though subsection 8(2) applies, the medicine only contains 2 active ingredients, which is less than four. Therefore, the exemption in 9(7)(c) does not apply, so the general requirement in 9(1)(c) to include the quantity or proportion of active ingredients on the label still applies."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine contains 5 active ingredients and is intended to be registered goods, is it required to include the quantity or proportion of all active ingredients on the main label?\", \"Answer\": \"No\", \"Answer Explanation\": \"According to section 9(7)(c), if the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. Paragraph 9(1)(c) states that the quantity or proportion of all active ingredients must be included on the main label. Therefore, since the medicine has 5 active ingredients, it is exempt from the requirement to include the quantity or proportion of all active ingredients on the main label, assuming subsection 8(2) applies.\"}, {\"Question\": \"Assuming a medicine contains 3 active ingredients and is intended to be registered goods, is it required to include the quantity or proportion of all active ingredients on the main label?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"Section 9(1)(c) states that the quantity or proportion of all active ingredients in the medicine must be included on the main label, subject to the qualifications in section 9. Section 9(7)(c) provides an exemption from 9(1)(c) if the medicine contains four or more active ingredients and subsection 8(2) applies. Since this medicine only contains 3 active ingredients, the exemption in 9(7)(c) does not apply, so the general requirement in 9(1)(c) to include the quantity or proportion of all active ingredients on the main label still applies.\"}, {\"Question\": \"Assuming subsection 8(2) does not apply, if a medicine contains 6 active ingredients and is intended to be registered goods, is it required to include the quantity or proportion of all active ingredients on the main label?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"Section 9(1)(c) requires the quantity or proportion of all active ingredients to be included on the main label, subject to the qualifications in section 9. Section 9(7)(c) provides an exemption from this requirement if the medicine contains four or more active ingredients and subsection 8(2) applies. However, this question states that subsection 8(2) does not apply. Therefore, even though the medicine contains more than four active ingredients, the exemption in 9(7)(c) does not apply, so the general requirement in 9(1)(c) to include the quantities or proportions on the label still applies.\"}, {\"Question\": \"Assuming subsection 8(2) applies, if a medicine contains 2 active ingredients and is intended to be registered goods, is it required to include the quantity or proportion of all active ingredients on the main label?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"Section 9(1)(c) states that the quantity or proportion of all active ingredients must be included on the main label of registered goods, subject to the qualifications in section 9. Section 9(7)(c) provides an exemption from this requirement if the medicine contains four or more active ingredients and subsection 8(2) applies. In this case, even though subsection 8(2) applies, the medicine only contains 2 active ingredients, which is less than four. Therefore, the exemption in 9(7)(c) does not apply, so the general requirement in 9(1)(c) to include the quantity or proportion of active ingredients on the label still applies.\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            1009020000,
            900000000
        ],
        "contexts": [
            " 10 Qualifications and special requirements (9) Strip, blister and dial dispenser packs (b) If, in relation to a medicine referred to in (a) there are: (i) four or more active ingredients in the medicine and the medicine is intended to be, or is, registered goods; or (ii) two or more active ingredients in the medicine and the medicine is intended to be, or is, listed goods, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iii) the name of the medicine; and (iv) the batch number of the medicine preceded by the batch number prefix; and (v) the expiry date of the medicine preceded by the expiry date prefix; and (vi) the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor of the medicine.",
            " 9 Information to be included on the main label (6) If the medicine is intended to be, or is, listed goods: (a) if the medicine is a sunscreen preparation - the name of every active ingredient, together with the quantity or proportion of every active ingredient, and the name of the dosage form, may appear on a side panel or side label or on a rear panel or rear label; or"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is intended to be registered goods and contains 5 active ingredients, what information must be displayed on the label of the strip, blister or dial dispenser pack to comply with sections 8 and 9?",
                    "Answer": "The name of the medicine, batch number preceded by the batch number prefix, expiry date preceded by the expiry date prefix, and the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor.",
                    "Answer Explanation": "Section 10(9)(b)(i) states that for a medicine intended to be registered goods with four or more active ingredients, the strip, blister or dial dispenser pack label must display the information listed in 10(9)(b)(iii) through (vi) to comply with sections 8 and 9. This includes the medicine name, batch number with prefix, expiry date with prefix, and sponsor\/distributor name or identifying trademark."
                },
                {
                    "Question": "Assuming a sunscreen preparation medicine is intended to be listed goods, can the name and quantity of every active ingredient appear on a side or rear panel or label?",
                    "Answer": "Yes, for a sunscreen preparation medicine intended to be listed goods, the name of every active ingredient, quantity of every active ingredient, and dosage form name may appear on a side panel, side label, rear panel or rear label.",
                    "Answer Explanation": "Section 9(6)(a) explicitly states that if a medicine is intended to be listed goods and is a sunscreen preparation, the name, quantity and proportion of every active ingredient, along with the dosage form name, may appear on a side panel, side label, rear panel or rear label."
                },
                {
                    "Question": "Assuming a medicine is intended to be listed goods and contains 3 active ingredients, what information must be displayed on the label of the strip, blister or dial dispenser pack to comply with sections 8 and 9?",
                    "Answer": "The medicine must display the name of the medicine, batch number preceded by the batch number prefix, expiry date preceded by the expiry date prefix, and the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor.",
                    "Answer Explanation": "Section 10(9)(b)(ii) states that for a medicine intended to be listed goods with two or more active ingredients, the strip, blister or dial dispenser pack label must display the information listed in 10(9)(b)(iii) through (vi) to comply with sections 8 and 9. This includes the medicine name, batch number with prefix, expiry date with prefix, and sponsor\/distributor name or identifying trademark."
                },
                {
                    "Question": "Assuming a medicine is not a sunscreen preparation and is intended to be listed goods, can the name and quantity of every active ingredient appear on a side or rear panel or label?",
                    "Answer": "No, section 9(6)(a) only allows the active ingredient names, quantities, proportions and dosage form name to appear on side or rear panels\/labels for sunscreen preparation medicines intended to be listed goods. Other listed medicines cannot use this labeling exception.",
                    "Answer Explanation": "Section 9(6)(a) specifically limits the allowance for active ingredient details to appear on side or rear panels\/labels to sunscreen preparation medicines intended to be listed goods. By omission, this labeling is not permitted for non-sunscreen listed medicines per the information provided in sections 9 and 10."
                }
            ]
        },
        "result_str": "{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming a medicine is intended to be registered goods and contains 5 active ingredients, what information must be displayed on the label of the strip, blister or dial dispenser pack to comply with sections 8 and 9?\",\n      \"Answer\": \"The name of the medicine, batch number preceded by the batch number prefix, expiry date preceded by the expiry date prefix, and the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor.\",\n      \"Answer Explanation\": \"Section 10(9)(b)(i) states that for a medicine intended to be registered goods with four or more active ingredients, the strip, blister or dial dispenser pack label must display the information listed in 10(9)(b)(iii) through (vi) to comply with sections 8 and 9. This includes the medicine name, batch number with prefix, expiry date with prefix, and sponsor\/distributor name or identifying trademark.\"\n    },\n    {\n      \"Question\": \"Assuming a sunscreen preparation medicine is intended to be listed goods, can the name and quantity of every active ingredient appear on a side or rear panel or label?\",\n      \"Answer\": \"Yes, for a sunscreen preparation medicine intended to be listed goods, the name of every active ingredient, quantity of every active ingredient, and dosage form name may appear on a side panel, side label, rear panel or rear label.\",\n      \"Answer Explanation\": \"Section 9(6)(a) explicitly states that if a medicine is intended to be listed goods and is a sunscreen preparation, the name, quantity and proportion of every active ingredient, along with the dosage form name, may appear on a side panel, side label, rear panel or rear label.\"\n    },\n    {\n      \"Question\": \"Assuming a medicine is intended to be listed goods and contains 3 active ingredients, what information must be displayed on the label of the strip, blister or dial dispenser pack to comply with sections 8 and 9?\", \n      \"Answer\": \"The medicine must display the name of the medicine, batch number preceded by the batch number prefix, expiry date preceded by the expiry date prefix, and the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor.\",\n      \"Answer Explanation\": \"Section 10(9)(b)(ii) states that for a medicine intended to be listed goods with two or more active ingredients, the strip, blister or dial dispenser pack label must display the information listed in 10(9)(b)(iii) through (vi) to comply with sections 8 and 9. This includes the medicine name, batch number with prefix, expiry date with prefix, and sponsor\/distributor name or identifying trademark.\"\n    },\n    {\n      \"Question\": \"Assuming a medicine is not a sunscreen preparation and is intended to be listed goods, can the name and quantity of every active ingredient appear on a side or rear panel or label?\",\n      \"Answer\": \"No, section 9(6)(a) only allows the active ingredient names, quantities, proportions and dosage form name to appear on side or rear panels\/labels for sunscreen preparation medicines intended to be listed goods. Other listed medicines cannot use this labeling exception.\",\n      \"Answer Explanation\": \"Section 9(6)(a) specifically limits the allowance for active ingredient details to appear on side or rear panels\/labels to sunscreen preparation medicines intended to be listed goods. By omission, this labeling is not permitted for non-sunscreen listed medicines per the information provided in sections 9 and 10.\"\n    }\n  ]\n}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            1005000000,
            900000000
        ],
        "contexts": [
            " 10 Qualifications and special requirements (5) Sunscreen preparations If: (b) is enclosed in a container with a capacity of not more than 25 millilitres, then, in relation to compliance with sections 8 and 9, it shall be sufficient if (i) the sun protection factor is displayed in a text size of not less than 1.5 millimetres; and (ii) all other information is displayed in a text size of not less than 1.0 millimetres.",
            " 9 Information to be included on the main label (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must: (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is a sunscreen preparation that comes in a container of 20 millilitres capacity, what is the minimum text size required for displaying the sun protection factor and all other information on the label to comply with sections 8 and 9?",
                    "Answer": "The minimum text size required is 1.5 millimetres for the sun protection factor and 1.0 millimetres for all other information.",
                    "Answer Explanation": "Section 10(5)(b) states that for sunscreen preparations in containers of not more than 25 millilitres capacity, to comply with sections 8 and 9, the sun protection factor must be displayed in a text size of at least 1.5 millimetres and all other information must be at least 1.0 millimetres. Since the given container is 20 millilitres, these minimum text size requirements apply."
                },
                {
                    "Question": "On the main label of a medicine, is it permitted for any text or graphics to separate the name of the medicine from the name(s) of active ingredient(s)? If so, under what conditions?",
                    "Answer": "Yes, text or graphics can separate the medicine name and active ingredient name(s) in specific cases allowed by the regulation.",
                    "Answer Explanation": "Section 9(3)(b) generally prohibits any text or graphics from separating the medicine name and active ingredient name(s) on the main label. However, it allows exceptions where additional information is: (i) required or permitted by paragraph 11(2)(h), subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A), or subsection 11(5); or (ii) related to identifying different formulations in a composite pack or medicine kit. In these specific cases, text or graphics may appear between the medicine and active ingredient names."
                },
                {
                    "Question": "Suppose a sunscreen preparation is in a 30 millilitre container. What minimum text sizes are required on the label for the sun protection factor and other information in order to be compliant with the relevant regulations?",
                    "Answer": "The standard minimum text size requirements in sections 8 and 9 apply, as the container exceeds 25 millilitres capacity.",
                    "Answer Explanation": "Section 10(5)(b) allows reduced minimum text sizes of 1.5mm for sun protection factor and 1.0mm for other information, but only for sunscreen containers of not more than 25 millilitres. Since this container is 30 millilitres, the special provision does not apply. The label must follow the normal minimum text size requirements set out in sections 8 and 9."
                },
                {
                    "Question": "Under what circumstances does the regulation permit text or graphics to appear between the medicine name and active ingredient name(s) on the main label, if that text or graphics relates to identifying different formulations contained in the product?",
                    "Answer": "Text or graphics identifying different formulations may appear between the medicine and active ingredient names if the product is a composite pack or medicine kit.",
                    "Answer Explanation": "Section 9(3)(b)(ii) allows text or graphics to separate the medicine name from the active ingredient name(s) on the main label when that additional information is related to identifying the different formulations of the medicines contained specifically in a composite pack or a medicine kit. For other types of products, this text or graphics would not be permitted in that position on the label."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine is a sunscreen preparation that comes in a container of 20 millilitres capacity, what is the minimum text size required for displaying the sun protection factor and all other information on the label to comply with sections 8 and 9?\", \"Answer\": \"The minimum text size required is 1.5 millimetres for the sun protection factor and 1.0 millimetres for all other information.\", \"Answer Explanation\": \"Section 10(5)(b) states that for sunscreen preparations in containers of not more than 25 millilitres capacity, to comply with sections 8 and 9, the sun protection factor must be displayed in a text size of at least 1.5 millimetres and all other information must be at least 1.0 millimetres. Since the given container is 20 millilitres, these minimum text size requirements apply.\"}, {\"Question\": \"On the main label of a medicine, is it permitted for any text or graphics to separate the name of the medicine from the name(s) of active ingredient(s)? If so, under what conditions?\", \"Answer\": \"Yes, text or graphics can separate the medicine name and active ingredient name(s) in specific cases allowed by the regulation.\", \"Answer Explanation\": \"Section 9(3)(b) generally prohibits any text or graphics from separating the medicine name and active ingredient name(s) on the main label. However, it allows exceptions where additional information is: (i) required or permitted by paragraph 11(2)(h), subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A), or subsection 11(5); or (ii) related to identifying different formulations in a composite pack or medicine kit. In these specific cases, text or graphics may appear between the medicine and active ingredient names.\"}, {\"Question\": \"Suppose a sunscreen preparation is in a 30 millilitre container. What minimum text sizes are required on the label for the sun protection factor and other information in order to be compliant with the relevant regulations?\", \"Answer\": \"The standard minimum text size requirements in sections 8 and 9 apply, as the container exceeds 25 millilitres capacity.\", \"Answer Explanation\": \"Section 10(5)(b) allows reduced minimum text sizes of 1.5mm for sun protection factor and 1.0mm for other information, but only for sunscreen containers of not more than 25 millilitres. Since this container is 30 millilitres, the special provision does not apply. The label must follow the normal minimum text size requirements set out in sections 8 and 9.\"}, {\"Question\": \"Under what circumstances does the regulation permit text or graphics to appear between the medicine name and active ingredient name(s) on the main label, if that text or graphics relates to identifying different formulations contained in the product?\", \"Answer\": \"Text or graphics identifying different formulations may appear between the medicine and active ingredient names if the product is a composite pack or medicine kit.\", \"Answer Explanation\": \"Section 9(3)(b)(ii) allows text or graphics to separate the medicine name from the active ingredient name(s) on the main label when that additional information is related to identifying the different formulations of the medicines contained specifically in a composite pack or a medicine kit. For other types of products, this text or graphics would not be permitted in that position on the label.\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            907020000,
            802000000
        ],
        "contexts": [
            " 9 Information to be included on the main label (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then: (b) where the medicine contains four or more active ingredients and subsection 8(2) does not apply, then the names and the quantities or proportions of the active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres; or",
            " 8 Information to be included on the label (2) (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or distributor contact details."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a non-prescription medicine contains 5 active ingredients and is registered goods, can the names and quantities of the active ingredients be included on a side or rear panel if displayed in a text size of 2.5 millimetres or greater?",
                    "Answer": "Yes",
                    "Answer Explanation": "Section 9(7)(b) states that if the medicine contains four or more active ingredients and is registered goods, then the names and quantities of the active ingredients may be included on a side panel, side label, rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres."
                },
                {
                    "Question": "Assuming a non-prescription medicine label includes 'Other information' after the critical health information, can it contain details about the medicine's dosage under this heading?",
                    "Answer": "No",
                    "Answer Explanation": "Section 8(2)(e) specifies that if information other than critical health information is included under the 'Other information' heading, it must not contain any additional information other than requirements relating to storage conditions, information about tamper evident packaging, names of excipients, and sponsor or distributor contact details. Dosage information is not permitted under this heading."
                },
                {
                    "Question": "Assuming a registered non-prescription medicine has 6 active ingredients, is it mandatory to include the names and quantities of the active ingredients on a side or rear panel in a minimum 2.5mm text size?",
                    "Answer": "No",
                    "Answer Explanation": "Section 9(7)(b) states that for registered goods with four or more active ingredients, the names and quantities 'may be' included on a side or rear panel in minimum 2.5mm text size. The word 'may' indicates this is optional, not mandatory, even if the medicine has more than 4 active ingredients."
                },
                {
                    "Question": "Assuming information about a non-prescription medicine's storage conditions is included on the label under the 'Other information' heading, can the sponsor contact details also be included under this same heading?",
                    "Answer": "Yes",
                    "Answer Explanation": "Section 8(2)(e) allows certain types of information to be included under the 'Other information' heading, including both storage condition requirements and sponsor or distributor contact details. Therefore, both of these pieces of information can be grouped together under this one heading."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a non-prescription medicine contains 5 active ingredients and is registered goods, can the names and quantities of the active ingredients be included on a side or rear panel if displayed in a text size of 2.5 millimetres or greater?\",\n    \"Answer\": \"Yes\",\n    \"Answer Explanation\": \"Section 9(7)(b) states that if the medicine contains four or more active ingredients and is registered goods, then the names and quantities of the active ingredients may be included on a side panel, side label, rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres.\"\n  },\n  {\n    \"Question\": \"Assuming a non-prescription medicine label includes 'Other information' after the critical health information, can it contain details about the medicine's dosage under this heading?\",\n    \"Answer\": \"No\",\n    \"Answer Explanation\": \"Section 8(2)(e) specifies that if information other than critical health information is included under the 'Other information' heading, it must not contain any additional information other than requirements relating to storage conditions, information about tamper evident packaging, names of excipients, and sponsor or distributor contact details. Dosage information is not permitted under this heading.\"\n  },\n  {\n    \"Question\": \"Assuming a registered non-prescription medicine has 6 active ingredients, is it mandatory to include the names and quantities of the active ingredients on a side or rear panel in a minimum 2.5mm text size?\", \n    \"Answer\": \"No\",\n    \"Answer Explanation\": \"Section 9(7)(b) states that for registered goods with four or more active ingredients, the names and quantities 'may be' included on a side or rear panel in minimum 2.5mm text size. The word 'may' indicates this is optional, not mandatory, even if the medicine has more than 4 active ingredients.\"\n  },\n  {\n    \"Question\": \"Assuming information about a non-prescription medicine's storage conditions is included on the label under the 'Other information' heading, can the sponsor contact details also be included under this same heading?\",\n    \"Answer\": \"Yes\",\n    \"Answer Explanation\": \"Section 8(2)(e) allows certain types of information to be included under the 'Other information' heading, including both storage condition requirements and sponsor or distributor contact details. Therefore, both of these pieces of information can be grouped together under this one heading.\"\n  }\n]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            601150000,
            801030000
        ],
        "contexts": [
            "6 Interpretation. \"critical health information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer;",
            " 8 Information to be included on the label (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include: (c) the quantity or proportion of all active ingredients in the medicine; and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a non-prescription medicine label only includes the quantity of active ingredients but no other information, would it be compliant with the regulation?",
                    "Answer": "No",
                    "Answer Explanation": "Paragraph 8(1)(c) requires the quantity or proportion of all active ingredients to be on the label. However, section 6 defines 'critical health information' as also requiring the information from paragraphs 8(1)(b), (j), (k), (l) and (n). Therefore, only including the quantity of active ingredients is not sufficient for compliance."
                },
                {
                    "Question": "If a non-prescription medicine label includes all the information required by paragraphs 8(1)(b), (c), (j), (k), (l) and (n), can any of that information be omitted?",
                    "Answer": "No",
                    "Answer Explanation": "Section 6 defines the information required by paragraphs 8(1)(b), (c), (j), (k), (l) and (n) as 'critical health information'. Paragraph 8(1) requires this information to be included on the label, subject to subsections 8(2), 8(3), and sections 9 and 10. Therefore, unless allowed by those other provisions, the information cannot be omitted."
                },
                {
                    "Question": "Assuming no other regulation sections apply, is the percentage of active ingredients in a non-prescription medicine required on the label?",
                    "Answer": "Yes",
                    "Answer Explanation": "Paragraph 8(1)(c) requires 'the quantity or proportion of all active ingredients' to be on the label. 'Proportion' includes percentages. Section 6 defines this as part of the 'critical health information'. Therefore, subject to subsections 8(2), 8(3), and sections 9 and 10, the percentage is required on the label."
                },
                {
                    "Question": "If a non-prescription medicine label is compliant with all aspects of the regulation except paragraph 8(1)(k), is it fully compliant overall?",
                    "Answer": "No",
                    "Answer Explanation": "Section 6 defines the information required by paragraph 8(1)(k) as part of the 'critical health information' that is required for safe use. Paragraph 8(1) requires this 'critical health information' on the label, subject to subsections 8(2), 8(3), and sections 9 and 10. Therefore, omitting the 8(1)(k) information means the label is not fully compliant."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a non-prescription medicine label only includes the quantity of active ingredients but no other information, would it be compliant with the regulation?\",\n    \"Answer\": \"No\",\n    \"Answer Explanation\": \"Paragraph 8(1)(c) requires the quantity or proportion of all active ingredients to be on the label. However, section 6 defines 'critical health information' as also requiring the information from paragraphs 8(1)(b), (j), (k), (l) and (n). Therefore, only including the quantity of active ingredients is not sufficient for compliance.\"\n  },\n  {\n    \"Question\": \"If a non-prescription medicine label includes all the information required by paragraphs 8(1)(b), (c), (j), (k), (l) and (n), can any of that information be omitted?\",\n    \"Answer\": \"No\",\n    \"Answer Explanation\": \"Section 6 defines the information required by paragraphs 8(1)(b), (c), (j), (k), (l) and (n) as 'critical health information'. Paragraph 8(1) requires this information to be included on the label, subject to subsections 8(2), 8(3), and sections 9 and 10. Therefore, unless allowed by those other provisions, the information cannot be omitted.\"\n  },\n  {\n    \"Question\": \"Assuming no other regulation sections apply, is the percentage of active ingredients in a non-prescription medicine required on the label?\",\n    \"Answer\": \"Yes\",\n    \"Answer Explanation\": \"Paragraph 8(1)(c) requires 'the quantity or proportion of all active ingredients' to be on the label. 'Proportion' includes percentages. Section 6 defines this as part of the 'critical health information'. Therefore, subject to subsections 8(2), 8(3), and sections 9 and 10, the percentage is required on the label.\"\n  },\n  {\n    \"Question\": \"If a non-prescription medicine label is compliant with all aspects of the regulation except paragraph 8(1)(k), is it fully compliant overall?\",\n    \"Answer\": \"No\",\n    \"Answer Explanation\": \"Section 6 defines the information required by paragraph 8(1)(k) as part of the 'critical health information' that is required for safe use. Paragraph 8(1) requires this 'critical health information' on the label, subject to subsections 8(2), 8(3), and sections 9 and 10. Therefore, omitting the 8(1)(k) information means the label is not fully compliant.\"\n  }\n]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            1102070000,
            1102060000
        ],
        "contexts": [
            " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (g) for preparations applied to the skin and mucous membranes, other than those covered by paragraph (f) - as a percentage expressed in terms of w\/w, w\/v, v\/v or v\/w, as appropriate, or as the weight or volume in a stated weight or volume of the medicine, as appropriate;",
            " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (f) for pressurised metered dose inhalers, dry powder inhalers and other metered dose products such as nasal sprays, the quantity of the active ingredient is: (i) the quantity delivered per actuation; or where the Secretary, when registering the medicine, has accepted that the dose of products containing those active ingredients was clinically established as the metered dose, then: (ii) the quantity metered per actuation;"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is a pressurized metered dose inhaler that contains an active ingredient where the dose was clinically established as the metered dose when the medicine was registered, how should the quantity of the active ingredient be expressed on the label?",
                    "Answer": "The quantity metered per actuation",
                    "Answer Explanation": "According to section 11(2)(f)(ii), for pressurized metered dose inhalers where the Secretary accepted that the dose was clinically established as the metered dose when registering the medicine, the quantity of the active ingredient should be expressed as the quantity metered per actuation."
                },
                {
                    "Question": "Assuming a medicine is a cream applied to the skin, how should the quantity or proportion of an active ingredient be expressed on the label?",
                    "Answer": "As a percentage expressed in terms of w\/w, w\/v, v\/v or v\/w, as appropriate, or as the weight or volume in a stated weight or volume of the medicine, as appropriate",
                    "Answer Explanation": "According to section 11(2)(g), for preparations applied to the skin and mucous membranes other than pressurized metered dose inhalers, dry powder inhalers and other metered dose products, the quantity or proportion of an active ingredient must be expressed as a percentage in terms of w\/w, w\/v, v\/v or v\/w, as appropriate, or as the weight or volume in a stated weight or volume of the medicine, as appropriate."
                },
                {
                    "Question": "Assuming a medicine is a nasal spray and the Secretary accepted the dose as the quantity delivered per actuation when the medicine was registered, how should the quantity of the active ingredient be expressed on the label?",
                    "Answer": "The quantity delivered per actuation",
                    "Answer Explanation": "According to section 11(2)(f)(i), for pressurized metered dose inhalers, dry powder inhalers and other metered dose products such as nasal sprays, the quantity of the active ingredient should be expressed as the quantity delivered per actuation."
                },
                {
                    "Question": "Assuming a medicine is a dry powder inhaler containing an active ingredient where the Secretary did not accept the dose as the metered dose when the medicine was registered, how should the quantity of the active ingredient be expressed on the label?",
                    "Answer": "The quantity delivered per actuation",
                    "Answer Explanation": "According to section 11(2)(f)(i), for pressurized metered dose inhalers, dry powder inhalers and other metered dose products, the quantity of the active ingredient should be expressed as the quantity delivered per actuation, unless section 11(2)(f)(ii) applies. Since the Secretary did not accept the dose as the metered dose when the medicine was registered, section 11(2)(f)(ii) does not apply, so the quantity should be expressed as the quantity delivered per actuation per section 11(2)(f)(i)."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine is a pressurized metered dose inhaler that contains an active ingredient where the dose was clinically established as the metered dose when the medicine was registered, how should the quantity of the active ingredient be expressed on the label?\", \"Answer\": \"The quantity metered per actuation\", \"Answer Explanation\": \"According to section 11(2)(f)(ii), for pressurized metered dose inhalers where the Secretary accepted that the dose was clinically established as the metered dose when registering the medicine, the quantity of the active ingredient should be expressed as the quantity metered per actuation.\"}, {\"Question\": \"Assuming a medicine is a cream applied to the skin, how should the quantity or proportion of an active ingredient be expressed on the label?\", \"Answer\": \"As a percentage expressed in terms of w\/w, w\/v, v\/v or v\/w, as appropriate, or as the weight or volume in a stated weight or volume of the medicine, as appropriate\", \"Answer Explanation\": \"According to section 11(2)(g), for preparations applied to the skin and mucous membranes other than pressurized metered dose inhalers, dry powder inhalers and other metered dose products, the quantity or proportion of an active ingredient must be expressed as a percentage in terms of w\/w, w\/v, v\/v or v\/w, as appropriate, or as the weight or volume in a stated weight or volume of the medicine, as appropriate.\"}, {\"Question\": \"Assuming a medicine is a nasal spray and the Secretary accepted the dose as the quantity delivered per actuation when the medicine was registered, how should the quantity of the active ingredient be expressed on the label?\", \"Answer\": \"The quantity delivered per actuation\", \"Answer Explanation\": \"According to section 11(2)(f)(i), for pressurized metered dose inhalers, dry powder inhalers and other metered dose products such as nasal sprays, the quantity of the active ingredient should be expressed as the quantity delivered per actuation.\"}, {\"Question\": \"Assuming a medicine is a dry powder inhaler containing an active ingredient where the Secretary did not accept the dose as the metered dose when the medicine was registered, how should the quantity of the active ingredient be expressed on the label?\", \"Answer\": \"The quantity delivered per actuation\", \"Answer Explanation\": \"According to section 11(2)(f)(i), for pressurized metered dose inhalers, dry powder inhalers and other metered dose products, the quantity of the active ingredient should be expressed as the quantity delivered per actuation, unless section 11(2)(f)(ii) applies. Since the Secretary did not accept the dose as the metered dose when the medicine was registered, section 11(2)(f)(ii) does not apply, so the quantity should be expressed as the quantity delivered per actuation per section 11(2)(f)(i).\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            805000000,
            801000000
        ],
        "contexts": [
            " 8 Information to be included on the label (5) If the container is enclosed in a delivery device such that it cannot be removed, the information required on its label under subsection 8(1) must be applied on the delivery device and not the container.",
            " 8 Information to be included on the label (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include: (k) relevant warning statements, where these are required in relation to a particular medicine or in specified circumstances applying to a particular medicine, such as the following: (i) where the medicine is for external use the required statement is \u2018Caution: Not to be Swallowed\u2019 or \u2018For External Use Only\u2019 or words to this effect; (ii) where: (A) the medicine is for oral use; and (B) the medicine contains active ingredient(s) included in category 'B' (including 'B1', 'B2', 'B3') or category 'C' in the document titled \u2018Prescribing medicines in pregnancy database\u2019 published on the TGA website as on the date of commencement of this Order; and (C) the medicine is not subject to other specific warning statement(s) relating to use during pregnancy, the required statement is: \u2018If pregnant or likely to become pregnant, consult a pharmacist or a doctor before use\u2019 or words to this effect; and (iii) where: (A) the medicine is a registered goods for oral use; and (B) the medicine contains active ingredient(s) included in category \u2018D\u2019 (except nicotine for smoking cessation) in the document titled \u2018Prescribing medicines in pregnancy database\u2019 published on the TGA website as at the date of commencement of this Order; and (C) the medicine is not subject to other specific warning statements(s) relating to use during pregnancy, the required statement is \u2018Do not use this medicine if pregnant or likely to become pregnant\u2019 or words to this effect; and"
        ],
        "result_dict": {},
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine is for oral use and contains an active ingredient in category 'B' of the 'Prescribing medicines in pregnancy database', what warning statement is required on the label if the medicine is in a container that cannot be removed from its delivery device?\", \"Answer\": \"The required warning statement is 'If pregnant or likely to become pregnant, consult a pharmacist or a doctor before use' or words to this effect.\", \"Answer Explanation\": \"According to 8(1)(k)(ii), if a medicine for oral use contains an active ingredient in category 'B' of the 'Prescribing medicines in pregnancy database' and is not subject to other specific warning statements relating to use during pregnancy, the required warning statement is 'If pregnant or likely to become pregnant, consult a pharmacist or a doctor before use' or words to this effect. 8(5) states that if the container is enclosed in a delivery device such that it cannot be removed, the information required on its label under 8(1) must be applied on the delivery device. Therefore, the required warning statement must be on the delivery device in this case.\"}, {\"Question\": \"Assuming a registered medicine for oral use contains an active ingredient in category 'D' of the 'Prescribing medicines in pregnancy database' and is not subject to other specific warning statements relating to use during pregnancy, what warning statement is required on the label if the medicine container can be removed from its delivery device?\", \"Answer\": \"The required warning statement is 'Do not use this medicine if pregnant or likely to become pregnant' or words to this effect, and it must be on the container label.\", \"Answer Explanation\": \"According to 8(1)(k)(iii), if a registered medicine for oral use contains an active ingredient in category 'D' of the 'Prescribing medicines in pregnancy database' (except nicotine for smoking cessation) and is not subject to other specific warning statements relating to use during pregnancy, the required warning statement is 'Do not use this medicine if pregnant or likely to become pregnant' or words to this effect. Since 8(5) only applies if the container cannot be removed from the delivery device, in this case where the container can be removed, the required warning statement must be on the container label as per 8(1).\"}, {\"Question\": \"Assuming a medicine is for external use and contains an active ingredient in category 'C' of the 'Prescribing medicines in pregnancy database', what warning statements are required on the label if the medicine is in a container that cannot be removed from its delivery device?\", \"Answer\": \"Two warning statements are required on the delivery device: 'Caution: Not to be Swallowed' or 'For External Use Only' or words to this effect, and 'If pregnant or likely to become pregnant, consult a pharmacist or a doctor before use' or words to this effect.\", \"Answer Explanation\": \"According to 8(1)(k)(i), if a medicine is for external use, the required warning statement is 'Caution: Not to be Swallowed' or 'For External Use Only' or words to this effect. Additionally, 8(1)(k)(ii) states that if a medicine for oral use contains an active ingredient in category 'C' of the 'Prescribing medicines in pregnancy database' and is not subject to other specific warning statements relating to use during pregnancy, the required warning statement is 'If pregnant or likely to become pregnant, consult a pharmacist or a doctor before use' or words to this effect. Since the medicine contains a category 'C' ingredient, this warning is also required even though the medicine is for external use. 8(5) states that if the container is enclosed in a delivery device such that it cannot be removed, the information required on its label under 8(1) must be applied on the delivery device. Therefore, both required warning statements must be on the delivery device in this case.\"}, {\"Question\": \"Assuming an unregistered medicine for oral use contains an active ingredient in category 'D' of the 'Prescribing medicines in pregnancy database' (except nicotine for smoking cessation) and is not subject to other specific warning statements relating to use during pregnancy, what warning statement, if any, is required on the label if the medicine container can be removed from its delivery device?\", \"Answer\": \"No warning statement relating to use during pregnancy is required on the label in this case.\", \"Answer Explanation\": \"According to 8(1)(k)(iii), if a registered medicine for oral use contains an active ingredient in category 'D' of the ",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            1008030000,
            900000000
        ],
        "contexts": [
            " 10 Qualifications and special requirements (8) Individually wrapped medicines (c) Where: (i) a medicine consists of dry herbs contained in individual bags and the bag is retained around the herbs during preparation; (ii) the bags are contained in a primary pack, the label of which complies with the requirements of this Order, then the individual bag need not be labelled with the information referred to in sections 8 and 9.",
            " 9 Information to be included on the main label (10) Subsection 9(9) does not apply: (a) where the medicine is supplied in a small container; or"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assume there is a dry herb medicine consisting of individual bags of herbs that are retained during preparation, and the bags are contained in a primary pack. If the primary pack label complies with sections 8 and 9, does the individual bag also need to be labelled with the information from sections 8 and 9?",
                    "Answer": "No",
                    "Answer Explanation": "According to section 10(8)(c), if a medicine consists of dry herbs in individual bags that are retained during preparation, and the bags are in a primary pack with a label that complies with sections 8 and 9, then the individual bags do not need to be labelled with the information from sections 8 and 9."
                },
                {
                    "Question": "Assume a medicine is supplied in a small container. Does the exception in section 9(10)(a) apply to the labelling requirements in section 9(9)?",
                    "Answer": "Yes",
                    "Answer Explanation": "Section 9(10)(a) states that subsection 9(9) does not apply where the medicine is supplied in a small container. Therefore, the labelling requirements in 9(9) do not need to be followed for medicines in small containers, as per the exception in 9(10)(a)."
                },
                {
                    "Question": "Assume a dry herb medicine has individual herb bags without labels, and the bags are in a primary pack. If the primary pack label does not comply with sections 8 and 9, can the individual bags be unlabelled as per section 10(8)(c)?",
                    "Answer": "No",
                    "Answer Explanation": "Section 10(8)(c) allows individual bags of dry herb medicines to be unlabelled only if the primary pack label complies with the requirements of sections 8 and 9. If the primary pack label does not comply with sections 8 and 9, then the exception in 10(8)(c) does not apply, and the individual bags must be labelled."
                },
                {
                    "Question": "Assume a medicine is supplied in a small container, and it consists of dry herbs in individual bags that are retained during preparation. Do the individual bags need to be labelled with the information from sections 8 and 9 if the primary pack label complies with those sections?",
                    "Answer": "No",
                    "Answer Explanation": "According to section 10(8)(c), if the dry herb medicine bags are in a primary pack with a label complying with sections 8 and 9, the individual bags do not need that information on their labels. Additionally, section 9(10)(a) provides an exception to 9(9) labelling requirements for medicines in small containers. Therefore, the individual bags do not require the labelling from sections 8 and 9, considering both 10(8)(c) and 9(10)(a)."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assume there is a dry herb medicine consisting of individual bags of herbs that are retained during preparation, and the bags are contained in a primary pack. If the primary pack label complies with sections 8 and 9, does the individual bag also need to be labelled with the information from sections 8 and 9?\", \"Answer\": \"No\", \"Answer Explanation\": \"According to section 10(8)(c), if a medicine consists of dry herbs in individual bags that are retained during preparation, and the bags are in a primary pack with a label that complies with sections 8 and 9, then the individual bags do not need to be labelled with the information from sections 8 and 9.\"}, {\"Question\": \"Assume a medicine is supplied in a small container. Does the exception in section 9(10)(a) apply to the labelling requirements in section 9(9)?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"Section 9(10)(a) states that subsection 9(9) does not apply where the medicine is supplied in a small container. Therefore, the labelling requirements in 9(9) do not need to be followed for medicines in small containers, as per the exception in 9(10)(a).\"}, {\"Question\": \"Assume a dry herb medicine has individual herb bags without labels, and the bags are in a primary pack. If the primary pack label does not comply with sections 8 and 9, can the individual bags be unlabelled as per section 10(8)(c)?\", \"Answer\": \"No\", \"Answer Explanation\": \"Section 10(8)(c) allows individual bags of dry herb medicines to be unlabelled only if the primary pack label complies with the requirements of sections 8 and 9. If the primary pack label does not comply with sections 8 and 9, then the exception in 10(8)(c) does not apply, and the individual bags must be labelled.\"}, {\"Question\": \"Assume a medicine is supplied in a small container, and it consists of dry herbs in individual bags that are retained during preparation. Do the individual bags need to be labelled with the information from sections 8 and 9 if the primary pack label complies with those sections?\", \"Answer\": \"No\", \"Answer Explanation\": \"According to section 10(8)(c), if the dry herb medicine bags are in a primary pack with a label complying with sections 8 and 9, the individual bags do not need that information on their labels. Additionally, section 9(10)(a) provides an exception to 9(9) labelling requirements for medicines in small containers. Therefore, the individual bags do not require the labelling from sections 8 and 9, considering both 10(8)(c) and 9(10)(a).\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            905030000,
            901030000
        ],
        "contexts": [
            " 9 Information to be included on the main label (5) If the medicine contains: (c) if the medicine is intended to be, or is, registered goods, and (i) subsection 8(2) does not apply, then the names, and quantities or proportions, of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres; or (ii) subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.",
            " 9 Information to be included on the main label (1) Subject to the qualifications and special requirements specified in this section and section 10 of this Order, the information on the main label of the medicine must include: (c) the quantity or proportion of all active ingredients in the medicine; and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is intended to be registered goods and contains active ingredients, what are the requirements for displaying the names and quantities or proportions of the active ingredients on the label if subsection 8(2) does not apply?",
                    "Answer": "The names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres.",
                    "Answer Explanation": "According to section 9(5)(c)(i), if the medicine is intended to be registered goods, contains active ingredients, and subsection 8(2) does not apply, then the names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres."
                },
                {
                    "Question": "Assuming a medicine is intended to be registered goods and subsection 8(2) applies, is compliance with paragraphs 9(1)(b) and 9(1)(c) required?",
                    "Answer": "No, compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.",
                    "Answer Explanation": "As per section 9(5)(c)(ii), if the medicine is intended to be registered goods and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required."
                },
                {
                    "Question": "Assuming the qualifications and special requirements specified in sections 9 and 10 do not apply, what information must be included on the main label of a medicine regarding the active ingredients?",
                    "Answer": "The quantity or proportion of all active ingredients in the medicine must be included on the main label.",
                    "Answer Explanation": "Section 9(1)(c) states that subject to the qualifications and special requirements specified in sections 9 and 10, the information on the main label of the medicine must include the quantity or proportion of all active ingredients in the medicine."
                },
                {
                    "Question": "Assuming a medicine is intended to be registered goods, contains active ingredients, and subsection 8(2) does not apply, is it necessary to include the quantity or proportion of all active ingredients on the main label as per section 9(1)(c)?",
                    "Answer": "No, it is not necessary to include the quantity or proportion of all active ingredients on the main label as per section 9(1)(c).",
                    "Answer Explanation": "Section 9(5)(c)(i) specifies that if the medicine is intended to be registered goods, contains active ingredients, and subsection 8(2) does not apply, then the names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres. This overrides the requirement in section 9(1)(c) to include the quantity or proportion of all active ingredients on the main label."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine is intended to be registered goods and contains active ingredients, what are the requirements for displaying the names and quantities or proportions of the active ingredients on the label if subsection 8(2) does not apply?\", \"Answer\": \"The names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres.\", \"Answer Explanation\": \"According to section 9(5)(c)(i), if the medicine is intended to be registered goods, contains active ingredients, and subsection 8(2) does not apply, then the names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres.\"}, {\"Question\": \"Assuming a medicine is intended to be registered goods and subsection 8(2) applies, is compliance with paragraphs 9(1)(b) and 9(1)(c) required?\", \"Answer\": \"No, compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.\", \"Answer Explanation\": \"As per section 9(5)(c)(ii), if the medicine is intended to be registered goods and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.\"}, {\"Question\": \"Assuming the qualifications and special requirements specified in sections 9 and 10 do not apply, what information must be included on the main label of a medicine regarding the active ingredients?\", \"Answer\": \"The quantity or proportion of all active ingredients in the medicine must be included on the main label.\", \"Answer Explanation\": \"Section 9(1)(c) states that subject to the qualifications and special requirements specified in sections 9 and 10, the information on the main label of the medicine must include the quantity or proportion of all active ingredients in the medicine.\"}, {\"Question\": \"Assuming a medicine is intended to be registered goods, contains active ingredients, and subsection 8(2) does not apply, is it necessary to include the quantity or proportion of all active ingredients on the main label as per section 9(1)(c)?\", \"Answer\": \"No, it is not necessary to include the quantity or proportion of all active ingredients on the main label as per section 9(1)(c).\", \"Answer Explanation\": \"Section 9(5)(c)(i) specifies that if the medicine is intended to be registered goods, contains active ingredients, and subsection 8(2) does not apply, then the names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres. This overrides the requirement in section 9(1)(c) to include the quantity or proportion of all active ingredients on the main label.\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            1009010000,
            900000000
        ],
        "contexts": [
            " 10 Qualifications and special requirements (9) Strip, blister and dial dispenser packs (a) Subject to paragraph (b), if: (i) a medicine consists of individual dosage units such as tablets, capsules, pills, pastilles, cachets, lozenges, pessaries, suppositories or single doses of powder; and (ii) two or more dosage units are individually enclosed in a strip, blister or dial dispenser pack such that the dosage units can only be extracted individually; and (iii) the strip, blister or dial dispenser pack is enclosed in a primary pack, the label of which complies with sections 8 and 9, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iv) the name of the medicine; and (v) the name(s) of all active ingredients in the medicine; and (vi) the quantity or proportion of all active ingredients in the medicine; and (vii) the batch number of the medicine preceded by the batch number prefix; and (viii) the expiry date of the medicine preceded by the expiry date prefix; and (ix) the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor of the medicine.",
            " 9 Information to be included on the main label (9) If the medicine is intended to be, or is, registered goods, and the name of an active ingredient included in the medicine comprises an ingredient name specified in Schedule 2 to this Order, either alone or in combination with any other descriptors, then the names of all active ingredients in the medicine, together with their quantity or proportion, must be displayed in a text size of not less than 2.5 millimetres."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine consists of individual dosage units enclosed in a blister pack, which is then enclosed in a primary pack with a label that complies with sections 8 and 9, what information must be displayed on the label of the blister pack itself to be compliant with the regulation?",
                    "Answer": "The name of the medicine, the name(s) and quantity\/proportion of all active ingredients, the batch number and expiry date with their respective prefixes, and the name of the sponsor\/distributor or their registered trademark.",
                    "Answer Explanation": "Section 10(9)(a) specifies that if the conditions in (i), (ii) and (iii) are met regarding dosage units in a blister pack enclosed in a compliant primary pack, then the blister pack label only needs to display the information listed in (iv) through (ix) to be compliant with sections 8 and 9. This includes the medicine name, active ingredient names and quantities, batch number and expiry date with prefixes, and sponsor\/distributor information."
                },
                {
                    "Question": "Consider a registered medicine where the name of an active ingredient comprises an ingredient name specified in Schedule 2 to this Order. What is the minimum text size that must be used to display the names and quantities of all active ingredients on the main label, as per the regulation?",
                    "Answer": "The names of all active ingredients in the medicine, together with their quantity or proportion, must be displayed in a text size of not less than 2.5 millimeters.",
                    "Answer Explanation": "Section 9(9) directly states that if a registered medicine has an active ingredient name specified in Schedule 2, then the names of all active ingredients and their quantities must be displayed on the main label in a text size of at least 2.5 millimeters to comply with the regulation."
                },
                {
                    "Question": "Supposing an over-the-counter medicine is packaged with individual tablets in a blister pack, which is then put inside a primary carton with fully compliant labeling. The active ingredient is listed in Schedule 2. What information needs to be on the blister pack label, and in what minimum text size?",
                    "Answer": "The blister pack label needs to show the medicine name, all active ingredient names and quantities, batch number and expiry date with prefixes, and sponsor\/distributor information, as per section 10(9)(a)(iv)-(ix). The active ingredient name and quantity must be in a minimum 2.5 mm text size, as required by section 9(9) for Schedule 2 ingredients.",
                    "Answer Explanation": "Section 10(9)(a) allows reduced labeling on a blister pack if it is inside a fully labeled primary pack. Only the information in 10(9)(a)(iv)-(ix) is required. However, section 9(9) mandates a minimum 2.5 mm text size for active ingredient details for Schedule 2 ingredients, which still applies to the blister pack label. So the blister label must have the 10(9)(a)(iv)-(ix) information, with active ingredients in 2.5+ mm text."
                },
                {
                    "Question": "For a registered medicine sold in single dose sachets packed inside a primary carton, is it acceptable for the sachets to omit the name and quantity of a minor active ingredient as long as it is declared on the outer carton label?",
                    "Answer": "No, this is not acceptable. The sachet labels must include the names and quantities of all active ingredients, even if they are also on the primary pack label.",
                    "Answer Explanation": "Section 10(9)(a) specifies that for medicine in individual dosage units like sachets packed in a primary pack, the sachet labels can have reduced information and still comply with sections 8 and 9. However, 10(9)(a)(v) and (vi) clearly state that the names and quantities of all active ingredients must still be on the sachet labels. Section 9(9) also requires this information for registered medicines with Schedule 2 ingredients. The active ingredient details cannot be omitted from the sachets."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine consists of individual dosage units enclosed in a blister pack, which is then enclosed in a primary pack with a label that complies with sections 8 and 9, what information must be displayed on the label of the blister pack itself to be compliant with the regulation?\", \"Answer\": \"The name of the medicine, the name(s) and quantity\/proportion of all active ingredients, the batch number and expiry date with their respective prefixes, and the name of the sponsor\/distributor or their registered trademark.\", \"Answer Explanation\": \"Section 10(9)(a) specifies that if the conditions in (i), (ii) and (iii) are met regarding dosage units in a blister pack enclosed in a compliant primary pack, then the blister pack label only needs to display the information listed in (iv) through (ix) to be compliant with sections 8 and 9. This includes the medicine name, active ingredient names and quantities, batch number and expiry date with prefixes, and sponsor\/distributor information.\"}, {\"Question\": \"Consider a registered medicine where the name of an active ingredient comprises an ingredient name specified in Schedule 2 to this Order. What is the minimum text size that must be used to display the names and quantities of all active ingredients on the main label, as per the regulation?\", \"Answer\": \"The names of all active ingredients in the medicine, together with their quantity or proportion, must be displayed in a text size of not less than 2.5 millimeters.\", \"Answer Explanation\": \"Section 9(9) directly states that if a registered medicine has an active ingredient name specified in Schedule 2, then the names of all active ingredients and their quantities must be displayed on the main label in a text size of at least 2.5 millimeters to comply with the regulation.\"}, {\"Question\": \"Supposing an over-the-counter medicine is packaged with individual tablets in a blister pack, which is then put inside a primary carton with fully compliant labeling. The active ingredient is listed in Schedule 2. What information needs to be on the blister pack label, and in what minimum text size?\", \"Answer\": \"The blister pack label needs to show the medicine name, all active ingredient names and quantities, batch number and expiry date with prefixes, and sponsor\/distributor information, as per section 10(9)(a)(iv)-(ix). The active ingredient name and quantity must be in a minimum 2.5 mm text size, as required by section 9(9) for Schedule 2 ingredients.\", \"Answer Explanation\": \"Section 10(9)(a) allows reduced labeling on a blister pack if it is inside a fully labeled primary pack. Only the information in 10(9)(a)(iv)-(ix) is required. However, section 9(9) mandates a minimum 2.5 mm text size for active ingredient details for Schedule 2 ingredients, which still applies to the blister pack label. So the blister label must have the 10(9)(a)(iv)-(ix) information, with active ingredients in 2.5+ mm text.\"}, {\"Question\": \"For a registered medicine sold in single dose sachets packed inside a primary carton, is it acceptable for the sachets to omit the name and quantity of a minor active ingredient as long as it is declared on the outer carton label?\", \"Answer\": \"No, this is not acceptable. The sachet labels must include the names and quantities of all active ingredients, even if they are also on the primary pack label.\", \"Answer Explanation\": \"Section 10(9)(a) specifies that for medicine in individual dosage units like sachets packed in a primary pack, the sachet labels can have reduced information and still comply with sections 8 and 9. However, 10(9)(a)(v) and (vi) clearly state that the names and quantities of all active ingredients must still be on the sachet labels. Section 9(9) also requires this information for registered medicines with Schedule 2 ingredients. The active ingredient details cannot be omitted from the sachets.\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            1001000000,
            1007000000
        ],
        "contexts": [
            " 10 Qualifications and special requirements (1) Preparations for ophthalmic use In addition to the requirements of sections 8 and 9 above, if a medicine is a preparation for ophthalmic use, the label on the container and on the primary pack or, where subsection 10(7) applies, the primary pack, must include: (c) if the medicine is for multidose use - a statement to the effect that \u2018the medicine should not be used more than four weeks\u2019, or such shorter period as specified in the approved product details in relation to the medicine, after the container is first opened;",
            " 10 Qualifications and special requirements (7) Small containers If: (d) the name(s) of all active ingredients in the medicine, unless there are four or more active ingredients; and the following information is displayed in a text size of not less than 1.5 millimetres:"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is a preparation for ophthalmic use and is for multidose use, what is the maximum time the medicine can be used after first opening the container if no shorter period is specified in the approved product details?",
                    "Answer": "4 weeks",
                    "Answer Explanation": "Section 10(1)(c) states that if a medicine is a preparation for ophthalmic use and is for multidose use, the label must include a statement that the medicine should not be used more than four weeks after the container is first opened, unless a shorter period is specified in the approved product details."
                },
                {
                    "Question": "For a small container of medicine with four or more active ingredients, is it required to list the names of all active ingredients on the label if the conditions in section 10(7) are met?",
                    "Answer": "No",
                    "Answer Explanation": "Section 10(7)(d) states that for small containers meeting the conditions in 10(7), the names of all active ingredients are not required on the label if there are four or more active ingredients."
                },
                {
                    "Question": "Assuming a medicine is in a small container that meets the conditions in section 10(7), what is the minimum text size required for displaying the information listed in 10(7)?",
                    "Answer": "1.5 millimetres",
                    "Answer Explanation": "The last part of section 10(7) states that for small containers meeting the conditions, the information listed must be displayed in a text size of not less than 1.5 millimetres."
                },
                {
                    "Question": "For a multidose ophthalmic medicine in a small container meeting the conditions of 10(7), is a statement about the maximum time the medicine can be used after opening required to be on the label?",
                    "Answer": "Yes",
                    "Answer Explanation": "Section 10(1)(c) requires the maximum usage time after opening statement for all multidose ophthalmic medicines. Section 10(7) provides some labeling exemptions for small containers but does not exempt the requirement from 10(1)(c). Therefore, the maximum usage time statement is still required even for small containers of multidose ophthalmic medicines."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine is a preparation for ophthalmic use and is for multidose use, what is the maximum time the medicine can be used after first opening the container if no shorter period is specified in the approved product details?\", \"Answer\": \"4 weeks\", \"Answer Explanation\": \"Section 10(1)(c) states that if a medicine is a preparation for ophthalmic use and is for multidose use, the label must include a statement that the medicine should not be used more than four weeks after the container is first opened, unless a shorter period is specified in the approved product details.\"}, {\"Question\": \"For a small container of medicine with four or more active ingredients, is it required to list the names of all active ingredients on the label if the conditions in section 10(7) are met?\", \"Answer\": \"No\", \"Answer Explanation\": \"Section 10(7)(d) states that for small containers meeting the conditions in 10(7), the names of all active ingredients are not required on the label if there are four or more active ingredients.\"}, {\"Question\": \"Assuming a medicine is in a small container that meets the conditions in section 10(7), what is the minimum text size required for displaying the information listed in 10(7)?\", \"Answer\": \"1.5 millimetres\", \"Answer Explanation\": \"The last part of section 10(7) states that for small containers meeting the conditions, the information listed must be displayed in a text size of not less than 1.5 millimetres.\"}, {\"Question\": \"For a multidose ophthalmic medicine in a small container meeting the conditions of 10(7), is a statement about the maximum time the medicine can be used after opening required to be on the label?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"Section 10(1)(c) requires the maximum usage time after opening statement for all multidose ophthalmic medicines. Section 10(7) provides some labeling exemptions for small containers but does not exempt the requirement from 10(1)(c). Therefore, the maximum usage time statement is still required even for small containers of multidose ophthalmic medicines.\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            905030000,
            802000000
        ],
        "contexts": [
            " 9 Information to be included on the main label (5) If the medicine contains: (c) if the medicine is intended to be, or is, registered goods, and (i) subsection 8(2) does not apply, then the names, and quantities or proportions, of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres; or (ii) subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.",
            " 8 Information to be included on the label (2) (c) The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is intended to be registered goods and subsection 8(2) applies, what information is not required to be displayed on the label according to section 9(5)(c)?",
                    "Answer": "The names and quantities or proportions of the active ingredients are not required to be displayed on the side or rear panel or label.",
                    "Answer Explanation": "According to section 9(5)(c)(ii), if the medicine is intended to be registered goods and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. This means the names and quantities or proportions of the active ingredients do not need to be displayed on the side or rear panel or label in this case."
                },
                {
                    "Question": "Assuming a medicine contains active ingredients and is not intended to be registered goods, what text size must the names and quantities or proportions of the active ingredients be displayed in on the side or rear panel or label?",
                    "Answer": "The names and quantities or proportions of the active ingredients must be displayed in a text size of not less than 2.5 millimetres.",
                    "Answer Explanation": "Section 9(5)(c)(i) states that if the medicine contains active ingredients, is intended to be registered goods, and subsection 8(2) does not apply, then the names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres."
                },
                {
                    "Question": "Assuming the information provided under paragraph 8(2)(b)(i) includes words describing the purpose of the active ingredients, what type of information can this include that is not required by the Order?",
                    "Answer": "The information provided under paragraph 8(2)(b)(i) may include words indicating the pharmacological category or the principal intended actions of the active ingredients that are not required by the Order.",
                    "Answer Explanation": "Section 8(2)(c) allows the information provided under paragraph 8(2)(b)(i) to include words describing the purpose of the active ingredients by indicating the pharmacological category or principal intended actions, even if this information is not required by the Order."
                },
                {
                    "Question": "Assuming a medicine is intended to be registered goods and subsection 8(2) applies, what information may still be optionally included about the active ingredients under paragraph 8(2)(b)(i)?",
                    "Answer": "Even if a medicine is intended to be registered goods and subsection 8(2) applies, the information provided under paragraph 8(2)(b)(i) may still optionally include words indicating the pharmacological category or principal intended actions of the active ingredients.",
                    "Answer Explanation": "Section 9(5)(c)(ii) states that the names and quantities of active ingredients are not required on the label if the medicine is intended to be registered goods and subsection 8(2) applies. However, section 8(2)(c) still allows optional inclusion of words describing the active ingredients' pharmacological category or intended actions under paragraph 8(2)(b)(i), even if not required by the Order."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine is intended to be registered goods and subsection 8(2) applies, what information is not required to be displayed on the label according to section 9(5)(c)?\", \"Answer\": \"The names and quantities or proportions of the active ingredients are not required to be displayed on the side or rear panel or label.\", \"Answer Explanation\": \"According to section 9(5)(c)(ii), if the medicine is intended to be registered goods and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. This means the names and quantities or proportions of the active ingredients do not need to be displayed on the side or rear panel or label in this case.\"}, {\"Question\": \"Assuming a medicine contains active ingredients and is not intended to be registered goods, what text size must the names and quantities or proportions of the active ingredients be displayed in on the side or rear panel or label?\", \"Answer\": \"The names and quantities or proportions of the active ingredients must be displayed in a text size of not less than 2.5 millimetres.\", \"Answer Explanation\": \"Section 9(5)(c)(i) states that if the medicine contains active ingredients, is intended to be registered goods, and subsection 8(2) does not apply, then the names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres.\"}, {\"Question\": \"Assuming the information provided under paragraph 8(2)(b)(i) includes words describing the purpose of the active ingredients, what type of information can this include that is not required by the Order?\", \"Answer\": \"The information provided under paragraph 8(2)(b)(i) may include words indicating the pharmacological category or the principal intended actions of the active ingredients that are not required by the Order.\", \"Answer Explanation\": \"Section 8(2)(c) allows the information provided under paragraph 8(2)(b)(i) to include words describing the purpose of the active ingredients by indicating the pharmacological category or principal intended actions, even if this information is not required by the Order.\"}, {\"Question\": \"Assuming a medicine is intended to be registered goods and subsection 8(2) applies, what information may still be optionally included about the active ingredients under paragraph 8(2)(b)(i)?\", \"Answer\": \"Even if a medicine is intended to be registered goods and subsection 8(2) applies, the information provided under paragraph 8(2)(b)(i) may still optionally include words indicating the pharmacological category or principal intended actions of the active ingredients.\", \"Answer Explanation\": \"Section 9(5)(c)(ii) states that the names and quantities of active ingredients are not required on the label if the medicine is intended to be registered goods and subsection 8(2) applies. However, section 8(2)(c) still allows optional inclusion of words describing the active ingredients' pharmacological category or intended actions under paragraph 8(2)(b)(i), even if not required by the Order.\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            907030000,
            901020000
        ],
        "contexts": [
            " 9 Information to be included on the main label (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then: (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or",
            " 9 Information to be included on the main label (1) Subject to the qualifications and special requirements specified in this section and section 10 of this Order, the information on the main label of the medicine must include: (b) the name(s) of all active ingredients in the medicine; and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is registered and contains exactly 4 active ingredients, is it required for the main label to include the names of all active ingredients?",
                    "Answer": "No",
                    "Answer Explanation": "According to section 9(7)(c), if the medicine is registered, contains four or more active ingredients, and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. Paragraph 9(1)(b) states that the names of all active ingredients must be included on the main label. Therefore, the main label is not required to include the names of all active ingredients in this case."
                },
                {
                    "Question": "Assuming a medicine is not registered and contains 5 active ingredients, is it required for the main label to include the names of all active ingredients?",
                    "Answer": "Yes",
                    "Answer Explanation": "Section 9(7)(c) provides an exception to the requirement in paragraph 9(1)(b) to include the names of all active ingredients on the main label. However, this exception only applies if the medicine is registered goods. Since the medicine in this case is not registered, the exception does not apply and the names of all active ingredients must be included on the main label as per paragraph 9(1)(b)."
                },
                {
                    "Question": "Assuming a medicine is registered and contains 3 active ingredients, is it required for the main label to include the names of all active ingredients?",
                    "Answer": "Yes",
                    "Answer Explanation": "Section 9(7)(c) provides an exception to the requirement in paragraph 9(1)(b) to include the names of all active ingredients on the main label. However, this exception only applies if the medicine contains four or more active ingredients. Since the medicine in this case contains only 3 active ingredients, the exception does not apply and the names of all active ingredients must be included on the main label as per paragraph 9(1)(b)."
                },
                {
                    "Question": "Assuming a medicine is registered, contains 6 active ingredients, and subsection 8(2) does not apply, is it required for the main label to include the names of all active ingredients?",
                    "Answer": "Yes",
                    "Answer Explanation": "Section 9(7)(c) provides an exception to the requirement in paragraph 9(1)(b) to include the names of all active ingredients on the main label. However, this exception only applies if subsection 8(2) applies. Since subsection 8(2) does not apply in this case, the exception does not apply and the names of all active ingredients must be included on the main label as per paragraph 9(1)(b), even though the medicine is registered and contains more than 4 active ingredients."
                }
            ]
        },
        "result_str": "{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming a medicine is registered and contains exactly 4 active ingredients, is it required for the main label to include the names of all active ingredients?\",\n      \"Answer\": \"No\",\n      \"Answer Explanation\": \"According to section 9(7)(c), if the medicine is registered, contains four or more active ingredients, and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. Paragraph 9(1)(b) states that the names of all active ingredients must be included on the main label. Therefore, the main label is not required to include the names of all active ingredients in this case.\"\n    },\n    {\n      \"Question\": \"Assuming a medicine is not registered and contains 5 active ingredients, is it required for the main label to include the names of all active ingredients?\",\n      \"Answer\": \"Yes\",\n      \"Answer Explanation\": \"Section 9(7)(c) provides an exception to the requirement in paragraph 9(1)(b) to include the names of all active ingredients on the main label. However, this exception only applies if the medicine is registered goods. Since the medicine in this case is not registered, the exception does not apply and the names of all active ingredients must be included on the main label as per paragraph 9(1)(b).\"\n    },\n    {\n      \"Question\": \"Assuming a medicine is registered and contains 3 active ingredients, is it required for the main label to include the names of all active ingredients?\",\n      \"Answer\": \"Yes\",\n      \"Answer Explanation\": \"Section 9(7)(c) provides an exception to the requirement in paragraph 9(1)(b) to include the names of all active ingredients on the main label. However, this exception only applies if the medicine contains four or more active ingredients. Since the medicine in this case contains only 3 active ingredients, the exception does not apply and the names of all active ingredients must be included on the main label as per paragraph 9(1)(b).\"\n    },\n    {\n      \"Question\": \"Assuming a medicine is registered, contains 6 active ingredients, and subsection 8(2) does not apply, is it required for the main label to include the names of all active ingredients?\",\n      \"Answer\": \"Yes\",\n      \"Answer Explanation\": \"Section 9(7)(c) provides an exception to the requirement in paragraph 9(1)(b) to include the names of all active ingredients on the main label. However, this exception only applies if subsection 8(2) applies. Since subsection 8(2) does not apply in this case, the exception does not apply and the names of all active ingredients must be included on the main label as per paragraph 9(1)(b), even though the medicine is registered and contains more than 4 active ingredients.\"\n    }\n  ]\n}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            1007000000,
            1001000000
        ],
        "contexts": [
            " 10 Qualifications and special requirements (7) Small containers If: (d) the name(s) of all active ingredients in the medicine, unless there are four or more active ingredients; and the following information is displayed in a text size of not less than 1.5 millimetres:",
            " 10 Qualifications and special requirements (1) Preparations for ophthalmic use In addition to the requirements of sections 8 and 9 above, if a medicine is a preparation for ophthalmic use, the label on the container and on the primary pack or, where subsection 10(7) applies, the primary pack, must include: (e) if the medicine consists of a solid ophthalmic medicine for preparing eye drops for multidose use - the words \u2018for eye drops\u2019."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a small container medicine has 5 active ingredients and is an ophthalmic solid medicine for preparing eye drops for multidose use, what information must be displayed on the label in a text size of at least 1.5 millimeters according to sections 10(1)(e) and 10(7)(d)?",
                    "Answer": "The words 'for eye drops' must be displayed in a text size of at least 1.5 millimeters.",
                    "Answer Explanation": "Section 10(1)(e) requires the words 'for eye drops' to be included on the label for a solid ophthalmic medicine for preparing eye drops for multidose use. Section 10(7)(d) allows the names of active ingredients to be omitted for small container medicines with 4 or more active ingredients, but still requires the information in 10(1)(e) to be displayed in a text size of at least 1.5 millimeters."
                },
                {
                    "Question": "Consider a small container ophthalmic medicine with 3 active ingredients that is not a solid for preparing eye drops. What information about the active ingredients must be displayed on the label based on sections 10(1)(e) and 10(7)(d)?",
                    "Answer": "The names of all 3 active ingredients must be displayed on the label.",
                    "Answer Explanation": "Section 10(7)(d) requires the names of all active ingredients to be displayed for small container medicines with fewer than 4 active ingredients. Section 10(1)(e) does not apply since the medicine is not a solid for preparing eye drops, so there is no exception to the requirement to list the active ingredients."
                },
                {
                    "Question": "For a small container solid ophthalmic medicine for preparing multidose eye drops that has 5 active ingredients, what is the minimum text size allowed for the words 'for eye drops' on the label per sections 10(1)(e) and 10(7)?",
                    "Answer": "The minimum allowed text size for the words 'for eye drops' is 1.5 millimeters.",
                    "Answer Explanation": "Section 10(1)(e) requires including the words 'for eye drops' on the label for solid ophthalmic medicines for preparing multidose eye drops. Section 10(7) specifies that for small container medicines, the information required by 10(1)(e) must be displayed in a text size of at least 1.5 millimeters, regardless of the number of active ingredients."
                },
                {
                    "Question": "Assuming an ophthalmic medicine in a small container is a liquid (not a solid for preparing eye drops) and has 6 active ingredients, what active ingredient information must be on the label and in what minimum text size per sections 10(1)(e) and 10(7)(d)?",
                    "Answer": "The names of the active ingredients are not required on the label for a small container liquid ophthalmic medicine with 6 active ingredients. No minimum text size for active ingredient information is specified.",
                    "Answer Explanation": "Section 10(1)(e) does not apply since the medicine is a liquid, not a solid for preparing eye drops. Section 10(7)(d) allows omitting the names of active ingredients for small container medicines with 4 or more active ingredients. With 6 active ingredients, no active ingredient information is required on the label and no minimum text size for such information is specified."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a small container medicine has 5 active ingredients and is an ophthalmic solid medicine for preparing eye drops for multidose use, what information must be displayed on the label in a text size of at least 1.5 millimeters according to sections 10(1)(e) and 10(7)(d)?\",\n    \"Answer\": \"The words 'for eye drops' must be displayed in a text size of at least 1.5 millimeters.\",\n    \"Answer Explanation\": \"Section 10(1)(e) requires the words 'for eye drops' to be included on the label for a solid ophthalmic medicine for preparing eye drops for multidose use. Section 10(7)(d) allows the names of active ingredients to be omitted for small container medicines with 4 or more active ingredients, but still requires the information in 10(1)(e) to be displayed in a text size of at least 1.5 millimeters.\"\n  },\n  {\n    \"Question\": \"Consider a small container ophthalmic medicine with 3 active ingredients that is not a solid for preparing eye drops. What information about the active ingredients must be displayed on the label based on sections 10(1)(e) and 10(7)(d)?\",\n    \"Answer\": \"The names of all 3 active ingredients must be displayed on the label.\",\n    \"Answer Explanation\": \"Section 10(7)(d) requires the names of all active ingredients to be displayed for small container medicines with fewer than 4 active ingredients. Section 10(1)(e) does not apply since the medicine is not a solid for preparing eye drops, so there is no exception to the requirement to list the active ingredients.\"\n  },\n  {\n    \"Question\": \"For a small container solid ophthalmic medicine for preparing multidose eye drops that has 5 active ingredients, what is the minimum text size allowed for the words 'for eye drops' on the label per sections 10(1)(e) and 10(7)?\",\n    \"Answer\": \"The minimum allowed text size for the words 'for eye drops' is 1.5 millimeters.\",\n    \"Answer Explanation\": \"Section 10(1)(e) requires including the words 'for eye drops' on the label for solid ophthalmic medicines for preparing multidose eye drops. Section 10(7) specifies that for small container medicines, the information required by 10(1)(e) must be displayed in a text size of at least 1.5 millimeters, regardless of the number of active ingredients.\"\n  },\n  {\n    \"Question\": \"Assuming an ophthalmic medicine in a small container is a liquid (not a solid for preparing eye drops) and has 6 active ingredients, what active ingredient information must be on the label and in what minimum text size per sections 10(1)(e) and 10(7)(d)?\",\n    \"Answer\": \"The names of the active ingredients are not required on the label for a small container liquid ophthalmic medicine with 6 active ingredients. No minimum text size for active ingredient information is specified.\",\n    \"Answer Explanation\": \"Section 10(1)(e) does not apply since the medicine is a liquid, not a solid for preparing eye drops. Section 10(7)(d) allows omitting the names of active ingredients for small container medicines with 4 or more active ingredients. With 6 active ingredients, no active ingredient information is required on the label and no minimum text size for such information is specified.\"\n  }\n]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            1009010000,
            800000000
        ],
        "contexts": [
            " 10 Qualifications and special requirements (9) Strip, blister and dial dispenser packs (a) Subject to paragraph (b), if: (i) a medicine consists of individual dosage units such as tablets, capsules, pills, pastilles, cachets, lozenges, pessaries, suppositories or single doses of powder; and (ii) two or more dosage units are individually enclosed in a strip, blister or dial dispenser pack such that the dosage units can only be extracted individually; and (iii) the strip, blister or dial dispenser pack is enclosed in a primary pack, the label of which complies with sections 8 and 9, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iv) the name of the medicine; and (v) the name(s) of all active ingredients in the medicine; and (vi) the quantity or proportion of all active ingredients in the medicine; and (vii) the batch number of the medicine preceded by the batch number prefix; and (viii) the expiry date of the medicine preceded by the expiry date prefix; and (ix) the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor of the medicine.",
            " 8 Information to be included on the label (4) If the information required on the label on the container is obscured by intermediate packaging, then the label on the intermediate packaging must include: (b) the name(s) of all active ingredients in the medicine; and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine consists of tablets individually enclosed in a blister pack, and this blister pack is further enclosed in a primary pack that has a label complying with sections 8 and 9, what information is required to be displayed on the label of the blister pack itself?",
                    "Answer": "The label on the blister pack is only required to display the name of the medicine, the name(s) and quantity or proportion of all active ingredients, the batch number and expiry date with their respective prefixes, and the name of the sponsor, distributor, or identifying registered trademark.",
                    "Answer Explanation": "Section 10(9)(a) states that if the conditions in (i), (ii) and (iii) are met, then the label on the blister pack only needs to include the information specified in (iv) through (ix), rather than fully complying with sections 8 and 9."
                },
                {
                    "Question": "If a medicine label is obscured by intermediate packaging, and the medicine consists of tablets in a blister pack further enclosed in a primary pack whose label complies with sections 8 and 9, is the name of the active ingredient required on both the intermediate packaging label and the blister pack label?",
                    "Answer": "Yes, the name(s) of all active ingredients is required on both the label of the intermediate packaging (section 8(4)(b)) and the label of the blister pack itself (section 10(9)(a)(v)).",
                    "Answer Explanation": "Section 8(4) states that if the label is obscured by intermediate packaging, the intermediate packaging label must include the name(s) of active ingredients. Additionally, section 10(9)(a)(v) requires the blister pack label to include the name(s) of active ingredients, even if the primary pack label complies with sections 8 and 9."
                },
                {
                    "Question": "Supposing a blister pack containing tablets is enclosed in a primary pack with a label complying with sections 8 and 9, and this primary pack is further enclosed in intermediate packaging that obscures the primary label. Is the expiry date of the medicine required to be on the label of the intermediate packaging?",
                    "Answer": "No, the expiry date is not explicitly required on the label of the intermediate packaging. It is only required on the blister pack label (section 10(9)(a)(viii)) and implicitly on the primary pack label by virtue of complying with sections 8 and 9.",
                    "Answer Explanation": "Section 8(4) lists the information required on the intermediate packaging label if it obscures the primary label, which includes the name(s) of active ingredients (8(4)(b)) but not the expiry date. The expiry date is required on the blister pack label as per section 10(9)(a)(viii)."
                },
                {
                    "Question": "In the case of a medicine consisting of single doses of powder individually enclosed in a dial dispenser pack, which is further enclosed in a primary pack with a label complying with sections 8 and 9, what prefix must be used before the batch number on the dial dispenser pack label?",
                    "Answer": "The batch number prefix must be used before the batch number on the dial dispenser pack label, as specified in section 10(9)(a)(vii).",
                    "Answer Explanation": "Section 10(9)(a) covers medicines with dosage units in strip, blister or dial dispenser packs. Sub-section (vii) states that the batch number on these inner pack labels must be preceded by the batch number prefix, even if the outer primary pack label complies with sections 8 and 9 which cover general labelling requirements."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a medicine consists of tablets individually enclosed in a blister pack, and this blister pack is further enclosed in a primary pack that has a label complying with sections 8 and 9, what information is required to be displayed on the label of the blister pack itself?\",\n    \"Answer\": \"The label on the blister pack is only required to display the name of the medicine, the name(s) and quantity or proportion of all active ingredients, the batch number and expiry date with their respective prefixes, and the name of the sponsor, distributor, or identifying registered trademark.\",\n    \"Answer Explanation\": \"Section 10(9)(a) states that if the conditions in (i), (ii) and (iii) are met, then the label on the blister pack only needs to include the information specified in (iv) through (ix), rather than fully complying with sections 8 and 9.\"\n  },\n  {\n    \"Question\": \"If a medicine label is obscured by intermediate packaging, and the medicine consists of tablets in a blister pack further enclosed in a primary pack whose label complies with sections 8 and 9, is the name of the active ingredient required on both the intermediate packaging label and the blister pack label?\",\n    \"Answer\": \"Yes, the name(s) of all active ingredients is required on both the label of the intermediate packaging (section 8(4)(b)) and the label of the blister pack itself (section 10(9)(a)(v)).\",\n    \"Answer Explanation\": \"Section 8(4) states that if the label is obscured by intermediate packaging, the intermediate packaging label must include the name(s) of active ingredients. Additionally, section 10(9)(a)(v) requires the blister pack label to include the name(s) of active ingredients, even if the primary pack label complies with sections 8 and 9.\"\n  },\n  {\n    \"Question\": \"Supposing a blister pack containing tablets is enclosed in a primary pack with a label complying with sections 8 and 9, and this primary pack is further enclosed in intermediate packaging that obscures the primary label. Is the expiry date of the medicine required to be on the label of the intermediate packaging?\",\n    \"Answer\": \"No, the expiry date is not explicitly required on the label of the intermediate packaging. It is only required on the blister pack label (section 10(9)(a)(viii)) and implicitly on the primary pack label by virtue of complying with sections 8 and 9.\",\n    \"Answer Explanation\": \"Section 8(4) lists the information required on the intermediate packaging label if it obscures the primary label, which includes the name(s) of active ingredients (8(4)(b)) but not the expiry date. The expiry date is required on the blister pack label as per section 10(9)(a)(viii).\"\n  },\n  {\n    \"Question\": \"In the case of a medicine consisting of single doses of powder individually enclosed in a dial dispenser pack, which is further enclosed in a primary pack with a label complying with sections 8 and 9, what prefix must be used before the batch number on the dial dispenser pack label?\",\n    \"Answer\": \"The batch number prefix must be used before the batch number on the dial dispenser pack label, as specified in section 10(9)(a)(vii).\",\n    \"Answer Explanation\": \"Section 10(9)(a) covers medicines with dosage units in strip, blister or dial dispenser packs. Sub-section (vii) states that the batch number on these inner pack labels must be preceded by the batch number prefix, even if the outer primary pack label complies with sections 8 and 9 which cover general labelling requirements.\"\n  }\n]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            910020000,
            911000000
        ],
        "contexts": [
            " 9 Information to be included on the main label (10) Subsection 9(9) does not apply: (b) where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2\u2014after 30 April 2026; or",
            " 9 Information to be included on the main label (11) An active ingredient specified in Part 1 of Schedule 2, either alone or in combination with any other descriptors, may be included on the main label of a medicine containing that ingredient as specified in that Part for medicine released for supply before 1 May 2026."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine containing an active ingredient specified in Part 1 of Schedule 2 is supplied in a small container and is not labelled in accordance with subsection 9(11) and Part 1 of Schedule 2, does subsection 9(9) apply to the medicine's main label after 30 April 2026?",
                    "Answer": "Yes, subsection 9(9) applies in this case.",
                    "Answer Explanation": "According to subsection 9(10)(b), subsection 9(9) does not apply where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2, after 30 April 2026. However, the question states that the medicine is supplied in a small container and is not labelled according to 9(11) and Part 1 of Schedule 2. Therefore, the exception in 9(10)(b) does not apply, meaning subsection 9(9) does apply to the medicine's main label after 30 April 2026."
                },
                {
                    "Question": "Assuming a medicine containing an active ingredient specified in Part 1 of Schedule 2 is not supplied in a small container, can the active ingredient be included on the main label as per Part 1 of Schedule 2 for medicine released for supply on 1 June 2026?",
                    "Answer": "No, the active ingredient cannot be included on the main label as per Part 1 of Schedule 2 in this case.",
                    "Answer Explanation": "Subsection 9(11) states that an active ingredient specified in Part 1 of Schedule 2 may be included on the main label of a medicine containing that ingredient as specified in that Part for medicine released for supply before 1 May 2026. However, the question concerns medicine released for supply on 1 June 2026, which is after the 1 May 2026 cutoff date. Therefore, subsection 9(11) does not apply, and the active ingredient cannot be included on the main label as per Part 1 of Schedule 2."
                },
                {
                    "Question": "Assuming a medicine containing an active ingredient specified in Part 1 of Schedule 2 is supplied in a small container and is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2, does subsection 9(9) apply to the medicine's main label before 1 May 2026?",
                    "Answer": "Yes, subsection 9(9) applies in this case.",
                    "Answer Explanation": "Subsection 9(10)(b) provides an exception where subsection 9(9) does not apply, but this exception only takes effect after 30 April 2026. The question concerns the applicability of subsection 9(9) before 1 May 2026. Since the exception in 9(10)(b) is not yet in effect during this time period, subsection 9(9) does apply to the medicine's main label, even though the medicine is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2."
                },
                {
                    "Question": "Assuming a medicine containing an active ingredient specified in Part 1 of Schedule 2 is not supplied in a small container and is not labelled in accordance with subsection 9(11) and Part 1 of Schedule 2, does subsection 9(9) apply to the medicine's main label after 30 April 2026?",
                    "Answer": "Yes, subsection 9(9) applies in this case.",
                    "Answer Explanation": "According to subsection 9(10)(b), subsection 9(9) does not apply where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2, after 30 April 2026. In this case, although the medicine is not supplied in a small container, it is also not labelled in accordance with subsection 9(11) and Part 1 of Schedule 2. Therefore, the exception in 9(10)(b) does not apply, meaning subsection 9(9) does apply to the medicine's main label after 30 April 2026."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine containing an active ingredient specified in Part 1 of Schedule 2 is supplied in a small container and is not labelled in accordance with subsection 9(11) and Part 1 of Schedule 2, does subsection 9(9) apply to the medicine's main label after 30 April 2026?\", \"Answer\": \"Yes, subsection 9(9) applies in this case.\", \"Answer Explanation\": \"According to subsection 9(10)(b), subsection 9(9) does not apply where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2, after 30 April 2026. However, the question states that the medicine is supplied in a small container and is not labelled according to 9(11) and Part 1 of Schedule 2. Therefore, the exception in 9(10)(b) does not apply, meaning subsection 9(9) does apply to the medicine's main label after 30 April 2026.\"}, {\"Question\": \"Assuming a medicine containing an active ingredient specified in Part 1 of Schedule 2 is not supplied in a small container, can the active ingredient be included on the main label as per Part 1 of Schedule 2 for medicine released for supply on 1 June 2026?\", \"Answer\": \"No, the active ingredient cannot be included on the main label as per Part 1 of Schedule 2 in this case.\", \"Answer Explanation\": \"Subsection 9(11) states that an active ingredient specified in Part 1 of Schedule 2 may be included on the main label of a medicine containing that ingredient as specified in that Part for medicine released for supply before 1 May 2026. However, the question concerns medicine released for supply on 1 June 2026, which is after the 1 May 2026 cutoff date. Therefore, subsection 9(11) does not apply, and the active ingredient cannot be included on the main label as per Part 1 of Schedule 2.\"}, {\"Question\": \"Assuming a medicine containing an active ingredient specified in Part 1 of Schedule 2 is supplied in a small container and is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2, does subsection 9(9) apply to the medicine's main label before 1 May 2026?\", \"Answer\": \"Yes, subsection 9(9) applies in this case.\", \"Answer Explanation\": \"Subsection 9(10)(b) provides an exception where subsection 9(9) does not apply, but this exception only takes effect after 30 April 2026. The question concerns the applicability of subsection 9(9) before 1 May 2026. Since the exception in 9(10)(b) is not yet in effect during this time period, subsection 9(9) does apply to the medicine's main label, even though the medicine is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2.\"}, {\"Question\": \"Assuming a medicine containing an active ingredient specified in Part 1 of Schedule 2 is not supplied in a small container and is not labelled in accordance with subsection 9(11) and Part 1 of Schedule 2, does subsection 9(9) apply to the medicine's main label after 30 April 2026?\", \"Answer\": \"Yes, subsection 9(9) applies in this case.\", \"Answer Explanation\": \"According to subsection 9(10)(b), subsection 9(9) does not apply where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2, after 30 April 2026. In this case, although the medicine is not supplied in a small container, it is also not labelled in accordance with subsection 9(11) and Part 1 of Schedule 2. Therefore, the exception in 9(10)(b) does not apply, meaning subsection 9(9) does apply to the medicine's main label after 30 April 2026.\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            907030000,
            802000000
        ],
        "contexts": [
            " 9 Information to be included on the main label (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then: (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or",
            " 8 Information to be included on the label (2) (b) The critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine contains 5 active ingredients and is intended to be registered goods, what information must be included on the main label according to the given regulation sections?",
                    "Answer": "The medicine is not required to list the active ingredients or their quantities on the main label.",
                    "Answer Explanation": "Section 9(7)(c) states that if a medicine contains four or more active ingredients and section 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. Since the medicine has 5 active ingredients and is intended to be registered goods, it falls under this exception and does not need to list the active ingredients or quantities on the main label."
                },
                {
                    "Question": "For a medicine label where section 8(2)(b) applies, in what order must the critical health information be presented?",
                    "Answer": "The critical health information must be presented in the following order: (i) Active ingredients, (ii) Indications, (iii) Warnings, (iv) Directions for use, (v) Other information.",
                    "Answer Explanation": "Section 8(2)(b) clearly specifies the required order for presenting the critical health information on the label under appropriate headings: (i) Active ingredients, (ii) Indications, (iii) Warnings, (iv) Directions for use, (v) Other information."
                },
                {
                    "Question": "Assuming a medicine contains 6 active ingredients, is intended to be registered goods, and section 8(2) applies, what information about the active ingredients must be included on the main label?",
                    "Answer": "The medicine is not required to include information about the active ingredients on the main label.",
                    "Answer Explanation": "According to section 9(7)(c), if a medicine contains four or more active ingredients and section 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. Since the medicine has 6 active ingredients, is intended to be registered goods, and section 8(2) applies, it is exempt from including active ingredient information on the main label as per 9(1)(b) and 9(1)(c)."
                },
                {
                    "Question": "Under the given regulation sections, if a medicine label must present critical health information according to section 8(2)(b), which of the following would be presented first: warnings or directions for use?",
                    "Answer": "According to section 8(2)(b), warnings would be presented before directions for use in the required order of critical health information on the medicine label.",
                    "Answer Explanation": "Section 8(2)(b) mandates the order in which critical health information must be presented on a medicine label. In the specified order, warnings (listed third) come before directions for use (listed fourth). Therefore, on a label complying with 8(2)(b), the warnings would be presented first, followed by the directions for use."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine contains 5 active ingredients and is intended to be registered goods, what information must be included on the main label according to the given regulation sections?\", \"Answer\": \"The medicine is not required to list the active ingredients or their quantities on the main label.\", \"Answer Explanation\": \"Section 9(7)(c) states that if a medicine contains four or more active ingredients and section 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. Since the medicine has 5 active ingredients and is intended to be registered goods, it falls under this exception and does not need to list the active ingredients or quantities on the main label.\"}, {\"Question\": \"For a medicine label where section 8(2)(b) applies, in what order must the critical health information be presented?\", \"Answer\": \"The critical health information must be presented in the following order: (i) Active ingredients, (ii) Indications, (iii) Warnings, (iv) Directions for use, (v) Other information.\", \"Answer Explanation\": \"Section 8(2)(b) clearly specifies the required order for presenting the critical health information on the label under appropriate headings: (i) Active ingredients, (ii) Indications, (iii) Warnings, (iv) Directions for use, (v) Other information.\"}, {\"Question\": \"Assuming a medicine contains 6 active ingredients, is intended to be registered goods, and section 8(2) applies, what information about the active ingredients must be included on the main label?\", \"Answer\": \"The medicine is not required to include information about the active ingredients on the main label.\", \"Answer Explanation\": \"According to section 9(7)(c), if a medicine contains four or more active ingredients and section 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. Since the medicine has 6 active ingredients, is intended to be registered goods, and section 8(2) applies, it is exempt from including active ingredient information on the main label as per 9(1)(b) and 9(1)(c).\"}, {\"Question\": \"Under the given regulation sections, if a medicine label must present critical health information according to section 8(2)(b), which of the following would be presented first: warnings or directions for use?\", \"Answer\": \"According to section 8(2)(b), warnings would be presented before directions for use in the required order of critical health information on the medicine label.\", \"Answer Explanation\": \"Section 8(2)(b) mandates the order in which critical health information must be presented on a medicine label. In the specified order, warnings (listed third) come before directions for use (listed fourth). Therefore, on a label complying with 8(2)(b), the warnings would be presented first, followed by the directions for use.\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            903020000,
            1102090000
        ],
        "contexts": [
            " 9 Information to be included on the main label (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must: (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;",
            " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (i) In addition to the requirements of paragraphs 11(2)(a) \u201311(2)(g), the following requirements apply in the circumstances specified in the following subparagraphs: (i) where the active ingredient is a herbal material, such as a dry, fresh, milled or powdered herb, as the weight of the herbal material; except where standardisation is claimed on the label, then the minimum dry or fresh weight of herbal material and also the quantity of standardised constituents(s) in the herbal material; (ii) where the active ingredient is a herbal preparation, as the dry or fresh weight of the herbal material from which the preparation was derived except: (A) where standardisation of the herbal preparation is claimed on the label, then, the minimum dry or fresh weight of herbal material from which the preparation is derived and the quantity of standardised constituents(s) in the herbal preparation; or (B) where the active ingredient is a herbal preparation that is an essential oil; (iii) where the active ingredient is an enzyme \u2013the activity unit as specified in Column 1 of Schedule 3 to this Order in relation to a particular enzyme set out in Column 3 of that Schedule; (iv) for preparations containing Vitamin A or a derivative of Vitamin A - as the quantity or proportion of Vitamin A expressed in terms of microgram retinol equivalents; (v) for preparations containing biological organisms - as the number of organisms present per metric unit for liquids and powders and as the number of organisms present per dosage unit for other dosage forms;"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a non-prescription medicine contains a single active ingredient that is a herbal preparation where standardisation is claimed on the label, what information must be included on the main label of the medicine, and how must it be expressed?",
                    "Answer": "The main label must include the name of the medicine and the name of the active ingredient expressed as the minimum dry or fresh weight of herbal material from which the preparation is derived and the quantity of standardised constituent(s) in the herbal preparation.",
                    "Answer Explanation": "According to paragraph 9(3)(b), the name of the medicine and name of active ingredient must not be separated by any text or graphics on the main label, with some exceptions. Subparagraph 11(2)(i)(ii)(A) states that for a herbal preparation where standardisation is claimed, the quantity of the active ingredient must be expressed as the minimum dry or fresh weight of herbal material from which it's derived and the quantity of standardised constituents in the preparation."
                },
                {
                    "Question": "Assuming a non-prescription medicine contains multiple active ingredients that are all herbal materials with no standardisation claimed, what information must be on the main label, and how must the quantities of the ingredients be expressed?",
                    "Answer": "The main label must include the name of the medicine and the names of all the active ingredients, with no text or graphics separating them. The quantities of each herbal material active ingredient must be expressed as their weight.",
                    "Answer Explanation": "Paragraph 9(3)(b) requires the name of the medicine and names of active ingredients to be on the main label with no intervening text or graphics, unless the additional information is permitted by certain other provisions. For multiple herbal material active ingredients with no standardisation, none of those exceptions apply. Subparagraph 11(2)(i)(i) states that quantities of herbal material active ingredients must be expressed as their weight when no standardisation is claimed."
                },
                {
                    "Question": "For a non-prescription medicine containing an active ingredient that is Vitamin A, assuming the main label must also identify different formulations of the medicine, how must the name of the medicine, name of the active ingredient, and quantity of the active ingredient be expressed on the main label?",
                    "Answer": "The name of the medicine and name of the active ingredient (Vitamin A) must be on the main label, and may be separated by text or graphics that identify the different formulations of the medicine. The quantity of Vitamin A must be expressed in terms of microgram retinol equivalents.",
                    "Answer Explanation": "Paragraph 9(3)(b) allows the name of the medicine and active ingredient to be separated by text or graphics that identify different formulations, as an exception to the general rule. Subparagraph 11(2)(i)(iv) specifies that for active ingredients that are Vitamin A or Vitamin A derivatives, the quantity must be expressed as micrograms of retinol equivalents."
                },
                {
                    "Question": "Assuming a non-prescription medicine kit contains multiple medicines with active ingredients that are biological organisms in liquid and tablet forms, what information must be on the main label and how must the quantities of the active ingredients be expressed?",
                    "Answer": "The main label must include the names of the medicines and the names of the active ingredients. Text or graphics may separate these to identify the different component medicines. For liquid medicines, quantities of the biological organisms must be expressed as number of organisms per metric unit. For tablets, quantities must be number of organisms per dosage unit.",
                    "Answer Explanation": "Per paragraph 9(3)(b), medicine and active ingredient names can be separated by text\/graphics to identify kit components. Subparagraph 11(2)(i)(v) requires quantities of biological organisms to be expressed as number per metric unit for liquids\/powders, and as number per dosage unit for other forms like tablets."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a non-prescription medicine contains a single active ingredient that is a herbal preparation where standardisation is claimed on the label, what information must be included on the main label of the medicine, and how must it be expressed?\",\n    \"Answer\": \"The main label must include the name of the medicine and the name of the active ingredient expressed as the minimum dry or fresh weight of herbal material from which the preparation is derived and the quantity of standardised constituent(s) in the herbal preparation.\",\n    \"Answer Explanation\": \"According to paragraph 9(3)(b), the name of the medicine and name of active ingredient must not be separated by any text or graphics on the main label, with some exceptions. Subparagraph 11(2)(i)(ii)(A) states that for a herbal preparation where standardisation is claimed, the quantity of the active ingredient must be expressed as the minimum dry or fresh weight of herbal material from which it's derived and the quantity of standardised constituents in the preparation.\"\n  },\n  {\n    \"Question\": \"Assuming a non-prescription medicine contains multiple active ingredients that are all herbal materials with no standardisation claimed, what information must be on the main label, and how must the quantities of the ingredients be expressed?\",\n    \"Answer\": \"The main label must include the name of the medicine and the names of all the active ingredients, with no text or graphics separating them. The quantities of each herbal material active ingredient must be expressed as their weight.\",\n    \"Answer Explanation\": \"Paragraph 9(3)(b) requires the name of the medicine and names of active ingredients to be on the main label with no intervening text or graphics, unless the additional information is permitted by certain other provisions. For multiple herbal material active ingredients with no standardisation, none of those exceptions apply. Subparagraph 11(2)(i)(i) states that quantities of herbal material active ingredients must be expressed as their weight when no standardisation is claimed.\"\n  },\n  {\n    \"Question\": \"For a non-prescription medicine containing an active ingredient that is Vitamin A, assuming the main label must also identify different formulations of the medicine, how must the name of the medicine, name of the active ingredient, and quantity of the active ingredient be expressed on the main label?\",\n    \"Answer\": \"The name of the medicine and name of the active ingredient (Vitamin A) must be on the main label, and may be separated by text or graphics that identify the different formulations of the medicine. The quantity of Vitamin A must be expressed in terms of microgram retinol equivalents.\",\n    \"Answer Explanation\": \"Paragraph 9(3)(b) allows the name of the medicine and active ingredient to be separated by text or graphics that identify different formulations, as an exception to the general rule. Subparagraph 11(2)(i)(iv) specifies that for active ingredients that are Vitamin A or Vitamin A derivatives, the quantity must be expressed as micrograms of retinol equivalents.\"\n  },\n  {\n    \"Question\": \"Assuming a non-prescription medicine kit contains multiple medicines with active ingredients that are biological organisms in liquid and tablet forms, what information must be on the main label and how must the quantities of the active ingredients be expressed?\",\n    \"Answer\": \"The main label must include the names of the medicines and the names of the active ingredients. Text or graphics may separate these to identify the different component medicines. For liquid medicines, quantities of the biological organisms must be expressed as number of organisms per metric unit. For tablets, quantities must be number of organisms per dosage unit.\",\n    \"Answer Explanation\": \"Per paragraph 9(3)(b), medicine and active ingredient names can be separated by text\/graphics to identify kit components. Subparagraph 11(2)(i)(v) requires quantities of biological organisms to be expressed as number per metric unit for liquids\/powders, and as number per dosage unit for other forms like tablets.\"\n  }\n]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            1102080000,
            1102040000
        ],
        "contexts": [
            " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (h) for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation.",
            " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (d) for a medicine required to be prepared before use, and: (i) where the process results in a medicine that is a liquid for ingestion: (A) as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid after preparation in accordance with the instructions set out on the label of the medicine; or (B) in the case where the medicine is one of a series of strengths containing the same active ingredient - as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid after preparation in accordance with the instructions set out on the label of the medicine with the quantity or proportion of active ingredient expressed consistently across the series in terms of the same stated dose volume; and Example: Where the dose volume is 5 mL after preparation, and there are strengths of 1 mg\/mL and 5 mg\/mL, these must be labelled as 5 mg in 5 mL and 25 mg in 5 mL, respectively. (ii) for any other medicines - as the weight or volume of active ingredient in a stated weight or volume of the medicine, after preparation in accordance with the instructions included in the label of the medicine;"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a liquid oral mineral supplement that contains iron as the active ingredient, how should the quantity of iron be expressed on the label?",
                    "Answer": "The quantity of iron should be expressed as the name of the active ingredient (iron) and the name and quantity of the element intended for mineral supplementation (e.g., Iron (as ferrous sulfate) 5 mg).",
                    "Answer Explanation": "According to 11(2)(h), for oral preparations containing active ingredients intended for mineral supplementation, the quantity of the active ingredient can be expressed as the name of the active ingredient and the name and quantity of the element intended for mineral supplementation. This applies to the given scenario of a liquid oral mineral supplement containing iron."
                },
                {
                    "Question": "Consider a medicine that needs to be prepared before use, resulting in a liquid for ingestion. The medicine is part of a series of strengths containing the same active ingredient. How should the quantity of the active ingredient be expressed on the label to ensure consistency across the series?",
                    "Answer": "The quantity of the active ingredient should be expressed as the quantity contained in the same stated volume of a suitable dose of the liquid after preparation, consistently across the series. For example, if the dose volume is 5 mL after preparation and there are strengths of 1 mg\/mL and 5 mg\/mL, they should be labeled as 5 mg in 5 mL and 25 mg in 5 mL, respectively.",
                    "Answer Explanation": "11(2)(d)(i)(B) states that for a medicine required to be prepared before use, resulting in a liquid for ingestion, and is part of a series of strengths with the same active ingredient, the quantity of the active ingredient should be expressed as the quantity contained in the same stated dose volume across the series after preparation. The provided example illustrates this requirement."
                },
                {
                    "Question": "For a medicine that needs to be prepared before use but does not result in a liquid for ingestion, how should the quantity of the active ingredient be expressed on the label?",
                    "Answer": "For a medicine that needs to be prepared before use but does not result in a liquid for ingestion, the quantity of the active ingredient should be expressed as the weight or volume of the active ingredient in a stated weight or volume of the medicine after preparation according to the instructions on the label.",
                    "Answer Explanation": "11(2)(d)(ii) specifies that for medicines required to be prepared before use, but not resulting in a liquid for ingestion, the quantity of the active ingredient should be expressed as the weight or volume of the active ingredient in a stated weight or volume of the medicine after preparation following the label instructions."
                },
                {
                    "Question": "Assuming an oral liquid mineral supplement containing calcium, is it acceptable to express the quantity of calcium on the label as just the weight of the active ingredient per unit volume (e.g., 500 mg\/5 mL)?",
                    "Answer": "No, it is not sufficient to express the quantity of calcium as just the weight per unit volume for an oral liquid mineral supplement. The label must include both the name of the active ingredient (calcium) and the name and quantity of the element intended for mineral supplementation (e.g., Calcium (as calcium carbonate) 500 mg).",
                    "Answer Explanation": "According to 11(2)(h), for oral preparations containing active ingredients for mineral supplementation, the label must include both the name of the active ingredient and the name and quantity of the element intended for mineral supplementation. Simply expressing the weight per unit volume does not meet this requirement."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a liquid oral mineral supplement that contains iron as the active ingredient, how should the quantity of iron be expressed on the label?\",\n    \"Answer\": \"The quantity of iron should be expressed as the name of the active ingredient (iron) and the name and quantity of the element intended for mineral supplementation (e.g., Iron (as ferrous sulfate) 5 mg).\",\n    \"Answer Explanation\": \"According to 11(2)(h), for oral preparations containing active ingredients intended for mineral supplementation, the quantity of the active ingredient can be expressed as the name of the active ingredient and the name and quantity of the element intended for mineral supplementation. This applies to the given scenario of a liquid oral mineral supplement containing iron.\"\n  },\n  {\n    \"Question\": \"Consider a medicine that needs to be prepared before use, resulting in a liquid for ingestion. The medicine is part of a series of strengths containing the same active ingredient. How should the quantity of the active ingredient be expressed on the label to ensure consistency across the series?\",\n    \"Answer\": \"The quantity of the active ingredient should be expressed as the quantity contained in the same stated volume of a suitable dose of the liquid after preparation, consistently across the series. For example, if the dose volume is 5 mL after preparation and there are strengths of 1 mg\/mL and 5 mg\/mL, they should be labeled as 5 mg in 5 mL and 25 mg in 5 mL, respectively.\",\n    \"Answer Explanation\": \"11(2)(d)(i)(B) states that for a medicine required to be prepared before use, resulting in a liquid for ingestion, and is part of a series of strengths with the same active ingredient, the quantity of the active ingredient should be expressed as the quantity contained in the same stated dose volume across the series after preparation. The provided example illustrates this requirement.\"\n  },\n  {\n    \"Question\": \"For a medicine that needs to be prepared before use but does not result in a liquid for ingestion, how should the quantity of the active ingredient be expressed on the label?\",\n    \"Answer\": \"For a medicine that needs to be prepared before use but does not result in a liquid for ingestion, the quantity of the active ingredient should be expressed as the weight or volume of the active ingredient in a stated weight or volume of the medicine after preparation according to the instructions on the label.\",\n    \"Answer Explanation\": \"11(2)(d)(ii) specifies that for medicines required to be prepared before use, but not resulting in a liquid for ingestion, the quantity of the active ingredient should be expressed as the weight or volume of the active ingredient in a stated weight or volume of the medicine after preparation following the label instructions.\"\n  },\n  {\n    \"Question\": \"Assuming an oral liquid mineral supplement containing calcium, is it acceptable to express the quantity of calcium on the label as just the weight of the active ingredient per unit volume (e.g., 500 mg\/5 mL)?\",\n    \"Answer\": \"No, it is not sufficient to express the quantity of calcium as just the weight per unit volume for an oral liquid mineral supplement. The label must include both the name of the active ingredient (calcium) and the name and quantity of the element intended for mineral supplementation (e.g., Calcium (as calcium carbonate) 500 mg).\",\n    \"Answer Explanation\": \"According to 11(2)(h), for oral preparations containing active ingredients for mineral supplementation, the label must include both the name of the active ingredient and the name and quantity of the element intended for mineral supplementation. Simply expressing the weight per unit volume does not meet this requirement.\"\n  }\n]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            1008030000,
            800000000
        ],
        "contexts": [
            " 10 Qualifications and special requirements (8) Individually wrapped medicines (c) Where: (i) a medicine consists of dry herbs contained in individual bags and the bag is retained around the herbs during preparation; (ii) the bags are contained in a primary pack, the label of which complies with the requirements of this Order, then the individual bag need not be labelled with the information referred to in sections 8 and 9.",
            " 8 Information to be included on the label (4) If the information required on the label on the container is obscured by intermediate packaging, then the label on the intermediate packaging must include: (a) the name of the medicine; and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming an individually wrapped medicine consists of dry herbs contained in individual bags that are retained during preparation and the bags are in a labeled primary pack, do the individual bags need to be labeled with the information from sections 8 and 9?",
                    "Answer": "No",
                    "Answer Explanation": "According to section 10(8)(c), if a medicine consists of dry herbs in individual bags retained during preparation, and the bags are in a primary pack with a label complying with the Order, then the individual bags do not need to be labeled with the information from sections 8 and 9."
                },
                {
                    "Question": "Assuming a medicine label is obscured by intermediate packaging, what information must be included on the label of the intermediate packaging?",
                    "Answer": "The name of the medicine",
                    "Answer Explanation": "Section 8(4)(a) states that if the information required on the medicine container label is obscured by intermediate packaging, then the label on the intermediate packaging must include the name of the medicine."
                },
                {
                    "Question": "Assuming a medicine consists of dry herbs in individual unlabeled bags within a labeled primary pack, and the primary pack label is then obscured by intermediate packaging, what information must be on the intermediate packaging label?",
                    "Answer": "The name of the medicine",
                    "Answer Explanation": "Section 10(8)(c) allows the individual herb bags to be unlabeled if they are in a primary pack with a compliant label. However, section 8(4)(a) requires that if that primary pack label is obscured by intermediate packaging, the intermediate packaging label must include the medicine name."
                },
                {
                    "Question": "Assuming a medicine consists of dry herbs in individual bags that are discarded before preparation, and the bags are in a primary pack with a label complying with the Order, do the individual bags need to include the information from sections 8 and 9?",
                    "Answer": "Yes",
                    "Answer Explanation": "Section 10(8)(c) only exempts individual herb bags from the labeling requirements in sections 8 and 9 if the bags are retained around the herbs during preparation. If the bags are discarded before preparation, this exemption does not apply and the bags must be labeled according to sections 8 and 9."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming an individually wrapped medicine consists of dry herbs contained in individual bags that are retained during preparation and the bags are in a labeled primary pack, do the individual bags need to be labeled with the information from sections 8 and 9?\", \"Answer\": \"No\", \"Answer Explanation\": \"According to section 10(8)(c), if a medicine consists of dry herbs in individual bags retained during preparation, and the bags are in a primary pack with a label complying with the Order, then the individual bags do not need to be labeled with the information from sections 8 and 9.\"}, {\"Question\": \"Assuming a medicine label is obscured by intermediate packaging, what information must be included on the label of the intermediate packaging?\", \"Answer\": \"The name of the medicine\", \"Answer Explanation\": \"Section 8(4)(a) states that if the information required on the medicine container label is obscured by intermediate packaging, then the label on the intermediate packaging must include the name of the medicine.\"}, {\"Question\": \"Assuming a medicine consists of dry herbs in individual unlabeled bags within a labeled primary pack, and the primary pack label is then obscured by intermediate packaging, what information must be on the intermediate packaging label?\", \"Answer\": \"The name of the medicine\", \"Answer Explanation\": \"Section 10(8)(c) allows the individual herb bags to be unlabeled if they are in a primary pack with a compliant label. However, section 8(4)(a) requires that if that primary pack label is obscured by intermediate packaging, the intermediate packaging label must include the medicine name.\"}, {\"Question\": \"Assuming a medicine consists of dry herbs in individual bags that are discarded before preparation, and the bags are in a primary pack with a label complying with the Order, do the individual bags need to include the information from sections 8 and 9?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"Section 10(8)(c) only exempts individual herb bags from the labeling requirements in sections 8 and 9 if the bags are retained around the herbs during preparation. If the bags are discarded before preparation, this exemption does not apply and the bags must be labeled according to sections 8 and 9.\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            1102080000,
            1102020000
        ],
        "contexts": [
            " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (h) for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation.",
            " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (b) for a solid for ingestion, where there is no discrete dosage unit - as the quantity of the active ingredient contained in the stated weight of a suitable dose of the solid;"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "For an oral preparation containing an active ingredient intended for mineral supplementation, how should the quantity or proportion of the active ingredient be expressed on the label, assuming no other information is given?",
                    "Answer": "The name of the active ingredient and the name and quantity of the element intended for mineral supplementation.",
                    "Answer Explanation": "According to 11(2)(h), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as the name of the active ingredient and the name and quantity of the element intended for mineral supplementation."
                },
                {
                    "Question": "For a solid oral preparation with no discrete dosage unit, how should the quantity of the active ingredient be expressed on the label, assuming no exceptions apply?",
                    "Answer": "As the quantity of the active ingredient contained in the stated weight of a suitable dose of the solid.",
                    "Answer Explanation": "According to 11(2)(b), for a solid for ingestion where there is no discrete dosage unit, the quantity of the active ingredient must be expressed as the quantity of the active ingredient contained in the stated weight of a suitable dose of the solid, subject to paragraph 11(2)(i) and subsection 11(3)."
                },
                {
                    "Question": "Assuming an oral preparation contains an active ingredient for mineral supplementation and has no discrete dosage units, how should the quantity of the active ingredient be expressed on the label?",
                    "Answer": "The name of the active ingredient and the name and quantity of the element intended for mineral supplementation.",
                    "Answer Explanation": "11(2)(b) states that for a solid for ingestion with no discrete dosage unit, the quantity of the active ingredient should be expressed as the quantity contained in the stated weight of a suitable dose. However, 11(2)(h) provides an exception for oral preparations containing active ingredients for mineral supplementation, allowing the quantity to be expressed as just the name of the active ingredient and the name and quantity of the element intended for supplementation. Since 11(2)(h) begins with \"Subject to paragraph 11(2)(i) and subsection 11(3)\", it takes precedence over the more general requirement in 11(2)(b)."
                },
                {
                    "Question": "How should the quantity of an active ingredient in an oral preparation be expressed on the label if the preparation has discrete dosage units and the active ingredient is not intended for mineral supplementation, assuming no other exceptions apply?",
                    "Answer": "The quantity of the active ingredient must be expressed according to one of the options in 11(2)(a) - 11(2)(d), such as the quantity per dosage unit combined with the number of units per package.",
                    "Answer Explanation": "11(2) states that the quantity of an active ingredient must be expressed according to the options listed in 11(2)(a) - 11(2)(d), subject to the exceptions in 11(2)(i) and 11(3). 11(2)(h) provides an exception for oral preparations with active ingredients for mineral supplementation. 11(2)(b) applies to solids for ingestion with no discrete dosage units. Since this question specifies the oral preparation has discrete dosage units and the active ingredient is not for mineral supplementation, neither exception applies, so the main requirement to express the quantity according to 11(2)(a) - 11(2)(d) must be followed."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"For an oral preparation containing an active ingredient intended for mineral supplementation, how should the quantity or proportion of the active ingredient be expressed on the label, assuming no other information is given?\", \"Answer\": \"The name of the active ingredient and the name and quantity of the element intended for mineral supplementation.\", \"Answer Explanation\": \"According to 11(2)(h), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as the name of the active ingredient and the name and quantity of the element intended for mineral supplementation.\"}, {\"Question\": \"For a solid oral preparation with no discrete dosage unit, how should the quantity of the active ingredient be expressed on the label, assuming no exceptions apply?\", \"Answer\": \"As the quantity of the active ingredient contained in the stated weight of a suitable dose of the solid.\", \"Answer Explanation\": \"According to 11(2)(b), for a solid for ingestion where there is no discrete dosage unit, the quantity of the active ingredient must be expressed as the quantity of the active ingredient contained in the stated weight of a suitable dose of the solid, subject to paragraph 11(2)(i) and subsection 11(3).\"}, {\"Question\": \"Assuming an oral preparation contains an active ingredient for mineral supplementation and has no discrete dosage units, how should the quantity of the active ingredient be expressed on the label?\", \"Answer\": \"The name of the active ingredient and the name and quantity of the element intended for mineral supplementation.\", \"Answer Explanation\": \"11(2)(b) states that for a solid for ingestion with no discrete dosage unit, the quantity of the active ingredient should be expressed as the quantity contained in the stated weight of a suitable dose. However, 11(2)(h) provides an exception for oral preparations containing active ingredients for mineral supplementation, allowing the quantity to be expressed as just the name of the active ingredient and the name and quantity of the element intended for supplementation. Since 11(2)(h) begins with \\\"Subject to paragraph 11(2)(i) and subsection 11(3)\\\", it takes precedence over the more general requirement in 11(2)(b).\"}, {\"Question\": \"How should the quantity of an active ingredient in an oral preparation be expressed on the label if the preparation has discrete dosage units and the active ingredient is not intended for mineral supplementation, assuming no other exceptions apply?\", \"Answer\": \"The quantity of the active ingredient must be expressed according to one of the options in 11(2)(a) - 11(2)(d), such as the quantity per dosage unit combined with the number of units per package.\", \"Answer Explanation\": \"11(2) states that the quantity of an active ingredient must be expressed according to the options listed in 11(2)(a) - 11(2)(d), subject to the exceptions in 11(2)(i) and 11(3). 11(2)(h) provides an exception for oral preparations with active ingredients for mineral supplementation. 11(2)(b) applies to solids for ingestion with no discrete dosage units. Since this question specifies the oral preparation has discrete dosage units and the active ingredient is not for mineral supplementation, neither exception applies, so the main requirement to express the quantity according to 11(2)(a) - 11(2)(d) must be followed.\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            802050000,
            802030000
        ],
        "contexts": [
            " 8 Information to be included on the label (2) (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or distributor contact details.",
            " 8 Information to be included on the label (2) (c) The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a non-prescription medicine label includes a pharmacological category for the active ingredient under paragraph 8(2)(b)(i), and the names of all excipients, can the names of the excipients be placed immediately below the information provided under paragraph 8(2)(b)(i)?",
                    "Answer": "No",
                    "Answer Explanation": "According to section 8(2)(e), if information other than the critical health information or information mentioned in 8(2)(c) or 8(2)(d) is included, such as the names of all excipients, it must be placed under the 'Other information' heading or another separate appropriate heading that follows immediately below the headings mentioned in 8(2)(b). It cannot be placed immediately below the pharmacological category information provided under 8(2)(b)(i)."
                },
                {
                    "Question": "Assuming a non-prescription medicine label includes the pharmacological category of the active ingredient under 8(2)(b)(i) and sponsor contact details, can the sponsor contact details be included under the same heading as the pharmacological category?",
                    "Answer": "No",
                    "Answer Explanation": "Section 8(2)(c) allows the pharmacological category of the active ingredient to be included under the information provided in 8(2)(b)(i). However, section 8(2)(e) specifies that sponsor contact details, being information other than critical health information or information in 8(2)(c) and 8(2)(d), must be under the 'Other information' heading or another separate appropriate heading following the headings in 8(2)(b). Therefore, the sponsor details cannot be under the same heading as the pharmacological category from 8(2)(b)(i)."
                },
                {
                    "Question": "If a non-prescription medicine label includes storage condition requirements, information about anti-tampering package features, names of all excipients, and distributor contact details, can all of this information be placed together under a single heading labeled 'Additional Details'?",
                    "Answer": "Yes",
                    "Answer Explanation": "Section 8(2)(e) states that if information other than critical health information or that mentioned in 8(2)(c) and 8(2)(d) is included, it must be placed under the 'Other information' heading or another separate appropriate heading following the 8(2)(b) headings. The listed items - storage conditions, tamper evident packaging info, excipient names, and distributor contact details - all fall into this 'other information' category according to 8(2)(e)(A-D). Therefore, they can be grouped together under a single appropriate heading like 'Additional Details' as long as this follows the 8(2)(b) headings."
                },
                {
                    "Question": "Assuming a non-prescription medicine label properly includes the principal intended actions of the active ingredient under 8(2)(b)(i) as permitted by 8(2)(c), and also includes the names of all excipients, is it acceptable to place the excipient names immediately below the principal intended actions?",
                    "Answer": "No",
                    "Answer Explanation": "Section 8(2)(c) allows the principal intended actions of the active ingredient to be stated under the information required by 8(2)(b)(i). However, according to 8(2)(e), information like the names of all excipients must be placed under the 'Other information' heading or another separate appropriate heading that follows the headings mentioned in 8(2)(b). Therefore, the excipient names cannot be placed immediately below the principal intended actions included under 8(2)(b)(i), but must be under a separate heading following the 8(2)(b) headings."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a non-prescription medicine label includes a pharmacological category for the active ingredient under paragraph 8(2)(b)(i), and the names of all excipients, can the names of the excipients be placed immediately below the information provided under paragraph 8(2)(b)(i)?\", \"Answer\": \"No\", \"Answer Explanation\": \"According to section 8(2)(e), if information other than the critical health information or information mentioned in 8(2)(c) or 8(2)(d) is included, such as the names of all excipients, it must be placed under the 'Other information' heading or another separate appropriate heading that follows immediately below the headings mentioned in 8(2)(b). It cannot be placed immediately below the pharmacological category information provided under 8(2)(b)(i).\"}, {\"Question\": \"Assuming a non-prescription medicine label includes the pharmacological category of the active ingredient under 8(2)(b)(i) and sponsor contact details, can the sponsor contact details be included under the same heading as the pharmacological category?\", \"Answer\": \"No\", \"Answer Explanation\": \"Section 8(2)(c) allows the pharmacological category of the active ingredient to be included under the information provided in 8(2)(b)(i). However, section 8(2)(e) specifies that sponsor contact details, being information other than critical health information or information in 8(2)(c) and 8(2)(d), must be under the 'Other information' heading or another separate appropriate heading following the headings in 8(2)(b). Therefore, the sponsor details cannot be under the same heading as the pharmacological category from 8(2)(b)(i).\"}, {\"Question\": \"If a non-prescription medicine label includes storage condition requirements, information about anti-tampering package features, names of all excipients, and distributor contact details, can all of this information be placed together under a single heading labeled 'Additional Details'?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"Section 8(2)(e) states that if information other than critical health information or that mentioned in 8(2)(c) and 8(2)(d) is included, it must be placed under the 'Other information' heading or another separate appropriate heading following the 8(2)(b) headings. The listed items - storage conditions, tamper evident packaging info, excipient names, and distributor contact details - all fall into this 'other information' category according to 8(2)(e)(A-D). Therefore, they can be grouped together under a single appropriate heading like 'Additional Details' as long as this follows the 8(2)(b) headings.\"}, {\"Question\": \"Assuming a non-prescription medicine label properly includes the principal intended actions of the active ingredient under 8(2)(b)(i) as permitted by 8(2)(c), and also includes the names of all excipients, is it acceptable to place the excipient names immediately below the principal intended actions?\", \"Answer\": \"No\", \"Answer Explanation\": \"Section 8(2)(c) allows the principal intended actions of the active ingredient to be stated under the information required by 8(2)(b)(i). However, according to 8(2)(e), information like the names of all excipients must be placed under the 'Other information' heading or another separate appropriate heading that follows the headings mentioned in 8(2)(b). Therefore, the excipient names cannot be placed immediately below the principal intended actions included under 8(2)(b)(i), but must be under a separate heading following the 8(2)(b) headings.\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            910030000,
            913000000
        ],
        "contexts": [
            " 9 Information to be included on the main label (10) Subsection 9(9) does not apply: (c) where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(13) and Part 2 of Schedule 2\u2014after 30 April 2028. Note: The minimum text size for active ingredients on labels of small containers is less than 2.5 millimetres and specified elsewhere in this Order.",
            " 9 Information to be included on the main label (13) An active ingredient specified in Part 2 of Schedule 2, either alone or in combination with any other descriptors, may be included on the main label of a medicine containing that ingredient as specified in that Part for medicine released for supply before 1 May 2028."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is not supplied in a small container and is labelled according to subsection 9(13) and Part 2 of Schedule 2, will subsection 9(9) apply to it after April 30, 2028?",
                    "Answer": "No",
                    "Answer Explanation": "Subsection 9(10)(c) states that subsection 9(9) does not apply where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(13) and Part 2 of Schedule 2, after 30 April 2028."
                },
                {
                    "Question": "If an active ingredient is specified in Part 2 of Schedule 2, can it be included on the main label of a medicine containing that ingredient as specified in that Part if the medicine is released for supply on May 15, 2028?",
                    "Answer": "No",
                    "Answer Explanation": "According to subsection 9(13), an active ingredient specified in Part 2 of Schedule 2 may be included on the main label of a medicine containing that ingredient as specified in that Part only for medicine released for supply before 1 May 2028."
                },
                {
                    "Question": "Assuming a medicine is not in a small container and its label complies with subsection 9(13) and Part 2 of Schedule 2, what is the earliest date after which subsection 9(9) will not apply to it?",
                    "Answer": "May 1, 2028",
                    "Answer Explanation": "Subsection 9(10)(c) states that subsection 9(9) does not apply after 30 April 2028 for medicines not supplied in a small container and labelled according to subsection 9(13) and Part 2 of Schedule 2. Therefore, the earliest date after which subsection 9(9) will not apply is May 1, 2028."
                },
                {
                    "Question": "If a medicine's active ingredient is listed in Part 2 of Schedule 2 and the medicine is released for supply on April 30, 2028, can the active ingredient be included on the main label as specified in Part 2 of Schedule 2 without complying with subsection 9(9)?",
                    "Answer": "Yes",
                    "Answer Explanation": "Subsection 9(13) allows an active ingredient specified in Part 2 of Schedule 2 to be included on the main label as specified in that Part for medicine released before 1 May 2028. Subsection 9(10)(c) exempts medicines labelled according to subsection 9(13) and Part 2 of Schedule 2 from subsection 9(9) after 30 April 2028. Therefore, a medicine released on April 30, 2028 with an active ingredient listed in Part 2 of Schedule 2 can include the ingredient on the main label as specified without complying with subsection 9(9)."
                }
            ]
        },
        "result_str": "{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming a medicine is not supplied in a small container and is labelled according to subsection 9(13) and Part 2 of Schedule 2, will subsection 9(9) apply to it after April 30, 2028?\",\n      \"Answer\": \"No\",\n      \"Answer Explanation\": \"Subsection 9(10)(c) states that subsection 9(9) does not apply where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(13) and Part 2 of Schedule 2, after 30 April 2028.\"\n    },\n    {\n      \"Question\": \"If an active ingredient is specified in Part 2 of Schedule 2, can it be included on the main label of a medicine containing that ingredient as specified in that Part if the medicine is released for supply on May 15, 2028?\",\n      \"Answer\": \"No\",\n      \"Answer Explanation\": \"According to subsection 9(13), an active ingredient specified in Part 2 of Schedule 2 may be included on the main label of a medicine containing that ingredient as specified in that Part only for medicine released for supply before 1 May 2028.\"\n    },\n    {\n      \"Question\": \"Assuming a medicine is not in a small container and its label complies with subsection 9(13) and Part 2 of Schedule 2, what is the earliest date after which subsection 9(9) will not apply to it?\",\n      \"Answer\": \"May 1, 2028\",\n      \"Answer Explanation\": \"Subsection 9(10)(c) states that subsection 9(9) does not apply after 30 April 2028 for medicines not supplied in a small container and labelled according to subsection 9(13) and Part 2 of Schedule 2. Therefore, the earliest date after which subsection 9(9) will not apply is May 1, 2028.\"\n    },\n    {\n      \"Question\": \"If a medicine's active ingredient is listed in Part 2 of Schedule 2 and the medicine is released for supply on April 30, 2028, can the active ingredient be included on the main label as specified in Part 2 of Schedule 2 without complying with subsection 9(9)?\",\n      \"Answer\": \"Yes\",\n      \"Answer Explanation\": \"Subsection 9(13) allows an active ingredient specified in Part 2 of Schedule 2 to be included on the main label as specified in that Part for medicine released before 1 May 2028. Subsection 9(10)(c) exempts medicines labelled according to subsection 9(13) and Part 2 of Schedule 2 from subsection 9(9) after 30 April 2028. Therefore, a medicine released on April 30, 2028 with an active ingredient listed in Part 2 of Schedule 2 can include the ingredient on the main label as specified without complying with subsection 9(9).\"\n    }\n  ]\n}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            908030000,
            906020000
        ],
        "contexts": [
            " 9 Information to be included on the main label (8) Where a medicine is: (c) (i) the total number of active ingredients in the different formulations in the composite pack or medicine kit are to be counted; and (ii) if the same active ingredient is contained in two or more formulations in the composite pack or medicine kit, each of those active ingredients is to be counted separately, for the purposes of determining if paragraph 9(6)(b) applies to the composite pack or medicine kit, or which paragraph in subsection 9(7) applies to the composite pack or medicine kit; and",
            " 9 Information to be included on the main label (6) If the medicine is intended to be, or is, listed goods: (b) if there are four or more active ingredients in the medicine - the name of every active ingredient, together with the quantity or proportion of every active ingredient, may appear on a side panel or side label or on a rear panel or rear label."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a non-prescription medicine is intended to be listed goods and is a composite pack containing four different formulations each with a unique active ingredient, can the names and quantities of the active ingredients be listed on a side panel of the label?",
                    "Answer": "Yes",
                    "Answer Explanation": "According to section 9(6)(b), if a medicine that is intended to be listed goods contains four or more active ingredients, the name and quantity of every active ingredient may appear on a side panel, side label, rear panel, or rear label. Section 9(8)(c)(i) specifies that for a composite pack, the total number of active ingredients in the different formulations are to be counted for the purposes of determining if 9(6)(b) applies. Therefore, a composite pack with four different formulations each containing a unique active ingredient would have a total of four active ingredients, allowing the names and quantities to be listed on a side panel per 9(6)(b)."
                },
                {
                    "Question": "Given a non-prescription medicine kit that is intended to be listed goods and contains two formulations of the same active ingredient along with one other unique active ingredient, is it required to list the names and quantities of the active ingredients on the main label?",
                    "Answer": "Yes",
                    "Answer Explanation": "Section 9(8)(c)(ii) states that for a medicine kit, if the same active ingredient is contained in two or more formulations, each instance is to be counted separately for determining which labeling requirements in 9(6) or 9(7) apply. In this case, there are considered to be three total active ingredients - two of the same one and one unique. Since there are less than four active ingredients when counted this way, 9(6)(b) does not apply, meaning the active ingredient names and quantities cannot be listed on a side or rear panel and must appear on the main label."
                },
                {
                    "Question": "For a composite pack medicine that is listed goods and has five formulations each with different active ingredients, is it acceptable to list the active ingredient information on a rear label instead of the main label?",
                    "Answer": "Yes",
                    "Answer Explanation": "Section 9(8)(c)(i) specifies that for composite packs, the total number of active ingredients across the different formulations is counted to determine labeling requirements. With five formulations each having a different active ingredient, the total active ingredient count is five. Section 9(6)(b) allows medicines that are listed goods with four or more active ingredients to have the active ingredient names and quantities listed on a side panel, side label, rear panel, or rear label rather than the main label. So in this case, it is permitted to put the active ingredient information on the rear label."
                },
                {
                    "Question": "Suppose a non-prescription medicine kit that will be listed goods has three formulations - two with the same active ingredient at different strengths, and one with two different active ingredients. Can the active ingredients be listed on a side label instead of the main label?",
                    "Answer": "No",
                    "Answer Explanation": "To determine the labeling requirements, section 9(8)(c) specifies how to count the number of active ingredients for medicine kits. 9(8)(c)(i) says the total number across the different formulations is counted. Additionally, 9(8)(c)(ii) states that if an active ingredient is repeated in multiple formulations, each instance is counted separately. So in this case, there are four active ingredients counted for labeling purposes - the repeated one is counted twice, plus the two unique ones in the third formulation. However, 9(6)(b) only allows the active ingredients to be on a side panel\/label or rear panel\/label for listed medicines with four or more active ingredients. Since this has exactly four rather than more than four, 9(6)(b) does not apply and the active ingredients must be listed on the main label."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a non-prescription medicine is intended to be listed goods and is a composite pack containing four different formulations each with a unique active ingredient, can the names and quantities of the active ingredients be listed on a side panel of the label?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"According to section 9(6)(b), if a medicine that is intended to be listed goods contains four or more active ingredients, the name and quantity of every active ingredient may appear on a side panel, side label, rear panel, or rear label. Section 9(8)(c)(i) specifies that for a composite pack, the total number of active ingredients in the different formulations are to be counted for the purposes of determining if 9(6)(b) applies. Therefore, a composite pack with four different formulations each containing a unique active ingredient would have a total of four active ingredients, allowing the names and quantities to be listed on a side panel per 9(6)(b).\"}, {\"Question\": \"Given a non-prescription medicine kit that is intended to be listed goods and contains two formulations of the same active ingredient along with one other unique active ingredient, is it required to list the names and quantities of the active ingredients on the main label?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"Section 9(8)(c)(ii) states that for a medicine kit, if the same active ingredient is contained in two or more formulations, each instance is to be counted separately for determining which labeling requirements in 9(6) or 9(7) apply. In this case, there are considered to be three total active ingredients - two of the same one and one unique. Since there are less than four active ingredients when counted this way, 9(6)(b) does not apply, meaning the active ingredient names and quantities cannot be listed on a side or rear panel and must appear on the main label.\"}, {\"Question\": \"For a composite pack medicine that is listed goods and has five formulations each with different active ingredients, is it acceptable to list the active ingredient information on a rear label instead of the main label?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"Section 9(8)(c)(i) specifies that for composite packs, the total number of active ingredients across the different formulations is counted to determine labeling requirements. With five formulations each having a different active ingredient, the total active ingredient count is five. Section 9(6)(b) allows medicines that are listed goods with four or more active ingredients to have the active ingredient names and quantities listed on a side panel, side label, rear panel, or rear label rather than the main label. So in this case, it is permitted to put the active ingredient information on the rear label.\"}, {\"Question\": \"Suppose a non-prescription medicine kit that will be listed goods has three formulations - two with the same active ingredient at different strengths, and one with two different active ingredients. Can the active ingredients be listed on a side label instead of the main label?\", \"Answer\": \"No\", \"Answer Explanation\": \"To determine the labeling requirements, section 9(8)(c) specifies how to count the number of active ingredients for medicine kits. 9(8)(c)(i) says the total number across the different formulations is counted. Additionally, 9(8)(c)(ii) states that if an active ingredient is repeated in multiple formulations, each instance is counted separately. So in this case, there are four active ingredients counted for labeling purposes - the repeated one is counted twice, plus the two unique ones in the third formulation. However, 9(6)(b) only allows the active ingredients to be on a side panel\/label or rear panel\/label for listed medicines with four or more active ingredients. Since this has exactly four rather than more than four, 9(6)(b) does not apply and the active ingredients must be listed on the main label.\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            302020000,
            500000000
        ],
        "contexts": [
            "3 Application - Therapeutic goods to which this Order applies(2) To avoid doubt, this Order will apply to the following medicines:(b) medicines exempt from the listing and registration requirements, other than those specified in section 5 of this Order.",
            "5 Exemptions \u2013 Medicines to which this Order does not apply (2) The requirements of this Order do not apply to a transparent covering that encloses or wraps the container or primary pack containing a medicine and where the information that is required to be set out on the label of the container or the primary pack is clearly visible through that transparent covering."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a non-prescription medicine is exempt from listing and registration requirements, and is not enclosed in a transparent covering that allows the required label information to be clearly visible, does this Order apply to the labelling requirements for that medicine?",
                    "Answer": "Yes, this Order applies.",
                    "Answer Explanation": "Section 3(2)(b) states that this Order applies to medicines exempt from listing and registration requirements, other than those specified in section 5. Section 5(2) exempts medicines from this Order only if they are enclosed in a transparent covering through which the required label information is clearly visible. Since the medicine in question is exempt but not enclosed in a qualifying transparent covering, the Order applies to its labelling requirements."
                },
                {
                    "Question": "Consider a non-prescription medicine that is exempt from listing and registration requirements. It is enclosed in a transparent covering, but the required label information on the container is not clearly visible through the covering. Does this Order apply to the labelling of this medicine?",
                    "Answer": "Yes, this Order applies.",
                    "Answer Explanation": "According to section 3(2)(b), this Order applies to medicines exempt from listing and registration requirements, unless they are specified in section 5. Section 5(2) only exempts a medicine from this Order if it is in a transparent covering AND the required label information is clearly visible through that covering. Since the label is not clearly visible in this case, the medicine is not exempt under 5(2), so the Order applies per 3(2)(b)."
                },
                {
                    "Question": "Suppose a non-prescription medicine is not exempt from listing and registration requirements, and it is not enclosed in any transparent covering. Assuming no other exemptions in section 5 apply, is the labelling of this medicine subject to the requirements of this Order?",
                    "Answer": "Yes, this Order applies.",
                    "Answer Explanation": "Section 3(2) states that this Order applies to non-prescription medicines, which includes both exempt and non-exempt medicines, unless specified in section 5. The only potentially relevant exemption in section 5 is in 5(2), which exempts medicines enclosed in a transparent covering through which the required label information is visible. Since this medicine is not exempt and has no transparent covering, no section 5 exemptions apply, so it is subject to this Order under the broad scope of section 3(2)."
                },
                {
                    "Question": "A non-prescription medicine is wrapped in a transparent covering. The container inside has a label with the required information, which can be clearly seen through the transparent outer wrap. Is the labelling of this medicine subject to the requirements of this Order?",
                    "Answer": "No, this Order does not apply.",
                    "Answer Explanation": "Section 3(2)(b) states that this Order applies to non-prescription medicines that are exempt from listing and registration, other than those specified in section 5. Section 5(2) specifically exempts medicines from this Order if they are enclosed in a transparent covering through which the required label information on the container or primary pack is clearly visible. Since this medicine meets the criteria in 5(2), it is exempt from the requirements of this Order."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a non-prescription medicine is exempt from listing and registration requirements, and is not enclosed in a transparent covering that allows the required label information to be clearly visible, does this Order apply to the labelling requirements for that medicine?\", \"Answer\": \"Yes, this Order applies.\", \"Answer Explanation\": \"Section 3(2)(b) states that this Order applies to medicines exempt from listing and registration requirements, other than those specified in section 5. Section 5(2) exempts medicines from this Order only if they are enclosed in a transparent covering through which the required label information is clearly visible. Since the medicine in question is exempt but not enclosed in a qualifying transparent covering, the Order applies to its labelling requirements.\"}, {\"Question\": \"Consider a non-prescription medicine that is exempt from listing and registration requirements. It is enclosed in a transparent covering, but the required label information on the container is not clearly visible through the covering. Does this Order apply to the labelling of this medicine?\", \"Answer\": \"Yes, this Order applies.\", \"Answer Explanation\": \"According to section 3(2)(b), this Order applies to medicines exempt from listing and registration requirements, unless they are specified in section 5. Section 5(2) only exempts a medicine from this Order if it is in a transparent covering AND the required label information is clearly visible through that covering. Since the label is not clearly visible in this case, the medicine is not exempt under 5(2), so the Order applies per 3(2)(b).\"}, {\"Question\": \"Suppose a non-prescription medicine is not exempt from listing and registration requirements, and it is not enclosed in any transparent covering. Assuming no other exemptions in section 5 apply, is the labelling of this medicine subject to the requirements of this Order?\", \"Answer\": \"Yes, this Order applies.\", \"Answer Explanation\": \"Section 3(2) states that this Order applies to non-prescription medicines, which includes both exempt and non-exempt medicines, unless specified in section 5. The only potentially relevant exemption in section 5 is in 5(2), which exempts medicines enclosed in a transparent covering through which the required label information is visible. Since this medicine is not exempt and has no transparent covering, no section 5 exemptions apply, so it is subject to this Order under the broad scope of section 3(2).\"}, {\"Question\": \"A non-prescription medicine is wrapped in a transparent covering. The container inside has a label with the required information, which can be clearly seen through the transparent outer wrap. Is the labelling of this medicine subject to the requirements of this Order?\", \"Answer\": \"No, this Order does not apply.\", \"Answer Explanation\": \"Section 3(2)(b) states that this Order applies to non-prescription medicines that are exempt from listing and registration, other than those specified in section 5. Section 5(2) specifically exempts medicines from this Order if they are enclosed in a transparent covering through which the required label information on the container or primary pack is clearly visible. Since this medicine meets the criteria in 5(2), it is exempt from the requirements of this Order.\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            802050000,
            802040000
        ],
        "contexts": [
            " 8 Information to be included on the label (2) (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or distributor contact details.",
            " 8 Information to be included on the label (2) (d) The information provided under paragraph 8(2)(b)(iii) may include safety related information not required by this Order (such as allergen advice, caution, additional warning or advisory statements)."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Under section 8(2)(d), can safety-related information not required by the Order, such as allergen advice, caution statements, or additional warnings, be included under the paragraph 8(2)(b)(iii) heading? Assume all information will be placed under the appropriate headings per 8(2)(e).",
                    "Answer": "Yes",
                    "Answer Explanation": "Section 8(2)(d) explicitly allows safety related information not required by the Order, such as allergen advice, caution statements, additional warnings or advisory statements, to be included under the paragraph 8(2)(b)(iii) heading. Section 8(2)(e) requires any additional non-critical information to be placed under appropriate separate headings following the headings in 8(2)(b), so the assumption that all information will be correctly placed is satisfied."
                },
                {
                    "Question": "If a non-prescription medicine label includes the names of all excipients under an 'Other ingredients' heading immediately following the headings mentioned in 8(2)(b), and no other non-critical information is included, does this comply with section 8(2)(e)?",
                    "Answer": "Yes",
                    "Answer Explanation": "Section 8(2)(e) allows the names of all excipients to be placed under an appropriate separate heading immediately following the headings in 8(2)(b). An 'Other ingredients' heading for the excipients would satisfy this requirement. Since no other non-critical information is included, the label complies with the restriction in 8(2)(e) on what additional information may be included."
                },
                {
                    "Question": "Assuming a label includes allergen advice under 8(2)(d) and lists excipient names under a separate heading per 8(2)(e), is the label allowed to also include the sponsor contact details under another heading below the excipient names?",
                    "Answer": "Yes",
                    "Answer Explanation": "Section 8(2)(d) allows allergen advice to be included under the 8(2)(b)(iii) heading. Section 8(2)(e) then permits excipient names to be listed under an appropriate separate heading after the 8(2)(b) headings. Finally, 8(2)(e) also allows sponsor contact details to be included under yet another heading following the excipient names. Therefore, the label described satisfies all the requirements of 8(2)(d) and 8(2)(e)."
                },
                {
                    "Question": "For a label that includes storage condition requirements under an 'Other information' heading per 8(2)(e), can that same 'Other information' heading also contain both the excipient names and distributor contact details?",
                    "Answer": "No",
                    "Answer Explanation": "Section 8(2)(e) allows requirements relating to storage conditions to be placed under an 'Other information' heading. However, it specifies that excipient names and distributor contact details must be under separate appropriate headings, not combined with storage conditions or each other under the same 'Other information' heading. Excipient names and distributor contacts must each have their own distinct heading according to 8(2)(e)."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Under section 8(2)(d), can safety-related information not required by the Order, such as allergen advice, caution statements, or additional warnings, be included under the paragraph 8(2)(b)(iii) heading? Assume all information will be placed under the appropriate headings per 8(2)(e).\",\n    \"Answer\": \"Yes\",\n    \"Answer Explanation\": \"Section 8(2)(d) explicitly allows safety related information not required by the Order, such as allergen advice, caution statements, additional warnings or advisory statements, to be included under the paragraph 8(2)(b)(iii) heading. Section 8(2)(e) requires any additional non-critical information to be placed under appropriate separate headings following the headings in 8(2)(b), so the assumption that all information will be correctly placed is satisfied.\"\n  },\n  {\n    \"Question\": \"If a non-prescription medicine label includes the names of all excipients under an 'Other ingredients' heading immediately following the headings mentioned in 8(2)(b), and no other non-critical information is included, does this comply with section 8(2)(e)?\", \n    \"Answer\": \"Yes\",\n    \"Answer Explanation\": \"Section 8(2)(e) allows the names of all excipients to be placed under an appropriate separate heading immediately following the headings in 8(2)(b). An 'Other ingredients' heading for the excipients would satisfy this requirement. Since no other non-critical information is included, the label complies with the restriction in 8(2)(e) on what additional information may be included.\"\n  },\n  {\n    \"Question\": \"Assuming a label includes allergen advice under 8(2)(d) and lists excipient names under a separate heading per 8(2)(e), is the label allowed to also include the sponsor contact details under another heading below the excipient names?\",\n    \"Answer\": \"Yes\", \n    \"Answer Explanation\": \"Section 8(2)(d) allows allergen advice to be included under the 8(2)(b)(iii) heading. Section 8(2)(e) then permits excipient names to be listed under an appropriate separate heading after the 8(2)(b) headings. Finally, 8(2)(e) also allows sponsor contact details to be included under yet another heading following the excipient names. Therefore, the label described satisfies all the requirements of 8(2)(d) and 8(2)(e).\"\n  },\n  {\n    \"Question\": \"For a label that includes storage condition requirements under an 'Other information' heading per 8(2)(e), can that same 'Other information' heading also contain both the excipient names and distributor contact details?\",\n    \"Answer\": \"No\",\n    \"Answer Explanation\": \"Section 8(2)(e) allows requirements relating to storage conditions to be placed under an 'Other information' heading. However, it specifies that excipient names and distributor contact details must be under separate appropriate headings, not combined with storage conditions or each other under the same 'Other information' heading. Excipient names and distributor contacts must each have their own distinct heading according to 8(2)(e).\"\n  }\n]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            403000000,
            402000000
        ],
        "contexts": [
            "4 Transition arrangements (3) Notwithstanding (1) and (2), medicines imported into or manufactured in Australia before 1 September 2020 but supplied by a person other than the sponsor after that date must comply with TGO 69 (2017) if at the time of their release for supply they complied with TGO 69 (2017).",
            "4 Transition arrangements (2) On and from 1 September 2020, each medicine to which this Order applies must comply with the requirements specified in this Order."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine was imported into Australia on 1 August 2020 and supplied by a sponsor on 1 October 2020, which version of TGO must it comply with?",
                    "Answer": "TGO 69 (2017)",
                    "Answer Explanation": "According to clause 4(2), medicines must comply with the requirements of this Order from 1 September 2020 onwards. However, clause 4(3) provides an exception for medicines imported before 1 September 2020 but supplied by someone other than the sponsor after that date. In this case, since the medicine was imported before 1 September 2020 and supplied by the sponsor after that date, it must comply with TGO 69 (2017) as per clause 4(3)."
                },
                {
                    "Question": "Assuming a medicine was manufactured in Australia on 1 July 2020 and supplied by a distributor on 1 November 2020, which version of TGO must it comply with at the time of release for supply?",
                    "Answer": "TGO 69 (2017)",
                    "Answer Explanation": "According to clause 4(2), medicines must comply with the requirements of this Order from 1 September 2020 onwards. However, clause 4(3) provides an exception for medicines manufactured in Australia before 1 September 2020 but supplied by someone other than the sponsor after that date, if at the time of their release for supply they complied with TGO 69 (2017). Since the medicine was manufactured before 1 September 2020 and supplied by a distributor (not the sponsor) after that date, it must comply with TGO 69 (2017) at the time of release for supply as per clause 4(3)."
                },
                {
                    "Question": "Assuming a medicine was imported into Australia on 1 October 2020 and supplied by the sponsor on 1 November 2020, which version of TGO must it comply with?",
                    "Answer": "The version specified in this Order",
                    "Answer Explanation": "According to clause 4(2), medicines must comply with the requirements specified in this Order from 1 September 2020 onwards. Clause 4(3) provides an exception only for medicines imported or manufactured before 1 September 2020. Since the medicine was imported on 1 October 2020, which is after 1 September 2020, it does not qualify for the exception in clause 4(3). Therefore, it must comply with the version of TGO specified in this Order as per clause 4(2)."
                },
                {
                    "Question": "Assuming a medicine was manufactured in Australia on 1 August 2020 and supplied by the sponsor on 1 December 2020, which version of TGO must it comply with?",
                    "Answer": "The version specified in this Order",
                    "Answer Explanation": "According to clause 4(2), medicines must comply with the requirements specified in this Order from 1 September 2020 onwards. Clause 4(3) provides an exception for medicines manufactured before 1 September 2020, but only if they are supplied by someone other than the sponsor after that date. Since the medicine was manufactured before 1 September 2020 but supplied by the sponsor after that date, it does not qualify for the exception in clause 4(3). Therefore, it must comply with the version of TGO specified in this Order as per clause 4(2)."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine was imported into Australia on 1 August 2020 and supplied by a sponsor on 1 October 2020, which version of TGO must it comply with?\", \"Answer\": \"TGO 69 (2017)\", \"Answer Explanation\": \"According to clause 4(2), medicines must comply with the requirements of this Order from 1 September 2020 onwards. However, clause 4(3) provides an exception for medicines imported before 1 September 2020 but supplied by someone other than the sponsor after that date. In this case, since the medicine was imported before 1 September 2020 and supplied by the sponsor after that date, it must comply with TGO 69 (2017) as per clause 4(3).\"}, {\"Question\": \"Assuming a medicine was manufactured in Australia on 1 July 2020 and supplied by a distributor on 1 November 2020, which version of TGO must it comply with at the time of release for supply?\", \"Answer\": \"TGO 69 (2017)\", \"Answer Explanation\": \"According to clause 4(2), medicines must comply with the requirements of this Order from 1 September 2020 onwards. However, clause 4(3) provides an exception for medicines manufactured in Australia before 1 September 2020 but supplied by someone other than the sponsor after that date, if at the time of their release for supply they complied with TGO 69 (2017). Since the medicine was manufactured before 1 September 2020 and supplied by a distributor (not the sponsor) after that date, it must comply with TGO 69 (2017) at the time of release for supply as per clause 4(3).\"}, {\"Question\": \"Assuming a medicine was imported into Australia on 1 October 2020 and supplied by the sponsor on 1 November 2020, which version of TGO must it comply with?\", \"Answer\": \"The version specified in this Order\", \"Answer Explanation\": \"According to clause 4(2), medicines must comply with the requirements specified in this Order from 1 September 2020 onwards. Clause 4(3) provides an exception only for medicines imported or manufactured before 1 September 2020. Since the medicine was imported on 1 October 2020, which is after 1 September 2020, it does not qualify for the exception in clause 4(3). Therefore, it must comply with the version of TGO specified in this Order as per clause 4(2).\"}, {\"Question\": \"Assuming a medicine was manufactured in Australia on 1 August 2020 and supplied by the sponsor on 1 December 2020, which version of TGO must it comply with?\", \"Answer\": \"The version specified in this Order\", \"Answer Explanation\": \"According to clause 4(2), medicines must comply with the requirements specified in this Order from 1 September 2020 onwards. Clause 4(3) provides an exception for medicines manufactured before 1 September 2020, but only if they are supplied by someone other than the sponsor after that date. Since the medicine was manufactured before 1 September 2020 but supplied by the sponsor after that date, it does not qualify for the exception in clause 4(3). Therefore, it must comply with the version of TGO specified in this Order as per clause 4(2).\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            301000000,
            500000000
        ],
        "contexts": [
            "3 Application - Therapeutic goods to which this Order applies(1) Subject to sections 4 and 5, this Order applies to medicines supplied or for supply in Australia, other than those specified under section 3 of the Therapeutic Goods Order No. 91 \u2013 Standard for labels of prescription and related medicines.",
            "5 Exemptions \u2013 Medicines to which this Order does not apply (2) The requirements of this Order do not apply to a transparent covering that encloses or wraps the container or primary pack containing a medicine and where the information that is required to be set out on the label of the container or the primary pack is clearly visible through that transparent covering."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is supplied in Australia and is not a prescription medicine, does this Order apply to the labelling requirements for that medicine?",
                    "Answer": "Yes",
                    "Answer Explanation": "Section 3(1) states that this Order applies to medicines supplied in Australia, other than those specified under Therapeutic Goods Order No. 91 which covers prescription medicines. Therefore, if a medicine is supplied in Australia and is not a prescription medicine, this Order applies to its labelling requirements."
                },
                {
                    "Question": "If a medicine to which this Order applies is enclosed in a transparent covering, and the required label information is clearly visible through the covering, do the labelling requirements of this Order still apply?",
                    "Answer": "No",
                    "Answer Explanation": "Section 5(2) provides an exemption from the requirements of this Order for medicines enclosed in a transparent covering, provided that the required label information on the container or primary pack is clearly visible through the covering."
                },
                {
                    "Question": "Assuming a medicine is an over-the-counter product supplied in Australia, enclosed in a transparent covering with the label visible, do the labelling requirements of this Order apply?",
                    "Answer": "No",
                    "Answer Explanation": "Based on sections 3(1) and 5(2), this Order applies to non-prescription medicines supplied in Australia, but provides an exemption if the medicine is in a transparent covering through which the required label information is clearly visible. As an over-the-counter medicine is non-prescription, and the label is visible through the covering, the labelling requirements of this Order do not apply in this scenario."
                },
                {
                    "Question": "For a complementary medicine supplied in Australia without a prescription, not enclosed in any covering, do the labelling requirements of this Order apply?",
                    "Answer": "Yes",
                    "Answer Explanation": "Section 3(1) makes this Order applicable to non-prescription medicines supplied in Australia. A complementary medicine supplied without a prescription falls into this category. Since section 5(2) only provides an exemption for medicines in a transparent covering with a visible label, which does not apply here as there is no covering, the labelling requirements of this Order are applicable to the complementary medicine in this scenario."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine is supplied in Australia and is not a prescription medicine, does this Order apply to the labelling requirements for that medicine?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"Section 3(1) states that this Order applies to medicines supplied in Australia, other than those specified under Therapeutic Goods Order No. 91 which covers prescription medicines. Therefore, if a medicine is supplied in Australia and is not a prescription medicine, this Order applies to its labelling requirements.\"}, {\"Question\": \"If a medicine to which this Order applies is enclosed in a transparent covering, and the required label information is clearly visible through the covering, do the labelling requirements of this Order still apply?\", \"Answer\": \"No\", \"Answer Explanation\": \"Section 5(2) provides an exemption from the requirements of this Order for medicines enclosed in a transparent covering, provided that the required label information on the container or primary pack is clearly visible through the covering.\"}, {\"Question\": \"Assuming a medicine is an over-the-counter product supplied in Australia, enclosed in a transparent covering with the label visible, do the labelling requirements of this Order apply?\", \"Answer\": \"No\", \"Answer Explanation\": \"Based on sections 3(1) and 5(2), this Order applies to non-prescription medicines supplied in Australia, but provides an exemption if the medicine is in a transparent covering through which the required label information is clearly visible. As an over-the-counter medicine is non-prescription, and the label is visible through the covering, the labelling requirements of this Order do not apply in this scenario.\"}, {\"Question\": \"For a complementary medicine supplied in Australia without a prescription, not enclosed in any covering, do the labelling requirements of this Order apply?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"Section 3(1) makes this Order applicable to non-prescription medicines supplied in Australia. A complementary medicine supplied without a prescription falls into this category. Since section 5(2) only provides an exemption for medicines in a transparent covering with a visible label, which does not apply here as there is no covering, the labelling requirements of this Order are applicable to the complementary medicine in this scenario.\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            1102080000,
            1102030000
        ],
        "contexts": [
            " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (h) for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation.",
            " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (c) subject to paragraph (d) below, if the medicine is a liquid for ingestion: (i) as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid; or (ii) in the case where the liquid for ingestion is one of a series of strengths containing the same active ingredient \u2013 as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid with the quantity or proportion of active ingredient expressed consistently across the series in terms of the same stated dose volume. Example: Where the dose volume is 5 mL, and there are strengths of 1 mg\/mL and 5 mg\/mL, these must be labelled as 5 mg in 5 mL and 25 mg in 5 mL, respectively."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "For an oral mineral supplement liquid with active ingredient magnesium at a strength of 2 mg\/mL, how should the quantity of magnesium be expressed on the label if the recommended dose is 10 mL? Assume no other information is required.",
                    "Answer": "20 mg in 10 mL",
                    "Answer Explanation": "According to 11(2)(h), for oral preparations containing active ingredients intended for mineral supplementation, the quantity of the active ingredient can be expressed as the name of the ingredient and the quantity of the element. 11(2)(c)(i) states that for liquid medicines, the quantity should be expressed as the amount of active ingredient in a stated dose volume. With a strength of 2 mg\/mL magnesium and a 10 mL dose, the label should state the quantity as 20 mg magnesium in 10 mL."
                },
                {
                    "Question": "How should the quantity of magnesium be expressed on the labels of oral liquid mineral supplements that come in strengths of 1 mg\/mL, 2 mg\/mL and 4 mg\/mL if the dose volume is 5 mL? Assume no other information is required.",
                    "Answer": "5 mg in 5 mL, 10 mg in 5 mL, 20 mg in 5 mL",
                    "Answer Explanation": "11(2)(h) allows oral mineral supplements to express the quantity as the name and amount of the mineral element. 11(2)(c)(ii) requires that for a series of strengths of the same active ingredient, the quantity must be expressed consistently in terms of the same dose volume across the series. With a 5 mL dose volume and strengths of 1, 2 and 4 mg\/mL of magnesium, the labels should state the quantities as 5 mg in 5 mL, 10 mg in 5 mL and 20 mg in 5 mL respectively."
                },
                {
                    "Question": "A company makes two oral magnesium supplement liquids, one at a strength of 2 mg\/mL and one at 10 mg\/mL. The dose is 10 mL for the 2 mg\/mL product and 5 mL for the 10 mg\/mL product. How should the quantity of magnesium be expressed on each label?",
                    "Answer": "20 mg in 10 mL for the 2 mg\/mL product, 50 mg in 5 mL for the 10 mg\/mL product",
                    "Answer Explanation": "11(2)(h) permits oral mineral supplements to express the quantity as the name and amount of the mineral element. 11(2)(c)(i) requires liquids to express the quantity as the amount in a stated dose volume. These are two different products with different strengths and dose volumes, so 11(2)(c)(ii) regarding consistent expression across a series does not apply. Therefore, the 2 mg\/mL product label should state 20 mg magnesium in 10 mL, and the 10 mg\/mL product label should state 50 mg magnesium in 5 mL."
                },
                {
                    "Question": "For an oral liquid vitamin D supplement with a strength of 400 IU\/mL, how should the quantity of vitamin D be expressed on the label if the dose is 1 mL? Assume no other information is required.",
                    "Answer": "400 IU in 1 mL",
                    "Answer Explanation": "11(2)(h) does not apply since vitamin D is not a mineral element. Therefore, 11(2)(c)(i) applies, requiring the quantity to be expressed as the amount of active ingredient (vitamin D) in a stated dose volume. With a strength of 400 IU\/mL and a 1 mL dose, the label should state the quantity as 400 IU vitamin D in 1 mL."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"For an oral mineral supplement liquid with active ingredient magnesium at a strength of 2 mg\/mL, how should the quantity of magnesium be expressed on the label if the recommended dose is 10 mL? Assume no other information is required.\", \"Answer\": \"20 mg in 10 mL\", \"Answer Explanation\": \"According to 11(2)(h), for oral preparations containing active ingredients intended for mineral supplementation, the quantity of the active ingredient can be expressed as the name of the ingredient and the quantity of the element. 11(2)(c)(i) states that for liquid medicines, the quantity should be expressed as the amount of active ingredient in a stated dose volume. With a strength of 2 mg\/mL magnesium and a 10 mL dose, the label should state the quantity as 20 mg magnesium in 10 mL.\"}, {\"Question\": \"How should the quantity of magnesium be expressed on the labels of oral liquid mineral supplements that come in strengths of 1 mg\/mL, 2 mg\/mL and 4 mg\/mL if the dose volume is 5 mL? Assume no other information is required.\", \"Answer\": \"5 mg in 5 mL, 10 mg in 5 mL, 20 mg in 5 mL\", \"Answer Explanation\": \"11(2)(h) allows oral mineral supplements to express the quantity as the name and amount of the mineral element. 11(2)(c)(ii) requires that for a series of strengths of the same active ingredient, the quantity must be expressed consistently in terms of the same dose volume across the series. With a 5 mL dose volume and strengths of 1, 2 and 4 mg\/mL of magnesium, the labels should state the quantities as 5 mg in 5 mL, 10 mg in 5 mL and 20 mg in 5 mL respectively.\"}, {\"Question\": \"A company makes two oral magnesium supplement liquids, one at a strength of 2 mg\/mL and one at 10 mg\/mL. The dose is 10 mL for the 2 mg\/mL product and 5 mL for the 10 mg\/mL product. How should the quantity of magnesium be expressed on each label?\", \"Answer\": \"20 mg in 10 mL for the 2 mg\/mL product, 50 mg in 5 mL for the 10 mg\/mL product\", \"Answer Explanation\": \"11(2)(h) permits oral mineral supplements to express the quantity as the name and amount of the mineral element. 11(2)(c)(i) requires liquids to express the quantity as the amount in a stated dose volume. These are two different products with different strengths and dose volumes, so 11(2)(c)(ii) regarding consistent expression across a series does not apply. Therefore, the 2 mg\/mL product label should state 20 mg magnesium in 10 mL, and the 10 mg\/mL product label should state 50 mg magnesium in 5 mL.\"}, {\"Question\": \"For an oral liquid vitamin D supplement with a strength of 400 IU\/mL, how should the quantity of vitamin D be expressed on the label if the dose is 1 mL? Assume no other information is required.\", \"Answer\": \"400 IU in 1 mL\", \"Answer Explanation\": \"11(2)(h) does not apply since vitamin D is not a mineral element. Therefore, 11(2)(c)(i) applies, requiring the quantity to be expressed as the amount of active ingredient (vitamin D) in a stated dose volume. With a strength of 400 IU\/mL and a 1 mL dose, the label should state the quantity as 400 IU vitamin D in 1 mL.\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            903020000,
            1102080000
        ],
        "contexts": [
            " 9 Information to be included on the main label (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must: (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;",
            " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (h) for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine contains an active ingredient intended for mineral supplementation and is an oral preparation, what information must be included on the label to express the quantity or proportion of that active ingredient?",
                    "Answer": "The name of the active ingredient and the name and quantity of the element intended for mineral supplementation.",
                    "Answer Explanation": "According to paragraph 11(2)(h), for oral preparations that contain active ingredients intended for mineral supplementation, the quantity or proportion of that active ingredient can be expressed as the name of the active ingredient and the name and quantity of the element intended for mineral supplementation."
                },
                {
                    "Question": "Assuming a medicine label includes the name of the medicine and the names of active ingredients, can any text or graphics be placed between the medicine name and the active ingredient names?",
                    "Answer": "No, text or graphics cannot be placed between the medicine name and active ingredient names, with a few specific exceptions.",
                    "Answer Explanation": "Paragraph 9(3)(b) states that the name of the medicine and the name(s) of active ingredient(s) must not be separated by any text or graphics, except where additional information is: (i) required or permitted by paragraph 11(2)(h), subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A), or subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit."
                },
                {
                    "Question": "Assuming an oral preparation contains an active ingredient for mineral supplementation, and the label expresses this using the format specified in paragraph 11(2)(h), can any text or graphics be placed between the medicine name and this mineral supplementation information on the main label?",
                    "Answer": "Yes, text or graphics can be placed between the medicine name and the mineral supplementation information in this case.",
                    "Answer Explanation": "Paragraph 9(3)(b)(i)(A) provides an exception allowing the mineral supplementation information required by paragraph 11(2)(h) to be separated from the medicine name by text or graphics on the main label."
                },
                {
                    "Question": "Assuming an oral preparation medicine label includes the active ingredient name and element name and quantity for mineral supplementation per paragraph 11(2)(h), is this sufficient to meet the general requirement to express the quantity or proportion of active ingredients on the label?",
                    "Answer": "Yes, for an oral preparation containing an active ingredient for mineral supplementation, expressing the information in the format specified by paragraph 11(2)(h) is sufficient to meet the general label requirements for expressing quantity or proportion of active ingredients, subject to the exceptions in paragraph 11(2)(i) and subsection 11(3).",
                    "Answer Explanation": "The opening text of paragraph 11(2) states that subject to paragraph 11(2)(i) and subsection 11(3), expressing the mineral supplementation information as specified in 11(2)(h) is sufficient to meet the active ingredient quantity\/proportion labeling requirement for applicable oral preparations."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a medicine contains an active ingredient intended for mineral supplementation and is an oral preparation, what information must be included on the label to express the quantity or proportion of that active ingredient?\",\n    \"Answer\": \"The name of the active ingredient and the name and quantity of the element intended for mineral supplementation.\",\n    \"Answer Explanation\": \"According to paragraph 11(2)(h), for oral preparations that contain active ingredients intended for mineral supplementation, the quantity or proportion of that active ingredient can be expressed as the name of the active ingredient and the name and quantity of the element intended for mineral supplementation.\"\n  },\n  {\n    \"Question\": \"Assuming a medicine label includes the name of the medicine and the names of active ingredients, can any text or graphics be placed between the medicine name and the active ingredient names?\",\n    \"Answer\": \"No, text or graphics cannot be placed between the medicine name and active ingredient names, with a few specific exceptions.\",\n    \"Answer Explanation\": \"Paragraph 9(3)(b) states that the name of the medicine and the name(s) of active ingredient(s) must not be separated by any text or graphics, except where additional information is: (i) required or permitted by paragraph 11(2)(h), subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A), or subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit.\"\n  },\n  {\n    \"Question\": \"Assuming an oral preparation contains an active ingredient for mineral supplementation, and the label expresses this using the format specified in paragraph 11(2)(h), can any text or graphics be placed between the medicine name and this mineral supplementation information on the main label?\",\n    \"Answer\": \"Yes, text or graphics can be placed between the medicine name and the mineral supplementation information in this case.\",\n    \"Answer Explanation\": \"Paragraph 9(3)(b)(i)(A) provides an exception allowing the mineral supplementation information required by paragraph 11(2)(h) to be separated from the medicine name by text or graphics on the main label.\"\n  },\n  {\n    \"Question\": \"Assuming an oral preparation medicine label includes the active ingredient name and element name and quantity for mineral supplementation per paragraph 11(2)(h), is this sufficient to meet the general requirement to express the quantity or proportion of active ingredients on the label?\",\n    \"Answer\": \"Yes, for an oral preparation containing an active ingredient for mineral supplementation, expressing the information in the format specified by paragraph 11(2)(h) is sufficient to meet the general label requirements for expressing quantity or proportion of active ingredients, subject to the exceptions in paragraph 11(2)(i) and subsection 11(3).\",\n    \"Answer Explanation\": \"The opening text of paragraph 11(2) states that subject to paragraph 11(2)(i) and subsection 11(3), expressing the mineral supplementation information as specified in 11(2)(h) is sufficient to meet the active ingredient quantity\/proportion labeling requirement for applicable oral preparations.\"\n  }\n]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            802030000,
            802020000
        ],
        "contexts": [
            " 8 Information to be included on the label (2) (c) The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order.",
            " 8 Information to be included on the label (2) (b) The critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a non-prescription drug label includes the pharmacological category or principal intended actions of the active ingredients under the 'Active ingredients' heading, would this be in compliance with the labeling requirements?",
                    "Answer": "Yes",
                    "Answer Explanation": "According to section 8(2)(b), the critical health information on the label must include the active ingredients, and this information should be presented under the 'Active ingredients' heading. Section 8(2)(c) further clarifies that the information provided under 8(2)(b)(i) (i.e., active ingredients) may include words describing the purpose of the active ingredients by indicating the pharmacological category or principal intended actions. Therefore, including the pharmacological category or principal intended actions under the 'Active ingredients' heading would be in compliance with the labeling requirements."
                },
                {
                    "Question": "Assuming a non-prescription drug label presents the critical health information in the following order: Warnings, Active ingredients, Indications, Directions for use, Other information. Would this be compliant with the labeling requirements?",
                    "Answer": "No",
                    "Answer Explanation": "According to section 8(2)(b), the critical health information must be presented under appropriate headings and in the following specific order: (i) Active ingredients, (ii) Indications, (iii) Warnings, (iv) Directions for use, (v) Other information. The order presented in the question (Warnings, Active ingredients, Indications, Directions for use, Other information) does not follow the required order specified in 8(2)(b). Therefore, this labeling would not be compliant with the requirements."
                },
                {
                    "Question": "Assuming a non-prescription drug label includes the pharmacological category of the active ingredients, but this information is presented under the 'Indications' heading. Would this be compliant with the labeling requirements?",
                    "Answer": "No",
                    "Answer Explanation": "According to section 8(2)(c), the information about the pharmacological category or principal intended actions of the active ingredients may be included under paragraph 8(2)(b)(i), which refers to the 'Active ingredients' heading. Section 8(2)(b) requires the critical health information to be presented under appropriate headings, with 'Active ingredients' and 'Indications' as separate headings. Therefore, including the pharmacological category under the 'Indications' heading instead of the 'Active ingredients' heading would not be compliant with the labeling requirements."
                },
                {
                    "Question": "Assuming a non-prescription drug label includes all the required critical health information under appropriate headings, but the order of the headings is: Active ingredients, Warnings, Indications, Other information, Directions for use. Would this be compliant with the labeling requirements?",
                    "Answer": "No",
                    "Answer Explanation": "According to section 8(2)(b), the critical health information must be presented under appropriate headings and in the following specific order: (i) Active ingredients, (ii) Indications, (iii) Warnings, (iv) Directions for use, (v) Other information. Although the label includes all the required information under appropriate headings, the order of the headings (Active ingredients, Warnings, Indications, Other information, Directions for use) does not match the order specified in 8(2)(b). Therefore, this labeling would not be compliant with the requirements."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a non-prescription drug label includes the pharmacological category or principal intended actions of the active ingredients under the 'Active ingredients' heading, would this be in compliance with the labeling requirements?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"According to section 8(2)(b), the critical health information on the label must include the active ingredients, and this information should be presented under the 'Active ingredients' heading. Section 8(2)(c) further clarifies that the information provided under 8(2)(b)(i) (i.e., active ingredients) may include words describing the purpose of the active ingredients by indicating the pharmacological category or principal intended actions. Therefore, including the pharmacological category or principal intended actions under the 'Active ingredients' heading would be in compliance with the labeling requirements.\"}, {\"Question\": \"Assuming a non-prescription drug label presents the critical health information in the following order: Warnings, Active ingredients, Indications, Directions for use, Other information. Would this be compliant with the labeling requirements?\", \"Answer\": \"No\", \"Answer Explanation\": \"According to section 8(2)(b), the critical health information must be presented under appropriate headings and in the following specific order: (i) Active ingredients, (ii) Indications, (iii) Warnings, (iv) Directions for use, (v) Other information. The order presented in the question (Warnings, Active ingredients, Indications, Directions for use, Other information) does not follow the required order specified in 8(2)(b). Therefore, this labeling would not be compliant with the requirements.\"}, {\"Question\": \"Assuming a non-prescription drug label includes the pharmacological category of the active ingredients, but this information is presented under the 'Indications' heading. Would this be compliant with the labeling requirements?\", \"Answer\": \"No\", \"Answer Explanation\": \"According to section 8(2)(c), the information about the pharmacological category or principal intended actions of the active ingredients may be included under paragraph 8(2)(b)(i), which refers to the 'Active ingredients' heading. Section 8(2)(b) requires the critical health information to be presented under appropriate headings, with 'Active ingredients' and 'Indications' as separate headings. Therefore, including the pharmacological category under the 'Indications' heading instead of the 'Active ingredients' heading would not be compliant with the labeling requirements.\"}, {\"Question\": \"Assuming a non-prescription drug label includes all the required critical health information under appropriate headings, but the order of the headings is: Active ingredients, Warnings, Indications, Other information, Directions for use. Would this be compliant with the labeling requirements?\", \"Answer\": \"No\", \"Answer Explanation\": \"According to section 8(2)(b), the critical health information must be presented under appropriate headings and in the following specific order: (i) Active ingredients, (ii) Indications, (iii) Warnings, (iv) Directions for use, (v) Other information. Although the label includes all the required information under appropriate headings, the order of the headings (Active ingredients, Warnings, Indications, Other information, Directions for use) does not match the order specified in 8(2)(b). Therefore, this labeling would not be compliant with the requirements.\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            601150000,
            801100000
        ],
        "contexts": [
            "6 Interpretation. \"critical health information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer;",
            " 8 Information to be included on the label (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include: (j) where: (i) a substance or substance within the group of substances referred to in Column 1 of Schedule 1 to this Order is present in the medicine; (ii) the circumstances as set out in Column 2 of Schedule 1 exist in relation to such a substance or no circumstances are set out in Column 2; and (iii) the medicine is intended to be administered via any one or more of the route(s) of administration referred to in Column 3 of Schedule 1, then: (iv) a statement: (A) indicating that the medicine contains the substance expressed using the Name stated in Column 4 of Schedule 1; and (B) where any of the circumstances and requirements set out in Column 2 of Schedule 1 exist in relation to the substance \u2013 a statement of the kind referred to as a \u2018requirement\u2019 in that Column (if any); and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a non-prescription medicine contains the substance Astemizole at 0.1% or less per dosage unit and is intended for oral administration, what information must be included on the label according to paragraphs 8(1)(j)(iv)(A) and 8(1)(j)(iv)(B)?",
                    "Answer": "The label must state that the medicine contains Astemizole.",
                    "Answer Explanation": "According to paragraph 8(1)(j)(iv)(A), the label must include a statement indicating that the medicine contains the substance Astemizole. Since the medicine contains 0.1% or less Astemizole per dosage unit and is intended for oral administration, it matches the criteria in Schedule 1 referenced in 8(1)(j)(i)-(iii). However, no additional statement is required per 8(1)(j)(iv)(B) since Column 2 of Schedule 1 does not specify any other circumstances or requirements for Astemizole."
                },
                {
                    "Question": "Assuming a non-prescription medicine is intended for rectal administration and contains Bisacodyl at more than 5 mg per dosage unit, what information must be included on the label per paragraphs 8(1)(j)(iv)(A) and 8(1)(j)(iv)(B)?",
                    "Answer": "The label must state that the medicine contains Bisacodyl and include the statement 'not for use in children under 12 years'.",
                    "Answer Explanation": "Per paragraph 8(1)(j)(iv)(A), the label must state the medicine contains Bisacodyl, since it matches the criteria in Schedule 1 referenced in 8(1)(j)(i)-(iii) for Bisacodyl administered rectally at over 5 mg per dose. Additionally, 8(1)(j)(iv)(B) requires including the statement 'not for use in children under 12 years', because Column 2 of Schedule 1 specifies this as a requirement for Bisacodyl under the given circumstances."
                },
                {
                    "Question": "Assuming a non-prescription medicine contains Potassium salts and is intended for oral administration, which pieces of information in paragraph 8(1) are considered 'critical health information' that must be included on the label per paragraph 6?",
                    "Answer": "The warning statement about Potassium content required by paragraph 8(1)(j)(iv)(B) is considered critical health information that must be on the label.",
                    "Answer Explanation": "Paragraph 6 defines 'critical health information' as including the information required under paragraph 8(1)(j). For a medicine containing Potassium salts intended for oral use, paragraph 8(1)(j)(iv)(B) requires the label to include the warning statement specified in Column 2 of Schedule 1. Therefore, this Potassium warning is critical health information per the definition in paragraph 6."
                },
                {
                    "Question": "Assuming an oral non-prescription medicine contains multiple substances listed in Schedule 1, including Salicylic acid at 12% w\/w and Zinc compounds at an equivalent of 25 mg zinc per dosage unit, what substance information must be stated on the label per paragraphs 8(1)(j)(iv)(A) and 8(1)(j)(iv)(B)?",
                    "Answer": "The label must state that the medicine contains Salicylic acid and Zinc, and include the warnings 'Not suitable for use in children' for the Salicylic acid and 'WARNING - Contains zinc which may be dangerous if taken in large amounts or for a long period' for the Zinc compounds.",
                    "Answer Explanation": "Per 8(1)(j)(iv)(A), the label must state the medicine contains both Salicylic acid and Zinc, since both match their respective Schedule 1 criteria referenced in 8(1)(j)(i)-(iii). For Salicylic acid, 8(1)(j)(iv)(B) requires the 'Not suitable for use in children' warning from Column 2 of Schedule 1. Similarly, for Zinc compounds, 8(1)(j)(iv)(B) mandates the zinc warning statement specified in Column 2. So the label must include the substance names and both warning statements to fully comply with paragraphs 8(1)(j)(iv)(A) and (B)."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a non-prescription medicine contains the substance Astemizole at 0.1% or less per dosage unit and is intended for oral administration, what information must be included on the label according to paragraphs 8(1)(j)(iv)(A) and 8(1)(j)(iv)(B)?\", \"Answer\": \"The label must state that the medicine contains Astemizole.\", \"Answer Explanation\": \"According to paragraph 8(1)(j)(iv)(A), the label must include a statement indicating that the medicine contains the substance Astemizole. Since the medicine contains 0.1% or less Astemizole per dosage unit and is intended for oral administration, it matches the criteria in Schedule 1 referenced in 8(1)(j)(i)-(iii). However, no additional statement is required per 8(1)(j)(iv)(B) since Column 2 of Schedule 1 does not specify any other circumstances or requirements for Astemizole.\"}, {\"Question\": \"Assuming a non-prescription medicine is intended for rectal administration and contains Bisacodyl at more than 5 mg per dosage unit, what information must be included on the label per paragraphs 8(1)(j)(iv)(A) and 8(1)(j)(iv)(B)?\", \"Answer\": \"The label must state that the medicine contains Bisacodyl and include the statement 'not for use in children under 12 years'.\", \"Answer Explanation\": \"Per paragraph 8(1)(j)(iv)(A), the label must state the medicine contains Bisacodyl, since it matches the criteria in Schedule 1 referenced in 8(1)(j)(i)-(iii) for Bisacodyl administered rectally at over 5 mg per dose. Additionally, 8(1)(j)(iv)(B) requires including the statement 'not for use in children under 12 years', because Column 2 of Schedule 1 specifies this as a requirement for Bisacodyl under the given circumstances.\"}, {\"Question\": \"Assuming a non-prescription medicine contains Potassium salts and is intended for oral administration, which pieces of information in paragraph 8(1) are considered 'critical health information' that must be included on the label per paragraph 6?\", \"Answer\": \"The warning statement about Potassium content required by paragraph 8(1)(j)(iv)(B) is considered critical health information that must be on the label.\", \"Answer Explanation\": \"Paragraph 6 defines 'critical health information' as including the information required under paragraph 8(1)(j). For a medicine containing Potassium salts intended for oral use, paragraph 8(1)(j)(iv)(B) requires the label to include the warning statement specified in Column 2 of Schedule 1. Therefore, this Potassium warning is critical health information per the definition in paragraph 6.\"}, {\"Question\": \"Assuming an oral non-prescription medicine contains multiple substances listed in Schedule 1, including Salicylic acid at 12% w\/w and Zinc compounds at an equivalent of 25 mg zinc per dosage unit, what substance information must be stated on the label per paragraphs 8(1)(j)(iv)(A) and 8(1)(j)(iv)(B)?\", \"Answer\": \"The label must state that the medicine contains Salicylic acid and Zinc, and include the warnings 'Not suitable for use in children' for the Salicylic acid and 'WARNING - Contains zinc which may be dangerous if taken in large amounts or for a long period' for the Zinc compounds.\", \"Answer Explanation\": \"Per 8(1)(j)(iv)(A), the label must state the medicine contains both Salicylic acid and Zinc, since both match their respective Schedule 1 criteria referenced in 8(1)(j)(i)-(iii). For Salicylic acid, 8(1)(j)(iv)(B) requires the 'Not suitable for use in children' warning from Column 2 of Schedule 1. Similarly, for Zinc compounds, 8(1)(j)(iv)(B) mandates the zinc warning statement specified in Column 2. So the label must include the substance names and both warning statements to fully comply with paragraphs 8(1)(j)(iv)(A) and (B).\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            910000000,
            909000000
        ],
        "contexts": [
            " 9 Information to be included on the main label (10) Subsection 9(9) does not apply: (b) where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2\u2014after 30 April 2026; or",
            " 9 Information to be included on the main label (9) If the medicine is intended to be, or is, registered goods, and the name of an active ingredient included in the medicine comprises an ingredient name specified in Schedule 2 to this Order, either alone or in combination with any other descriptors, then the names of all active ingredients in the medicine, together with their quantity or proportion, must be displayed in a text size of not less than 2.5 millimetres."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a non-prescription medicine is registered goods and contains an active ingredient with a name specified in Schedule 2, and it is supplied in a container that is not small, under what conditions can the name and quantity\/proportion of the active ingredient be displayed in text less than 2.5 millimeters on the main label?",
                    "Answer": "The name and quantity\/proportion of the active ingredient can be displayed in text less than 2.5 millimeters if the medicine is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2, and this occurs after 30 April 2026.",
                    "Answer Explanation": "Subsection 9(9) requires the names and quantities\/proportions of active ingredients to be in at least 2.5mm text on the main label for registered medicines containing Schedule 2 ingredients. However, 9(10)(b) provides an exception to 9(9) for medicines not in small containers that are labelled per 9(11) and Part 1 of Schedule 2, after 30 April 2026."
                },
                {
                    "Question": "Assuming a registered non-prescription medicine contains an active ingredient listed in Schedule 2 and is packaged in a small container, is it ever permitted to display the active ingredient name and quantity in text smaller than 2.5 millimeters on the main label?",
                    "Answer": "No, it is never permitted to display the active ingredient name and quantity in text smaller than 2.5 millimeters on the main label in this case.",
                    "Answer Explanation": "Subsection 9(9) mandates that for registered medicines with Schedule 2 ingredients, the active ingredient names and quantities must be in minimum 2.5mm text on the main label. The exception in 9(10)(b) allowing smaller text only applies to medicines not in small containers. Since this medicine is in a small container, the minimum 2.5mm text size requirement in 9(9) always applies."
                },
                {
                    "Question": "Assuming a registered non-prescription medicine contains multiple active ingredients, one of which has a name listed in Schedule 2, and the medicine is not packaged in a small container, what is the earliest date the main label can display the names and quantities of the active ingredients in text smaller than 2.5 millimeters if it complies with the labelling requirements in 9(11) and Part 1 of Schedule 2?",
                    "Answer": "1 May 2026 is the earliest date the main label can display the active ingredient names and quantities in text smaller than 2.5 millimeters in this scenario.",
                    "Answer Explanation": "Subsection 9(9) requires at least 2.5mm text for active ingredient details on registered medicines with a Schedule 2 ingredient. However, 9(10)(b) allows an exception for medicines not in small containers that are labelled according to 9(11) and Part 1 of Schedule 2, but only after 30 April 2026. So 1 May 2026 is the earliest date the smaller text is permitted."
                },
                {
                    "Question": "Assuming a non-prescription medicine is not registered goods but it contains an active ingredient that has a name specified in Schedule 2, and the medicine is not packaged in a small container, do the requirements in subsections 9(9) and 9(10) regarding minimum text size for displaying the active ingredient names and quantities on the main label apply?",
                    "Answer": "No, the minimum text size requirements in subsections 9(9) and 9(10) do not apply in this case.",
                    "Answer Explanation": "Subsection 9(9) specifies that the minimum 2.5mm text size for active ingredient names and quantities only applies if the medicine is intended to be, or is, registered goods. Since this medicine is stated to not be registered goods, 9(9) does not apply, and therefore the exception in 9(10) is also not applicable, even though the medicine is not in a small container."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a non-prescription medicine is registered goods and contains an active ingredient with a name specified in Schedule 2, and it is supplied in a container that is not small, under what conditions can the name and quantity\/proportion of the active ingredient be displayed in text less than 2.5 millimeters on the main label?\",\n    \"Answer\": \"The name and quantity\/proportion of the active ingredient can be displayed in text less than 2.5 millimeters if the medicine is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2, and this occurs after 30 April 2026.\",\n    \"Answer Explanation\": \"Subsection 9(9) requires the names and quantities\/proportions of active ingredients to be in at least 2.5mm text on the main label for registered medicines containing Schedule 2 ingredients. However, 9(10)(b) provides an exception to 9(9) for medicines not in small containers that are labelled per 9(11) and Part 1 of Schedule 2, after 30 April 2026.\"\n  },\n  {\n    \"Question\": \"Assuming a registered non-prescription medicine contains an active ingredient listed in Schedule 2 and is packaged in a small container, is it ever permitted to display the active ingredient name and quantity in text smaller than 2.5 millimeters on the main label?\",\n    \"Answer\": \"No, it is never permitted to display the active ingredient name and quantity in text smaller than 2.5 millimeters on the main label in this case.\",\n    \"Answer Explanation\": \"Subsection 9(9) mandates that for registered medicines with Schedule 2 ingredients, the active ingredient names and quantities must be in minimum 2.5mm text on the main label. The exception in 9(10)(b) allowing smaller text only applies to medicines not in small containers. Since this medicine is in a small container, the minimum 2.5mm text size requirement in 9(9) always applies.\"\n  },\n  {\n    \"Question\": \"Assuming a registered non-prescription medicine contains multiple active ingredients, one of which has a name listed in Schedule 2, and the medicine is not packaged in a small container, what is the earliest date the main label can display the names and quantities of the active ingredients in text smaller than 2.5 millimeters if it complies with the labelling requirements in 9(11) and Part 1 of Schedule 2?\",\n    \"Answer\": \"1 May 2026 is the earliest date the main label can display the active ingredient names and quantities in text smaller than 2.5 millimeters in this scenario.\",\n    \"Answer Explanation\": \"Subsection 9(9) requires at least 2.5mm text for active ingredient details on registered medicines with a Schedule 2 ingredient. However, 9(10)(b) allows an exception for medicines not in small containers that are labelled according to 9(11) and Part 1 of Schedule 2, but only after 30 April 2026. So 1 May 2026 is the earliest date the smaller text is permitted.\"\n  },\n  {\n    \"Question\": \"Assuming a non-prescription medicine is not registered goods but it contains an active ingredient that has a name specified in Schedule 2, and the medicine is not packaged in a small container, do the requirements in subsections 9(9) and 9(10) regarding minimum text size for displaying the active ingredient names and quantities on the main label apply?\",\n    \"Answer\": \"No, the minimum text size requirements in subsections 9(9) and 9(10) do not apply in this case.\",\n    \"Answer Explanation\": \"Subsection 9(9) specifies that the minimum 2.5mm text size for active ingredient names and quantities only applies if the medicine is intended to be, or is, registered goods. Since this medicine is stated to not be registered goods, 9(9) does not apply, and therefore the exception in 9(10) is also not applicable, even though the medicine is not in a small container.\"\n  }\n]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            1009020000,
            800000000
        ],
        "contexts": [
            " 10 Qualifications and special requirements (9) Strip, blister and dial dispenser packs (b) If, in relation to a medicine referred to in (a) there are: (i) four or more active ingredients in the medicine and the medicine is intended to be, or is, registered goods; or (ii) two or more active ingredients in the medicine and the medicine is intended to be, or is, listed goods, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iii) the name of the medicine; and (iv) the batch number of the medicine preceded by the batch number prefix; and (v) the expiry date of the medicine preceded by the expiry date prefix; and (vi) the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor of the medicine.",
            " 8 Information to be included on the label (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include: (n) a statement of the purpose or purposes for which it is intended that the medicine be used, except where: (i) the medicine is: (A) supplied solely to a complementary healthcare practitioner for supply to a person after affixing by the practitioner of an instruction label on the medicine following a consultation with that person; and (B) the label of the medicine includes the words \u2018For Practitioner Dispensing Only\u2019; and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is supplied solely to a complementary healthcare practitioner for supply to a person after affixing an instruction label on the medicine following a consultation, and the medicine label includes 'For Practitioner Dispensing Only', does the label need to include a statement of the purpose for which the medicine is intended to be used according to sections 8(1)(n) and 10(9)(b)?",
                    "Answer": "No",
                    "Answer Explanation": "According to section 8(1)(n), the label does not need to include a statement of purpose if the medicine is supplied solely to a complementary healthcare practitioner for dispensing after consultation, and the label includes 'For Practitioner Dispensing Only'. Section 10(9)(b) does not override this exception."
                },
                {
                    "Question": "For a registered medicine with 4 active ingredients, packaged in a blister pack, assuming sections 8 and 9 are not fully complied with on the blister pack label, what information must be displayed on the blister pack label to be sufficient for compliance per section 10(9)(b)?",
                    "Answer": "The name of the medicine, batch number preceded by the batch number prefix, expiry date preceded by the expiry date prefix, and name of the sponsor\/distributor or registered trademark if it identifies them.",
                    "Answer Explanation": "Section 10(9)(b) states that for a registered medicine with 4 or more active ingredients in a blister pack, if the label does not fully comply with sections 8 and 9, it is sufficient to display the medicine name, batch number with prefix, expiry date with prefix, and sponsor\/distributor name or identifying trademark."
                },
                {
                    "Question": "Assuming a listed medicine has 3 active ingredients and is packaged in strip packs, does section 10(9)(b) specify reduced labeling requirements for the strip pack labels if sections 8 and 9 are not fully met?",
                    "Answer": "No",
                    "Answer Explanation": "Section 10(9)(b)(ii) specifies reduced labeling requirements only for listed medicines with 2 or more active ingredients. Since this is a listed medicine with 3 active ingredients, it does not meet the criteria in 10(9)(b) for the labeling exception. Full compliance with sections 8 and 9 would be required."
                },
                {
                    "Question": "If a registered medicine with 5 active ingredients is packaged in dial dispenser packs and the dial pack labels do not state the purpose for which the medicine is intended to be used, can section 10(9)(b) be applied to allow reduced labeling requirements and consider the labels compliant?",
                    "Answer": "Yes",
                    "Answer Explanation": "The medicine has more than 4 active ingredients and is registered, so it meets the criteria in section 10(9)(b)(i). This allows the reduced labeling on the dial pack specified in 10(9)(b)(iii)-(vi) to be considered sufficient for compliance with sections 8 and 9. Section 8(1)(n) normally requires the label to state the purpose, but 10(9)(b) provides an exception."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a medicine is supplied solely to a complementary healthcare practitioner for supply to a person after affixing an instruction label on the medicine following a consultation, and the medicine label includes 'For Practitioner Dispensing Only', does the label need to include a statement of the purpose for which the medicine is intended to be used according to sections 8(1)(n) and 10(9)(b)?\",\n    \"Answer\": \"No\",\n    \"Answer Explanation\": \"According to section 8(1)(n), the label does not need to include a statement of purpose if the medicine is supplied solely to a complementary healthcare practitioner for dispensing after consultation, and the label includes 'For Practitioner Dispensing Only'. Section 10(9)(b) does not override this exception.\"\n  },\n  {\n    \"Question\": \"For a registered medicine with 4 active ingredients, packaged in a blister pack, assuming sections 8 and 9 are not fully complied with on the blister pack label, what information must be displayed on the blister pack label to be sufficient for compliance per section 10(9)(b)?\",\n    \"Answer\": \"The name of the medicine, batch number preceded by the batch number prefix, expiry date preceded by the expiry date prefix, and name of the sponsor\/distributor or registered trademark if it identifies them.\",\n    \"Answer Explanation\": \"Section 10(9)(b) states that for a registered medicine with 4 or more active ingredients in a blister pack, if the label does not fully comply with sections 8 and 9, it is sufficient to display the medicine name, batch number with prefix, expiry date with prefix, and sponsor\/distributor name or identifying trademark.\"\n  },  \n  {\n    \"Question\": \"Assuming a listed medicine has 3 active ingredients and is packaged in strip packs, does section 10(9)(b) specify reduced labeling requirements for the strip pack labels if sections 8 and 9 are not fully met?\",\n    \"Answer\": \"No\",\n    \"Answer Explanation\": \"Section 10(9)(b)(ii) specifies reduced labeling requirements only for listed medicines with 2 or more active ingredients. Since this is a listed medicine with 3 active ingredients, it does not meet the criteria in 10(9)(b) for the labeling exception. Full compliance with sections 8 and 9 would be required.\"\n  },\n  {\n    \"Question\": \"If a registered medicine with 5 active ingredients is packaged in dial dispenser packs and the dial pack labels do not state the purpose for which the medicine is intended to be used, can section 10(9)(b) be applied to allow reduced labeling requirements and consider the labels compliant?\",\n    \"Answer\": \"Yes\",\n    \"Answer Explanation\": \"The medicine has more than 4 active ingredients and is registered, so it meets the criteria in section 10(9)(b)(i). This allows the reduced labeling on the dial pack specified in 10(9)(b)(iii)-(vi) to be considered sufficient for compliance with sections 8 and 9. Section 8(1)(n) normally requires the label to state the purpose, but 10(9)(b) provides an exception.\"\n  }\n]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            908040000,
            906020000
        ],
        "contexts": [
            " 9 Information to be included on the main label (8) Where a medicine is: (d) the information required under either paragraph 9(6)(b) or subsection 9(7) must be provided separately in relation to each formulation of medicine in the composite pack or medicine kit.",
            " 9 Information to be included on the main label (6) If the medicine is intended to be, or is, listed goods: (b) if there are four or more active ingredients in the medicine - the name of every active ingredient, together with the quantity or proportion of every active ingredient, may appear on a side panel or side label or on a rear panel or rear label."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is listed goods and contains 5 active ingredients, can the name and quantity of every active ingredient appear on the main label? If not, where must this information appear?",
                    "Answer": "No, the name and quantity of every active ingredient cannot appear on the main label.",
                    "Answer Explanation": "According to 9(6)(b), if the medicine is intended to be, or is, listed goods and has four or more active ingredients, the name and quantity or proportion of every active ingredient may appear on a side panel, side label, rear panel or rear label, rather than the main label."
                },
                {
                    "Question": "For a medicine that is listed goods and comes in a composite pack with multiple formulations, is the name and quantity of active ingredients required to be provided separately for each formulation, or can it be provided collectively? Assume there are 5 active ingredients per formulation.",
                    "Answer": "The name and quantity of active ingredients must be provided separately for each formulation in the composite pack.",
                    "Answer Explanation": "9(8)(d) states that where a listed medicine comes in a composite pack, the information required under 9(6)(b) (name and quantity of 4 or more active ingredients appearing on side\/rear panel\/label rather than main label) must be provided separately in relation to each formulation of medicine in the composite pack."
                },
                {
                    "Question": "A listed medicine kit contains 3 different medicine formulations, each with 6 active ingredients. Assuming the name and quantity of active ingredients is not on the main label, can this information be provided collectively for all formulations on a single side panel of the kit? Why or why not?",
                    "Answer": "No, the name and quantity of the 6 active ingredients for each of the 3 formulations cannot be provided collectively on a single side panel of the medicine kit.",
                    "Answer Explanation": "9(6)(b) allows the name and quantity of 4 or more active ingredients in a listed medicine to appear on a side\/rear panel or label rather than the main label. However, 9(8)(d) clarifies that for a medicine kit, this information must be provided separately for each formulation in the kit. Therefore, the active ingredient details need to be listed separately for the 3 different formulations, not collectively."
                },
                {
                    "Question": "For a listed medicine containing 7 active ingredients, if the name and quantity of each ingredient is included on a side label, can any part of this information also appear on the main label? Justify your answer.",
                    "Answer": "Yes, some or all of the name and quantity information for the 7 active ingredients can appear on the main label in addition to the side label.",
                    "Answer Explanation": "9(6)(b) states that for a listed medicine with 4 or more active ingredients, the name and quantity of every active ingredient may appear on a side\/rear panel or label. The use of \"may\" indicates this location is optional, not mandatory. Therefore, this information can appear on the main label as well as the side label. 9(6)(b) does not prohibit any of these details from the main label."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine is listed goods and contains 5 active ingredients, can the name and quantity of every active ingredient appear on the main label? If not, where must this information appear?\", \"Answer\": \"No, the name and quantity of every active ingredient cannot appear on the main label.\", \"Answer Explanation\": \"According to 9(6)(b), if the medicine is intended to be, or is, listed goods and has four or more active ingredients, the name and quantity or proportion of every active ingredient may appear on a side panel, side label, rear panel or rear label, rather than the main label.\"}, {\"Question\": \"For a medicine that is listed goods and comes in a composite pack with multiple formulations, is the name and quantity of active ingredients required to be provided separately for each formulation, or can it be provided collectively? Assume there are 5 active ingredients per formulation.\", \"Answer\": \"The name and quantity of active ingredients must be provided separately for each formulation in the composite pack.\", \"Answer Explanation\": \"9(8)(d) states that where a listed medicine comes in a composite pack, the information required under 9(6)(b) (name and quantity of 4 or more active ingredients appearing on side\/rear panel\/label rather than main label) must be provided separately in relation to each formulation of medicine in the composite pack.\"}, {\"Question\": \"A listed medicine kit contains 3 different medicine formulations, each with 6 active ingredients. Assuming the name and quantity of active ingredients is not on the main label, can this information be provided collectively for all formulations on a single side panel of the kit? Why or why not?\", \"Answer\": \"No, the name and quantity of the 6 active ingredients for each of the 3 formulations cannot be provided collectively on a single side panel of the medicine kit.\", \"Answer Explanation\": \"9(6)(b) allows the name and quantity of 4 or more active ingredients in a listed medicine to appear on a side\/rear panel or label rather than the main label. However, 9(8)(d) clarifies that for a medicine kit, this information must be provided separately for each formulation in the kit. Therefore, the active ingredient details need to be listed separately for the 3 different formulations, not collectively.\"}, {\"Question\": \"For a listed medicine containing 7 active ingredients, if the name and quantity of each ingredient is included on a side label, can any part of this information also appear on the main label? Justify your answer.\", \"Answer\": \"Yes, some or all of the name and quantity information for the 7 active ingredients can appear on the main label in addition to the side label.\", \"Answer Explanation\": \"9(6)(b) states that for a listed medicine with 4 or more active ingredients, the name and quantity of every active ingredient may appear on a side\/rear panel or label. The use of \\\"may\\\" indicates this location is optional, not mandatory. Therefore, this information can appear on the main label as well as the side label. 9(6)(b) does not prohibit any of these details from the main label.\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            1103030000,
            1103020000
        ],
        "contexts": [
            " 11 How information is to be expressed (3) Expression of quantity or proportion of active ingredients for homoeopathic preparations The label on the container and on the primary pack of a medicine that contains a homoeopathic preparation must include: (c) where paragraphs (a) and (b) do not apply- the quantity of the preparation in one millilitre or in one gram of the medicine",
            " 11 How information is to be expressed (3) Expression of quantity or proportion of active ingredients for homoeopathic preparations The label on the container and on the primary pack of a medicine that contains a homoeopathic preparation must include: (b) where all active ingredients of the medicine are homoeopathic preparations and are all included in the medicine in the same proportion - as \u2018Contains equal parts of ...\u2019 followed by the name of each active ingredient; or"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a homoeopathic medicine contains active ingredients X and Y in equal proportion, what information must be included on the label of the container and primary pack of this medicine regarding the quantity or proportion of the active ingredients, according to the given regulation sections?",
                    "Answer": "The label must include the text 'Contains equal parts of ...' followed by the names of the active ingredients X and Y.",
                    "Answer Explanation": "Section 11(3)(b) states that if all active ingredients of a homoeopathic medicine are included in the same proportion, the label must include the text 'Contains equal parts of ...' followed by the name of each active ingredient. Since the question assumes active ingredients X and Y are in equal proportion, this clause applies."
                },
                {
                    "Question": "Consider a homoeopathic medicine where the active ingredients are not all included in the same proportion, and sections 11(3)(a) and 11(3)(b) do not apply. According to the given regulation, what quantity or proportion information must be provided on the label of the container and primary pack of this medicine?",
                    "Answer": "The label must include the quantity of the homoeopathic preparation in one millilitre or in one gram of the medicine.",
                    "Answer Explanation": "Section 11(3)(c) states that where paragraphs (a) and (b) do not apply, the label on the container and primary pack of a homoeopathic medicine must include the quantity of the preparation in one millilitre or one gram of the medicine. The question assumes sections 11(3)(a) and 11(3)(b) do not apply, so section 11(3)(c) is the relevant requirement here."
                },
                {
                    "Question": "A homoeopathic medicine contains three active ingredients: A, B, and C. Ingredients A and B are in equal proportion, but ingredient C is in a different proportion. Assuming sections 11(3)(a) and 11(3)(b) do not apply, what quantity or proportion information must be included on the label as per the given regulation sections?",
                    "Answer": "The label must include the quantity of the homoeopathic preparation in one millilitre or in one gram of the medicine.",
                    "Answer Explanation": "Although ingredients A and B are in equal proportion, ingredient C is in a different proportion. Therefore, not all active ingredients are included in the same proportion, so section 11(3)(b) does not apply. The question also assumes section 11(3)(a) does not apply. In this case, section 11(3)(c) requires that the label include the quantity of the preparation in one millilitre or one gram of the medicine."
                },
                {
                    "Question": "For a homoeopathic medicine where sections 11(3)(a), 11(3)(b), and 11(3)(c) all do not apply, what quantity or proportion information about the active ingredients, if any, is required to be on the label of the container and primary pack based solely on the given regulation sections?",
                    "Answer": "The given regulation sections do not specify any labelling requirements for quantity or proportion of active ingredients in a homoeopathic medicine if sections 11(3)(a), 11(3)(b), and 11(3)(c) all do not apply.",
                    "Answer Explanation": "Sections 11(3)(a), 11(3)(b), and 11(3)(c) cover different scenarios for expressing the quantity or proportion of active ingredients on the label of a homoeopathic medicine. However, these are the only relevant provisions in the given regulation sections. If none of these three sections apply, the given regulation excerpts do not mandate any other requirements for indicating quantity or proportion of active ingredients on the label."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a homoeopathic medicine contains active ingredients X and Y in equal proportion, what information must be included on the label of the container and primary pack of this medicine regarding the quantity or proportion of the active ingredients, according to the given regulation sections?\", \"Answer\": \"The label must include the text 'Contains equal parts of ...' followed by the names of the active ingredients X and Y.\", \"Answer Explanation\": \"Section 11(3)(b) states that if all active ingredients of a homoeopathic medicine are included in the same proportion, the label must include the text 'Contains equal parts of ...' followed by the name of each active ingredient. Since the question assumes active ingredients X and Y are in equal proportion, this clause applies.\"}, {\"Question\": \"Consider a homoeopathic medicine where the active ingredients are not all included in the same proportion, and sections 11(3)(a) and 11(3)(b) do not apply. According to the given regulation, what quantity or proportion information must be provided on the label of the container and primary pack of this medicine?\", \"Answer\": \"The label must include the quantity of the homoeopathic preparation in one millilitre or in one gram of the medicine.\", \"Answer Explanation\": \"Section 11(3)(c) states that where paragraphs (a) and (b) do not apply, the label on the container and primary pack of a homoeopathic medicine must include the quantity of the preparation in one millilitre or one gram of the medicine. The question assumes sections 11(3)(a) and 11(3)(b) do not apply, so section 11(3)(c) is the relevant requirement here.\"}, {\"Question\": \"A homoeopathic medicine contains three active ingredients: A, B, and C. Ingredients A and B are in equal proportion, but ingredient C is in a different proportion. Assuming sections 11(3)(a) and 11(3)(b) do not apply, what quantity or proportion information must be included on the label as per the given regulation sections?\", \"Answer\": \"The label must include the quantity of the homoeopathic preparation in one millilitre or in one gram of the medicine.\", \"Answer Explanation\": \"Although ingredients A and B are in equal proportion, ingredient C is in a different proportion. Therefore, not all active ingredients are included in the same proportion, so section 11(3)(b) does not apply. The question also assumes section 11(3)(a) does not apply. In this case, section 11(3)(c) requires that the label include the quantity of the preparation in one millilitre or one gram of the medicine.\"}, {\"Question\": \"For a homoeopathic medicine where sections 11(3)(a), 11(3)(b), and 11(3)(c) all do not apply, what quantity or proportion information about the active ingredients, if any, is required to be on the label of the container and primary pack based solely on the given regulation sections?\", \"Answer\": \"The given regulation sections do not specify any labelling requirements for quantity or proportion of active ingredients in a homoeopathic medicine if sections 11(3)(a), 11(3)(b), and 11(3)(c) all do not apply.\", \"Answer Explanation\": \"Sections 11(3)(a), 11(3)(b), and 11(3)(c) cover different scenarios for expressing the quantity or proportion of active ingredients on the label of a homoeopathic medicine. However, these are the only relevant provisions in the given regulation sections. If none of these three sections apply, the given regulation excerpts do not mandate any other requirements for indicating quantity or proportion of active ingredients on the label.\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            903020000,
            1105000000
        ],
        "contexts": [
            " 9 Information to be included on the main label (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must: (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;",
            " 11 How information is to be expressed (5) Inclusion of common names of vitamins Where a medicine contains an active ingredient that is a vitamin, then the word \u2018vitamin\u2019, or any suitable unambiguous abbreviation of the word vitamin, together with the common name of that vitamin, may appear on a main label of the medicine either: (b) on a separate line of text - immediately below the related name of the active ingredient that is a vitamin and the quantity of that active ingredient."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine contains an active ingredient that is a vitamin, can the common name of that vitamin appear on the main label immediately below the related name and quantity of the active ingredient, on a separate line of text?",
                    "Answer": "Yes",
                    "Answer Explanation": "According to paragraph 11(5)(b), where a medicine contains an active ingredient that is a vitamin, the word 'vitamin' or any suitable unambiguous abbreviation, together with the common name of that vitamin, may appear on a main label immediately below the related name of the active ingredient and the quantity of that active ingredient, on a separate line of text."
                },
                {
                    "Question": "Assuming a medicine contains an active ingredient that is a vitamin, can any text or graphics separate the name of the medicine from the name of that active ingredient on the main label?",
                    "Answer": "No, with some exceptions",
                    "Answer Explanation": "According to paragraph 9(3)(b), the name of the medicine and the name(s) of active ingredient(s) on the main label must not be separated by any text or graphics, with some specific exceptions listed in subparagraphs 9(3)(b)(i) and (ii). One of those exceptions, as per 9(3)(b)(i)(C), is the inclusion of the common name of a vitamin active ingredient as permitted by subsection 11(5)."
                },
                {
                    "Question": "Assuming a medicine contains an active ingredient that is a vitamin, can the common name of that vitamin be included on the main label without the word 'vitamin' or a suitable abbreviation?",
                    "Answer": "No",
                    "Answer Explanation": "Subsection 11(5) states that where a medicine contains an active ingredient that is a vitamin, the word 'vitamin', or any suitable unambiguous abbreviation of the word vitamin, together with the common name of that vitamin, may appear on a main label of the medicine. This implies that the common name of the vitamin cannot be included without the word 'vitamin' or a suitable abbreviation."
                },
                {
                    "Question": "Assuming a medicine contains an active ingredient that is a vitamin, is it required to include the common name of that vitamin on the main label?",
                    "Answer": "No",
                    "Answer Explanation": "The wording in subsection 11(5) uses 'may' when referring to the inclusion of the word 'vitamin' together with the common name of that vitamin on the main label. This indicates that it is permitted but not required to include this information for active ingredients that are vitamins."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine contains an active ingredient that is a vitamin, can the common name of that vitamin appear on the main label immediately below the related name and quantity of the active ingredient, on a separate line of text?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"According to paragraph 11(5)(b), where a medicine contains an active ingredient that is a vitamin, the word 'vitamin' or any suitable unambiguous abbreviation, together with the common name of that vitamin, may appear on a main label immediately below the related name of the active ingredient and the quantity of that active ingredient, on a separate line of text.\"}, {\"Question\": \"Assuming a medicine contains an active ingredient that is a vitamin, can any text or graphics separate the name of the medicine from the name of that active ingredient on the main label?\", \"Answer\": \"No, with some exceptions\", \"Answer Explanation\": \"According to paragraph 9(3)(b), the name of the medicine and the name(s) of active ingredient(s) on the main label must not be separated by any text or graphics, with some specific exceptions listed in subparagraphs 9(3)(b)(i) and (ii). One of those exceptions, as per 9(3)(b)(i)(C), is the inclusion of the common name of a vitamin active ingredient as permitted by subsection 11(5).\"}, {\"Question\": \"Assuming a medicine contains an active ingredient that is a vitamin, can the common name of that vitamin be included on the main label without the word 'vitamin' or a suitable abbreviation?\", \"Answer\": \"No\", \"Answer Explanation\": \"Subsection 11(5) states that where a medicine contains an active ingredient that is a vitamin, the word 'vitamin', or any suitable unambiguous abbreviation of the word vitamin, together with the common name of that vitamin, may appear on a main label of the medicine. This implies that the common name of the vitamin cannot be included without the word 'vitamin' or a suitable abbreviation.\"}, {\"Question\": \"Assuming a medicine contains an active ingredient that is a vitamin, is it required to include the common name of that vitamin on the main label?\", \"Answer\": \"No\", \"Answer Explanation\": \"The wording in subsection 11(5) uses 'may' when referring to the inclusion of the word 'vitamin' together with the common name of that vitamin on the main label. This indicates that it is permitted but not required to include this information for active ingredients that are vitamins.\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            1007000000,
            900000000
        ],
        "contexts": [
            " 10 Qualifications and special requirements (7) Small containers If: (j) the expiry date of the medicine preceded by the expiry date prefix; and",
            " 9 Information to be included on the main label (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must: (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a small container of medicine has an expiry date of January 2025 and active ingredients are listed on the main label, what information must be included on the main label and how should it be formatted?",
                    "Answer": "The main label must include the name of the medicine, name(s) of active ingredient(s), and the expiry date preceded by the expiry date prefix. The name of the medicine and active ingredient(s) must not be separated by any text or graphics, with some exceptions as outlined in 9(3)(b).",
                    "Answer Explanation": "Section 10(7)(j) requires the expiry date preceded by the expiry date prefix on small containers. Section 9(3)(b) specifies that the name of the medicine and active ingredient(s) must not be separated by text or graphics on the main label, with some exceptions."
                },
                {
                    "Question": "Assuming a medicine is packaged in a small container and has multiple active ingredients, what information is required on the main label and how must the expiry date be formatted?",
                    "Answer": "The main label must include the name of the medicine, the names of all active ingredients, and the expiry date preceded by the expiry date prefix. The name of the medicine and active ingredients must not be separated by any text or graphics, with some exceptions as outlined in 9(3)(b).",
                    "Answer Explanation": "Section 10(7)(j) requires the expiry date preceded by the expiry date prefix on small containers. Section 9(3)(b) specifies that the name of the medicine and names of active ingredients must not be separated by text or graphics on the main label, with some exceptions."
                },
                {
                    "Question": "For a medicine in a small container with an expiry date of June 2023, assuming the active ingredients are required to be listed on the main label, how should this information be presented to comply with the regulations?",
                    "Answer": "The main label must include the expiry date 'June 2023' preceded by the expiry date prefix, as well as the name of the medicine and names of the active ingredients. The medicine name and active ingredients must not be separated by any text or graphics, except as permitted by the exceptions in 9(3)(b).",
                    "Answer Explanation": "10(7)(j) requires the expiry date format with prefix for small containers. 9(3)(b) specifies the medicine name and active ingredients must not be separated on the main label, with some allowed exceptions."
                },
                {
                    "Question": "Assuming a small container of medicine lists the active ingredients on the main label, what is the required format for displaying the expiry date, and how must the active ingredients be presented in relation to the medicine name?",
                    "Answer": "The expiry date on the small container must be preceded by the expiry date prefix. The active ingredients and medicine name must be on the main label and cannot be separated by any text or graphics, except where permitted by the specific exceptions outlined in 9(3)(b).",
                    "Answer Explanation": "The expiry date format for small containers is specified in 10(7)(j). The requirement for active ingredients and medicine name to be unseparated on the main label, with limited exceptions, is stated in 9(3)(b)."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a small container of medicine has an expiry date of January 2025 and active ingredients are listed on the main label, what information must be included on the main label and how should it be formatted?\", \"Answer\": \"The main label must include the name of the medicine, name(s) of active ingredient(s), and the expiry date preceded by the expiry date prefix. The name of the medicine and active ingredient(s) must not be separated by any text or graphics, with some exceptions as outlined in 9(3)(b).\", \"Answer Explanation\": \"Section 10(7)(j) requires the expiry date preceded by the expiry date prefix on small containers. Section 9(3)(b) specifies that the name of the medicine and active ingredient(s) must not be separated by text or graphics on the main label, with some exceptions.\"}, {\"Question\": \"Assuming a medicine is packaged in a small container and has multiple active ingredients, what information is required on the main label and how must the expiry date be formatted?\", \"Answer\": \"The main label must include the name of the medicine, the names of all active ingredients, and the expiry date preceded by the expiry date prefix. The name of the medicine and active ingredients must not be separated by any text or graphics, with some exceptions as outlined in 9(3)(b).\", \"Answer Explanation\": \"Section 10(7)(j) requires the expiry date preceded by the expiry date prefix on small containers. Section 9(3)(b) specifies that the name of the medicine and names of active ingredients must not be separated by text or graphics on the main label, with some exceptions.\"}, {\"Question\": \"For a medicine in a small container with an expiry date of June 2023, assuming the active ingredients are required to be listed on the main label, how should this information be presented to comply with the regulations?\", \"Answer\": \"The main label must include the expiry date 'June 2023' preceded by the expiry date prefix, as well as the name of the medicine and names of the active ingredients. The medicine name and active ingredients must not be separated by any text or graphics, except as permitted by the exceptions in 9(3)(b).\", \"Answer Explanation\": \"10(7)(j) requires the expiry date format with prefix for small containers. 9(3)(b) specifies the medicine name and active ingredients must not be separated on the main label, with some allowed exceptions.\"}, {\"Question\": \"Assuming a small container of medicine lists the active ingredients on the main label, what is the required format for displaying the expiry date, and how must the active ingredients be presented in relation to the medicine name?\", \"Answer\": \"The expiry date on the small container must be preceded by the expiry date prefix. The active ingredients and medicine name must be on the main label and cannot be separated by any text or graphics, except where permitted by the specific exceptions outlined in 9(3)(b).\", \"Answer Explanation\": \"The expiry date format for small containers is specified in 10(7)(j). The requirement for active ingredients and medicine name to be unseparated on the main label, with limited exceptions, is stated in 9(3)(b).\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            301000000,
            400000000
        ],
        "contexts": [
            "3 Application - Therapeutic goods to which this Order applies(1) Subject to sections 4 and 5, this Order applies to medicines supplied or for supply in Australia, other than those specified under section 3 of the Therapeutic Goods Order No. 91 \u2013 Standard for labels of prescription and related medicines.",
            "4 Transition arrangements (3) Notwithstanding (1) and (2), medicines imported into or manufactured in Australia before 1 September 2020 but supplied by a person other than the sponsor after that date must comply with TGO 69 (2017) if at the time of their release for supply they complied with TGO 69 (2017)."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine was supplied in Australia on 1 October 2020 by a sponsor, and it did not meet the requirements of section 3 of the Therapeutic Goods Order No. 91, which Order would the medicine's label need to comply with?",
                    "Answer": "The medicine's label would need to comply with this Order (the Standard for labels of non-prescription medicines).",
                    "Answer Explanation": "Section 3(1) states that this Order applies to medicines supplied in Australia, other than those specified under section 3 of the Therapeutic Goods Order No. 91. Since the medicine was supplied on 1 October 2020 (after the 1 September 2020 transition date mentioned in section 4) by a sponsor and did not meet the requirements of section 3 of TGO No. 91, its label must comply with this Order."
                },
                {
                    "Question": "Assuming a medicine was manufactured in Australia on 1 August 2020, imported into Australia before 1 September 2020, and supplied by a person other than the sponsor after 1 September 2020, which Order would the medicine's label need to comply with if it complied with TGO 69 (2017) at the time of release for supply?",
                    "Answer": "The medicine's label would need to comply with TGO 69 (2017).",
                    "Answer Explanation": "Section 4(3) states that medicines imported into or manufactured in Australia before 1 September 2020 but supplied by a person other than the sponsor after that date must comply with TGO 69 (2017) if at the time of their release for supply they complied with TGO 69 (2017). Since the medicine was manufactured on 1 August 2020 (before 1 September 2020), imported before 1 September 2020, and complied with TGO 69 (2017) at the time of release for supply, its label must comply with TGO 69 (2017) even though it was supplied after 1 September 2020."
                },
                {
                    "Question": "Assuming a medicine was supplied in Australia on 1 October 2020 by a sponsor and met the requirements of section 3 of the Therapeutic Goods Order No. 91, which Order would the medicine's label need to comply with?",
                    "Answer": "The medicine's label would not need to comply with this Order (the Standard for labels of non-prescription medicines).",
                    "Answer Explanation": "Section 3(1) states that this Order applies to medicines supplied in Australia, other than those specified under section 3 of the Therapeutic Goods Order No. 91. Since the medicine met the requirements of section 3 of TGO No. 91, it is exempt from this Order per section 3(1)."
                },
                {
                    "Question": "Assuming a medicine was manufactured in Australia on 1 October 2020, supplied by the sponsor on the same date, and did not meet the requirements of section 3 of the Therapeutic Goods Order No. 91, which Order would the medicine's label need to comply with?",
                    "Answer": "The medicine's label would need to comply with this Order (the Standard for labels of non-prescription medicines).",
                    "Answer Explanation": "Section 3(1) states that this Order applies to medicines supplied in Australia, other than those specified under section 3 of the Therapeutic Goods Order No. 91. Section 4(3) provides a transition arrangement only for medicines manufactured before 1 September 2020 and supplied by someone other than the sponsor after that date. Since the medicine was manufactured on 1 October 2020 (after 1 September 2020), supplied by the sponsor, and did not meet the requirements of section 3 of TGO No. 91, its label must comply with this Order."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine was supplied in Australia on 1 October 2020 by a sponsor, and it did not meet the requirements of section 3 of the Therapeutic Goods Order No. 91, which Order would the medicine's label need to comply with?\", \"Answer\": \"The medicine's label would need to comply with this Order (the Standard for labels of non-prescription medicines).\", \"Answer Explanation\": \"Section 3(1) states that this Order applies to medicines supplied in Australia, other than those specified under section 3 of the Therapeutic Goods Order No. 91. Since the medicine was supplied on 1 October 2020 (after the 1 September 2020 transition date mentioned in section 4) by a sponsor and did not meet the requirements of section 3 of TGO No. 91, its label must comply with this Order.\"}, {\"Question\": \"Assuming a medicine was manufactured in Australia on 1 August 2020, imported into Australia before 1 September 2020, and supplied by a person other than the sponsor after 1 September 2020, which Order would the medicine's label need to comply with if it complied with TGO 69 (2017) at the time of release for supply?\", \"Answer\": \"The medicine's label would need to comply with TGO 69 (2017).\", \"Answer Explanation\": \"Section 4(3) states that medicines imported into or manufactured in Australia before 1 September 2020 but supplied by a person other than the sponsor after that date must comply with TGO 69 (2017) if at the time of their release for supply they complied with TGO 69 (2017). Since the medicine was manufactured on 1 August 2020 (before 1 September 2020), imported before 1 September 2020, and complied with TGO 69 (2017) at the time of release for supply, its label must comply with TGO 69 (2017) even though it was supplied after 1 September 2020.\"}, {\"Question\": \"Assuming a medicine was supplied in Australia on 1 October 2020 by a sponsor and met the requirements of section 3 of the Therapeutic Goods Order No. 91, which Order would the medicine's label need to comply with?\", \"Answer\": \"The medicine's label would not need to comply with this Order (the Standard for labels of non-prescription medicines).\", \"Answer Explanation\": \"Section 3(1) states that this Order applies to medicines supplied in Australia, other than those specified under section 3 of the Therapeutic Goods Order No. 91. Since the medicine met the requirements of section 3 of TGO No. 91, it is exempt from this Order per section 3(1).\"}, {\"Question\": \"Assuming a medicine was manufactured in Australia on 1 October 2020, supplied by the sponsor on the same date, and did not meet the requirements of section 3 of the Therapeutic Goods Order No. 91, which Order would the medicine's label need to comply with?\", \"Answer\": \"The medicine's label would need to comply with this Order (the Standard for labels of non-prescription medicines).\", \"Answer Explanation\": \"Section 3(1) states that this Order applies to medicines supplied in Australia, other than those specified under section 3 of the Therapeutic Goods Order No. 91. Section 4(3) provides a transition arrangement only for medicines manufactured before 1 September 2020 and supplied by someone other than the sponsor after that date. Since the medicine was manufactured on 1 October 2020 (after 1 September 2020), supplied by the sponsor, and did not meet the requirements of section 3 of TGO No. 91, its label must comply with this Order.\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            1008020000,
            900000000
        ],
        "contexts": [
            " 10 Qualifications and special requirements (8) Individually wrapped medicines (b) If: (i) the medicine consists only of pastilles or lozenges; and (ii) each dosage unit is enclosed in an unsealed individual wrapper; and (iii) each dosage unit is, after being so wrapped, enclosed in a primary pack that complies with sections 8 and 9, then, in relation to compliance of the label for each individual wrapper with sections 8 and 9, it shall be sufficient if the name of the medicine is displayed.",
            " 9 Information to be included on the main label (9) If the medicine is intended to be, or is, registered goods, and the name of an active ingredient included in the medicine comprises an ingredient name specified in Schedule 2 to this Order, either alone or in combination with any other descriptors, then the names of all active ingredients in the medicine, together with their quantity or proportion, must be displayed in a text size of not less than 2.5 millimetres."
        ],
        "result_dict": {},
        "result_str": "Here is the output formatted as a JSON object conforming to the provided schema:\n\n{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming a medicine consists only of pastilles or lozenges, each dosage unit is enclosed in an unsealed individual wrapper, and each wrapped dosage unit is then enclosed in a primary pack that complies with sections 8 and 9: What information is required to be displayed on the label of each individual wrapper for it to be considered compliant with sections 8 and 9?\",\n      \"Answer\": \"The name of the medicine.\",\n      \"Answer Explanation\": \"Section 10(8)(b) states that if the specified conditions are met (medicine consists only of pastilles\/lozenges, each dose individually wrapped, and the wrapped doses are enclosed in a compliant primary pack), then for the individual dose wrappers to comply with sections 8 and 9, it is sufficient to just display the name of the medicine on the individual wrappers.\"\n    },\n    {\n      \"Question\": \"Consider a registered medicine where the name of one of its active ingredients is a name specified in Schedule 2 of this Order. Assuming no other relevant exceptions apply, what information about the active ingredients must the main label display and in what minimum text size?\",\n      \"Answer\": \"The names of all active ingredients in the medicine, along with their quantities or proportions, must be displayed on the main label in a text size of at least 2.5 millimetres.\",\n      \"Answer Explanation\": \"Section 9(9) requires that if a registered medicine contains an active ingredient whose name is listed in Schedule 2 of the Order, the main label must list the names of all active ingredients and their quantities\/proportions in a minimum text size of 2.5 mm, assuming no other exceptions specified elsewhere in sections 8-10 apply.\"\n    },\n    {\n      \"Question\": \"Suppose a registered medicine is in the form of individually wrapped lozenges. Each lozenge is enclosed in an unsealed wrapper that only displays the name of the medicine. The wrapped lozenges are then packaged in a primary pack that fully complies with sections 8 and 9, including listing all active ingredients and their quantities in the required text size. Does this labelling meet the requirements?\",\n      \"Answer\": \"Yes, this labelling meets the requirements.\",\n      \"Answer Explanation\": \"The individual lozenge wrappers meet the reduced labelling requirements allowed by section 10(8)(b), since the medicine consists of individually wrapped lozenges enclosed in a fully compliant primary pack. Section 9(9)'s requirement to list active ingredient names and quantities in a minimum 2.5 mm text size on the main label is satisfied by the primary pack label. Together, the individual wrappers and primary pack meet the labelling requirements of sections 8-10.\"\n    },\n    {\n      \"Question\": \"For a non-prescription registered medicine sold as individually wrapped pastilles, is it acceptable for the unsealed individual pastille wrappers to omit listing the active ingredients and their quantities, even if one of the ingredients has a name specified in Schedule 2? Assume the pastilles are enclosed in a primary pack meeting all labelling requirements of sections 8 and 9.\",\n      \"Answer\": \"Yes, it is acceptable in this case for the individual pastille wrappers to omit listing the active ingredients and their quantities.\",\n      \"Answer Explanation\": \"Section 10(8)(b) provides an exception for individually wrapped pastilles\/lozenges, allowing their individual wrappers to display only the medicine name, provided the wrapped units are enclosed in a primary pack fully complying with the labelling requirements in sections 8-9. So even if section 9(9) would normally require listing all active ingredients and quantities due to one having a Schedule 2 name, section 10(8)(b)'s exception overrides that requirement for the individual wrappers in this case.\"\n    }\n  ]\n}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            1005000000,
            800000000
        ],
        "contexts": [
            " 10 Qualifications and special requirements (5) Sunscreen preparations If: (a) the medicine is a sunscreen preparation; and",
            " 8 Information to be included on the label (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include: (l) directions for use of the medicine except where: (i) the dose of the medicine is usually determined for each individual patient by a health professional authorised under a law of a State or Territory to determine the dose; or (ii) there is insufficient space on the label of either the container or the primary pack, or both, to include directions for use, and: (A) those directions for use are set out in a package insert provided in the primary pack of the medicine; and (B) a statement is included on whichever label on the container, or the primary pack, or both, that does not set out the directions for use itself, that those directions are set out in the package insert; and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a sunscreen preparation medicine has a label that does not have enough space to include the full directions for use, and the directions are instead provided in a package insert, what statement must be included on the label according to the regulation?",
                    "Answer": "The label must include a statement that the directions for use are set out in the package insert.",
                    "Answer Explanation": "Section 8(1)(l)(ii)(B) states that if there is insufficient space on the label to include directions for use, and the directions are set out in a package insert, then a statement must be included on the label indicating that the directions are in the package insert."
                },
                {
                    "Question": "Given a sunscreen preparation medicine whose dose is typically determined for each patient by an authorized health professional, is the medicine's label required to include directions for use based on the information provided in the regulation sections?",
                    "Answer": "No, the label is not required to include directions for use in this case.",
                    "Answer Explanation": "Section 10(5)(a) specifies that the medicine is a sunscreen preparation. Section 8(1)(l)(i) states that directions for use are not required on the label if the dose is usually determined for each patient by an authorized health professional. Therefore, the sunscreen preparation label does not need to include directions for use."
                },
                {
                    "Question": "Suppose a sunscreen preparation medicine label lacks sufficient space for including directions for use. Assuming the primary pack contains a package insert with the full usage directions, does the regulation mandate that both the container label and primary pack label include a statement referring to the insert?",
                    "Answer": "No, the regulation does not require both labels to include the statement referring to the package insert in this case.",
                    "Answer Explanation": "Section 10(5)(a) establishes that the medicine is a sunscreen preparation. Section 8(1)(l)(ii) allows for directions for use to be omitted from the label if space is insufficient and they are instead provided in a package insert. Part (B) specifies that a statement referring to the insert must be included on 'whichever label on the container, or the primary pack, or both, that does not set out the directions for use itself.' This means only the label(s) lacking the full directions need the referral statement, not necessarily both."
                },
                {
                    "Question": "For a sunscreen preparation medicine, if the label has inadequate space for directions for use, they are instead provided in a package insert, and the primary pack label already has a statement referring to this insert, is it required that the container label also include an identical statement according to the regulation sections?",
                    "Answer": "No, it is not required for the container label to also have the statement in this situation.",
                    "Answer Explanation": "Section 10(5)(a) confirms the medicine is a sunscreen preparation. Section 8(1)(l)(ii) permits directions for use to be excluded from the label if space is insufficient, provided they are in a package insert instead. Subsection (B) states that a referral statement must be on 'whichever label on the container, or the primary pack, or both, that does not set out the directions for use itself.' Since the primary pack label already has this statement, the container label is not obligated to repeat it."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a sunscreen preparation medicine has a label that does not have enough space to include the full directions for use, and the directions are instead provided in a package insert, what statement must be included on the label according to the regulation?\", \"Answer\": \"The label must include a statement that the directions for use are set out in the package insert.\", \"Answer Explanation\": \"Section 8(1)(l)(ii)(B) states that if there is insufficient space on the label to include directions for use, and the directions are set out in a package insert, then a statement must be included on the label indicating that the directions are in the package insert.\"}, {\"Question\": \"Given a sunscreen preparation medicine whose dose is typically determined for each patient by an authorized health professional, is the medicine's label required to include directions for use based on the information provided in the regulation sections?\", \"Answer\": \"No, the label is not required to include directions for use in this case.\", \"Answer Explanation\": \"Section 10(5)(a) specifies that the medicine is a sunscreen preparation. Section 8(1)(l)(i) states that directions for use are not required on the label if the dose is usually determined for each patient by an authorized health professional. Therefore, the sunscreen preparation label does not need to include directions for use.\"}, {\"Question\": \"Suppose a sunscreen preparation medicine label lacks sufficient space for including directions for use. Assuming the primary pack contains a package insert with the full usage directions, does the regulation mandate that both the container label and primary pack label include a statement referring to the insert?\", \"Answer\": \"No, the regulation does not require both labels to include the statement referring to the package insert in this case.\", \"Answer Explanation\": \"Section 10(5)(a) establishes that the medicine is a sunscreen preparation. Section 8(1)(l)(ii) allows for directions for use to be omitted from the label if space is insufficient and they are instead provided in a package insert. Part (B) specifies that a statement referring to the insert must be included on 'whichever label on the container, or the primary pack, or both, that does not set out the directions for use itself.' This means only the label(s) lacking the full directions need the referral statement, not necessarily both.\"}, {\"Question\": \"For a sunscreen preparation medicine, if the label has inadequate space for directions for use, they are instead provided in a package insert, and the primary pack label already has a statement referring to this insert, is it required that the container label also include an identical statement according to the regulation sections?\", \"Answer\": \"No, it is not required for the container label to also have the statement in this situation.\", \"Answer Explanation\": \"Section 10(5)(a) confirms the medicine is a sunscreen preparation. Section 8(1)(l)(ii) permits directions for use to be excluded from the label if space is insufficient, provided they are in a package insert instead. Subsection (B) states that a referral statement must be on 'whichever label on the container, or the primary pack, or both, that does not set out the directions for use itself.' Since the primary pack label already has this statement, the container label is not obligated to repeat it.\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            601150000,
            801020000
        ],
        "contexts": [
            "6 Interpretation. \"critical health information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer;",
            " 8 Information to be included on the label (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include: (b) the name(s) of all active ingredients in the medicine; and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine contains the active ingredients acetaminophen and caffeine, and the label lists only acetaminophen as an active ingredient, does the label meet the requirements of the regulation?",
                    "Answer": "No",
                    "Answer Explanation": "According to section 8(1)(b), the labels of a medicine must include the names of all active ingredients. Since the label only lists acetaminophen and omits caffeine, it does not meet the requirements specified in 8(1)(b)."
                },
                {
                    "Question": "Assuming a medicine label omits the information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n), but includes all other required information, does the label comply with the definition of 'critical health information' in section 6?",
                    "Answer": "No",
                    "Answer Explanation": "Section 6 defines 'critical health information' as the information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n). Since the label omits all of this information, it does not comply with the definition of 'critical health information' provided in section 6, even though it includes the other required label information specified in section 8(1)."
                },
                {
                    "Question": "Assuming a non-prescription medicine is self-selected by a consumer, and the label omits the name of one of the active ingredients, as required by 8(1)(b), can the label still contain the 'critical health information' as defined in section 6?",
                    "Answer": "No",
                    "Answer Explanation": "Section 6 states that for medicines self-selected by a consumer, the information required under 8(1)(b) is part of the 'critical health information'. 8(1)(b) requires the label to include the names of all active ingredients. Since the label omits the name of one active ingredient, it does not contain the 'critical health information' as defined in section 6 for self-selected medicines."
                },
                {
                    "Question": "Assuming the label on a non-prescription medicine includes all required information except the name of one inactive ingredient, does the label meet the requirements of section 8(1), subject to the qualifications in 8(2), 8(3), 9 and 10?",
                    "Answer": "Yes",
                    "Answer Explanation": "Section 8(1)(b) only requires the label to include the names of active ingredients, not inactive ingredients. The question states the label includes all other required information under 8(1). Therefore, even with one inactive ingredient omitted, the label meets the requirements of 8(1), subject to any additional qualifications specified in subsections 8(2), 8(3), and sections 9 and 10."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n{\n\"Question\": \"Assuming a medicine contains the active ingredients acetaminophen and caffeine, and the label lists only acetaminophen as an active ingredient, does the label meet the requirements of the regulation?\",\n\"Answer\": \"No\",\n\"Answer Explanation\": \"According to section 8(1)(b), the labels of a medicine must include the names of all active ingredients. Since the label only lists acetaminophen and omits caffeine, it does not meet the requirements specified in 8(1)(b).\"\n},\n\n{\n\"Question\": \"Assuming a medicine label omits the information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n), but includes all other required information, does the label comply with the definition of 'critical health information' in section 6?\",\n\"Answer\": \"No\",  \n\"Answer Explanation\": \"Section 6 defines 'critical health information' as the information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n). Since the label omits all of this information, it does not comply with the definition of 'critical health information' provided in section 6, even though it includes the other required label information specified in section 8(1).\"\n},\n\n{\n\"Question\": \"Assuming a non-prescription medicine is self-selected by a consumer, and the label omits the name of one of the active ingredients, as required by 8(1)(b), can the label still contain the 'critical health information' as defined in section 6?\",\n\"Answer\": \"No\",\n\"Answer Explanation\": \"Section 6 states that for medicines self-selected by a consumer, the information required under 8(1)(b) is part of the 'critical health information'. 8(1)(b) requires the label to include the names of all active ingredients. Since the label omits the name of one active ingredient, it does not contain the 'critical health information' as defined in section 6 for self-selected medicines.\"  \n},\n\n{\n\"Question\": \"Assuming the label on a non-prescription medicine includes all required information except the name of one inactive ingredient, does the label meet the requirements of section 8(1), subject to the qualifications in 8(2), 8(3), 9 and 10?\",\n\"Answer\": \"Yes\",\n\"Answer Explanation\": \"Section 8(1)(b) only requires the label to include the names of active ingredients, not inactive ingredients. The question states the label includes all other required information under 8(1). Therefore, even with one inactive ingredient omitted, the label meets the requirements of 8(1), subject to any additional qualifications specified in subsections 8(2), 8(3), and sections 9 and 10.\"\n}\n]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            903030000,
            903010000
        ],
        "contexts": [
            " 9 Information to be included on the main label (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must: (c) if the medicine is: (i) supplied in either a small or a medium container; and (ii) contains multiple active ingredients then, in relation to compliance of the label with paragraph 9(3)(a), the names of the multiple active ingredients and their quantities may be presented together on a continuous line, or lines, of text.",
            " 9 Information to be included on the main label (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must: (a) appear as a cohesive unit by the placing of the name and quantity of each active ingredient together on separate lines of text either (i) immediately below the name of the medicine; or (ii) where the trademark of the medicine might be disrupted or obscured, adjacent to the name of the medicine; and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine contains multiple active ingredients and is supplied in a small container, can the names and quantities of the active ingredients be presented together on a continuous line of text on the main label, while still complying with the requirement in 9(3)(a) for the name and quantity of each active ingredient to appear together on separate lines of text either immediately below or adjacent to the name of the medicine?",
                    "Answer": "Yes",
                    "Answer Explanation": "According to 9(3)(c), if a medicine is supplied in a small or medium container and contains multiple active ingredients, then the names and quantities of the active ingredients may be presented together on a continuous line or lines of text, in relation to compliance with 9(3)(a). This means that the requirement in 9(3)(a) for the name and quantity of each active ingredient to appear together on separate lines either immediately below or adjacent to the name of the medicine does not apply in this case."
                },
                {
                    "Question": "Assuming a medicine is supplied in a large container and contains multiple active ingredients, can the names and quantities of the active ingredients be presented together on a continuous line of text on the main label, while still complying with the requirement in 9(3)(a)?",
                    "Answer": "No",
                    "Answer Explanation": "The exception in 9(3)(c) that allows the names and quantities of multiple active ingredients to be presented together on a continuous line only applies if the medicine is supplied in a small or medium container. For a medicine in a large container, the general requirement in 9(3)(a) would still apply, meaning the name and quantity of each active ingredient must appear together on separate lines of text either immediately below or adjacent to the name of the medicine."
                },
                {
                    "Question": "Assuming a medicine contains a single active ingredient and is supplied in a small container, do the name and quantity of the active ingredient need to appear together on a separate line of text immediately below or adjacent to the name of the medicine on the main label?",
                    "Answer": "Yes",
                    "Answer Explanation": "The exception in 9(3)(c) only applies to medicines that contain multiple active ingredients. For a medicine with a single active ingredient, regardless of the container size, the requirement in 9(3)(a) applies. This means the name and quantity of the single active ingredient must appear together on a separate line of text either immediately below or adjacent to the name of the medicine on the main label."
                },
                {
                    "Question": "Assuming the trademark of a medicine might be disrupted or obscured if the name and quantity of the active ingredient appeared immediately below the name of the medicine on the main label, where should the name and quantity of the active ingredient be placed to comply with 9(3)(a)?",
                    "Answer": "Adjacent to the name of the medicine",
                    "Answer Explanation": "9(3)(a)(ii) provides that where the trademark of the medicine might be disrupted or obscured by placing the name and quantity of the active ingredient immediately below the name of the medicine, they may instead be placed adjacent to the name of the medicine. This allows compliance with the general requirement for the active ingredient name and quantity to appear together with the medicine name as a cohesive unit, without risking disruption to the medicine's trademark."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine contains multiple active ingredients and is supplied in a small container, can the names and quantities of the active ingredients be presented together on a continuous line of text on the main label, while still complying with the requirement in 9(3)(a) for the name and quantity of each active ingredient to appear together on separate lines of text either immediately below or adjacent to the name of the medicine?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"According to 9(3)(c), if a medicine is supplied in a small or medium container and contains multiple active ingredients, then the names and quantities of the active ingredients may be presented together on a continuous line or lines of text, in relation to compliance with 9(3)(a). This means that the requirement in 9(3)(a) for the name and quantity of each active ingredient to appear together on separate lines either immediately below or adjacent to the name of the medicine does not apply in this case.\"}, {\"Question\": \"Assuming a medicine is supplied in a large container and contains multiple active ingredients, can the names and quantities of the active ingredients be presented together on a continuous line of text on the main label, while still complying with the requirement in 9(3)(a)?\", \"Answer\": \"No\", \"Answer Explanation\": \"The exception in 9(3)(c) that allows the names and quantities of multiple active ingredients to be presented together on a continuous line only applies if the medicine is supplied in a small or medium container. For a medicine in a large container, the general requirement in 9(3)(a) would still apply, meaning the name and quantity of each active ingredient must appear together on separate lines of text either immediately below or adjacent to the name of the medicine.\"}, {\"Question\": \"Assuming a medicine contains a single active ingredient and is supplied in a small container, do the name and quantity of the active ingredient need to appear together on a separate line of text immediately below or adjacent to the name of the medicine on the main label?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"The exception in 9(3)(c) only applies to medicines that contain multiple active ingredients. For a medicine with a single active ingredient, regardless of the container size, the requirement in 9(3)(a) applies. This means the name and quantity of the single active ingredient must appear together on a separate line of text either immediately below or adjacent to the name of the medicine on the main label.\"}, {\"Question\": \"Assuming the trademark of a medicine might be disrupted or obscured if the name and quantity of the active ingredient appeared immediately below the name of the medicine on the main label, where should the name and quantity of the active ingredient be placed to comply with 9(3)(a)?\", \"Answer\": \"Adjacent to the name of the medicine\", \"Answer Explanation\": \"9(3)(a)(ii) provides that where the trademark of the medicine might be disrupted or obscured by placing the name and quantity of the active ingredient immediately below the name of the medicine, they may instead be placed adjacent to the name of the medicine. This allows compliance with the general requirement for the active ingredient name and quantity to appear together with the medicine name as a cohesive unit, without risking disruption to the medicine's trademark.\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            1103030000,
            1103010000
        ],
        "contexts": [
            " 11 How information is to be expressed (3) Expression of quantity or proportion of active ingredients for homoeopathic preparations The label on the container and on the primary pack of a medicine that contains a homoeopathic preparation must include: (c) where paragraphs (a) and (b) do not apply- the quantity of the preparation in one millilitre or in one gram of the medicine",
            " 11 How information is to be expressed (3) Expression of quantity or proportion of active ingredients for homoeopathic preparations The label on the container and on the primary pack of a medicine that contains a homoeopathic preparation must include: (a) where the medicine is a fully potentised, single ingredient, homoeopathic medicine and it is clear that the ingredient comprises 100% of the medicine \u2013 the name of the active ingredient; or"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a homoeopathic medicine is a fully potentised, single ingredient preparation and it is clear that the ingredient comprises 100% of the medicine, what information must the label on the container and primary pack include regarding the quantity or proportion of active ingredients?",
                    "Answer": "The name of the active ingredient.",
                    "Answer Explanation": "According to section 11(3)(a), if a homoeopathic medicine is a fully potentised, single ingredient preparation and it is clear that the ingredient comprises 100% of the medicine, the label on the container and primary pack must include the name of the active ingredient."
                },
                {
                    "Question": "Assuming a homoeopathic medicine does not meet the criteria in sections 11(3)(a) and 11(3)(b), what information must the label on the container and primary pack include regarding the quantity or proportion of active ingredients?",
                    "Answer": "The quantity of the preparation in one millilitre or in one gram of the medicine.",
                    "Answer Explanation": "According to section 11(3)(c), if a homoeopathic medicine does not meet the criteria in sections 11(3)(a) and 11(3)(b), the label on the container and primary pack must include the quantity of the preparation in one millilitre or in one gram of the medicine."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a homoeopathic medicine is a fully potentised, single ingredient preparation and it is clear that the ingredient comprises 100% of the medicine, what information must the label on the container and primary pack include regarding the quantity or proportion of active ingredients?\", \"Answer\": \"The name of the active ingredient.\", \"Answer Explanation\": \"According to section 11(3)(a), if a homoeopathic medicine is a fully potentised, single ingredient preparation and it is clear that the ingredient comprises 100% of the medicine, the label on the container and primary pack must include the name of the active ingredient.\"}, {\"Question\": \"Assuming a homoeopathic medicine does not meet the criteria in sections 11(3)(a) and 11(3)(b), what information must the label on the container and primary pack include regarding the quantity or proportion of active ingredients?\", \"Answer\": \"The quantity of the preparation in one millilitre or in one gram of the medicine.\", \"Answer Explanation\": \"According to section 11(3)(c), if a homoeopathic medicine does not meet the criteria in sections 11(3)(a) and 11(3)(b), the label on the container and primary pack must include the quantity of the preparation in one millilitre or in one gram of the medicine.\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            601150000,
            801120000
        ],
        "contexts": [
            "6 Interpretation. \"critical health information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer;",
            " 8 Information to be included on the label (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include: (l) directions for use of the medicine except where: (i) the dose of the medicine is usually determined for each individual patient by a health professional authorised under a law of a State or Territory to determine the dose; or (ii) there is insufficient space on the label of either the container or the primary pack, or both, to include directions for use, and: (A) those directions for use are set out in a package insert provided in the primary pack of the medicine; and (B) a statement is included on whichever label on the container, or the primary pack, or both, that does not set out the directions for use itself, that those directions are set out in the package insert; and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine label does not have space to include the directions for use on the container or primary pack label, what two conditions must be met in order to omit the directions from the label?",
                    "Answer": "The directions for use can be omitted if: 1) They are provided in a package insert in the primary pack, and 2) The label that does not contain the directions includes a statement that the directions are in the package insert.",
                    "Answer Explanation": "Section 8(1)(l)(ii) states that if there is insufficient space on the label to include directions, they can be omitted if: (A) the directions are set out in a package insert provided in the primary pack, and (B) a statement is included on the label without directions indicating they are in the package insert."
                },
                {
                    "Question": "Assuming a medicine's dose is usually determined for each patient by an authorized health professional, is it required to include directions for use on the medicine label?",
                    "Answer": "No, directions for use are not required on the label in this case.",
                    "Answer Explanation": "Section 8(1)(l)(i) provides an exception to including directions for use on the label when the dose is usually determined for each individual patient by an authorized health professional."
                },
                {
                    "Question": "Assuming a medicine label meets the space and packaging insert requirements to omit directions for use, is the information required by paragraph 8(1)(b) of the Order still considered 'critical health information' that must be on the label?",
                    "Answer": "Yes, the information required by paragraph 8(1)(b) is still considered 'critical health information' even if the directions for use are omitted from the label.",
                    "Answer Explanation": "Section 6 defines 'critical health information' as including the information required under paragraph 8(1)(b). This is independent of the exceptions that allow omitting directions for use from the label under 8(1)(l)."
                },
                {
                    "Question": "Assuming a medicine's dose is usually determined by an authorized health professional and the directions for use are omitted following section 8(1)(l)(i), is a package insert with directions for use still required to be provided in the primary pack?",
                    "Answer": "No, if the directions for use are omitted under the 8(1)(l)(i) exception for doses determined by a health professional, a package insert with directions is not required.",
                    "Answer Explanation": "Section 8(1)(l) provides two independent exceptions allowing directions for use to be omitted. 8(1)(l)(i) for doses determined by a health professional does not require a package insert, while 8(1)(l)(ii) for insufficient label space requires a package insert with the directions."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine label does not have space to include the directions for use on the container or primary pack label, what two conditions must be met in order to omit the directions from the label?\", \"Answer\": \"The directions for use can be omitted if: 1) They are provided in a package insert in the primary pack, and 2) The label that does not contain the directions includes a statement that the directions are in the package insert.\", \"Answer Explanation\": \"Section 8(1)(l)(ii) states that if there is insufficient space on the label to include directions, they can be omitted if: (A) the directions are set out in a package insert provided in the primary pack, and (B) a statement is included on the label without directions indicating they are in the package insert.\"}, {\"Question\": \"Assuming a medicine's dose is usually determined for each patient by an authorized health professional, is it required to include directions for use on the medicine label?\", \"Answer\": \"No, directions for use are not required on the label in this case.\", \"Answer Explanation\": \"Section 8(1)(l)(i) provides an exception to including directions for use on the label when the dose is usually determined for each individual patient by an authorized health professional.\"}, {\"Question\": \"Assuming a medicine label meets the space and packaging insert requirements to omit directions for use, is the information required by paragraph 8(1)(b) of the Order still considered 'critical health information' that must be on the label?\", \"Answer\": \"Yes, the information required by paragraph 8(1)(b) is still considered 'critical health information' even if the directions for use are omitted from the label.\", \"Answer Explanation\": \"Section 6 defines 'critical health information' as including the information required under paragraph 8(1)(b). This is independent of the exceptions that allow omitting directions for use from the label under 8(1)(l).\"}, {\"Question\": \"Assuming a medicine's dose is usually determined by an authorized health professional and the directions for use are omitted following section 8(1)(l)(i), is a package insert with directions for use still required to be provided in the primary pack?\", \"Answer\": \"No, if the directions for use are omitted under the 8(1)(l)(i) exception for doses determined by a health professional, a package insert with directions is not required.\", \"Answer Explanation\": \"Section 8(1)(l) provides two independent exceptions allowing directions for use to be omitted. 8(1)(l)(i) for doses determined by a health professional does not require a package insert, while 8(1)(l)(ii) for insufficient label space requires a package insert with the directions.\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            802050000,
            802020000
        ],
        "contexts": [
            " 8 Information to be included on the label (2) (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or distributor contact details.",
            " 8 Information to be included on the label (2) (b) The critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine label includes a section titled 'Storage Conditions', where would this section be placed according to the regulation?",
                    "Answer": "Under the 'Other information' heading",
                    "Answer Explanation": "According to section 8(2)(e), information about storage conditions must be placed under the 'Other information' heading or another separate appropriate heading that follows immediately below the headings mentioned in 8(2)(b). Section 8(2)(b) specifies the order of critical health information headings."
                },
                {
                    "Question": "Based on the regulation, is it permissible for a medicine label to include a section titled 'Excipient List' directly after the 'Directions for use' section?",
                    "Answer": "No",
                    "Answer Explanation": "Section 8(2)(b) states that the critical health information must be presented in a specific order, ending with 'Other information'. Section 8(2)(e) then specifies that any additional information, including excipient names, must be placed under the 'Other information' heading or another separate appropriate heading that follows the 8(2)(b) headings."
                },
                {
                    "Question": "Assuming no other regulation sections are relevant, can a medicine label include sponsor contact details under the 'Warnings' heading?",
                    "Answer": "No",
                    "Answer Explanation": "Based on sections 8(2)(b) and 8(2)(e), sponsor contact details cannot be included under the 'Warnings' heading. Section 8(2)(b) specifies the order of critical health information headings, with 'Warnings' coming before 'Other information'. Section 8(2)(e) states that sponsor contact details must be under 'Other information' or another appropriate heading after the 8(2)(b) headings."
                },
                {
                    "Question": "Considering only the provided regulation sections, is information about package tamper-evident features allowed to be placed between the 'Indications' and 'Warnings' headings?",
                    "Answer": "No",
                    "Answer Explanation": "Section 8(2)(b) mandates that the critical health information headings, including 'Indications' and 'Warnings', must be presented in the specified order without other information between them. Section 8(2)(e) requires information about tamper-evident packaging to be under 'Other information' or another heading after the 8(2)(b) headings."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine label includes a section titled 'Storage Conditions', where would this section be placed according to the regulation?\", \"Answer\": \"Under the 'Other information' heading\", \"Answer Explanation\": \"According to section 8(2)(e), information about storage conditions must be placed under the 'Other information' heading or another separate appropriate heading that follows immediately below the headings mentioned in 8(2)(b). Section 8(2)(b) specifies the order of critical health information headings.\"}, {\"Question\": \"Based on the regulation, is it permissible for a medicine label to include a section titled 'Excipient List' directly after the 'Directions for use' section?\", \"Answer\": \"No\", \"Answer Explanation\": \"Section 8(2)(b) states that the critical health information must be presented in a specific order, ending with 'Other information'. Section 8(2)(e) then specifies that any additional information, including excipient names, must be placed under the 'Other information' heading or another separate appropriate heading that follows the 8(2)(b) headings.\"}, {\"Question\": \"Assuming no other regulation sections are relevant, can a medicine label include sponsor contact details under the 'Warnings' heading?\", \"Answer\": \"No\", \"Answer Explanation\": \"Based on sections 8(2)(b) and 8(2)(e), sponsor contact details cannot be included under the 'Warnings' heading. Section 8(2)(b) specifies the order of critical health information headings, with 'Warnings' coming before 'Other information'. Section 8(2)(e) states that sponsor contact details must be under 'Other information' or another appropriate heading after the 8(2)(b) headings.\"}, {\"Question\": \"Considering only the provided regulation sections, is information about package tamper-evident features allowed to be placed between the 'Indications' and 'Warnings' headings?\", \"Answer\": \"No\", \"Answer Explanation\": \"Section 8(2)(b) mandates that the critical health information headings, including 'Indications' and 'Warnings', must be presented in the specified order without other information between them. Section 8(2)(e) requires information about tamper-evident packaging to be under 'Other information' or another heading after the 8(2)(b) headings.\"}]}",
        "misc_info": {
            "guided_entity_path": []
        }
    },
    {
        "path": [
            908040000,
            907000000
        ],
        "contexts": [
            " 9 Information to be included on the main label (8) Where a medicine is: (d) the information required under either paragraph 9(6)(b) or subsection 9(7) must be provided separately in relation to each formulation of medicine in the composite pack or medicine kit.",
            " 9 Information to be included on the main label (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then: (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is a composite pack or medicine kit containing multiple formulations, and the medicine is intended to be registered goods, what information must be provided separately for each formulation according to the regulation?",
                    "Answer": "The information required under either paragraph 9(6)(b) or subsection 9(7) must be provided separately for each formulation of medicine in the composite pack or medicine kit.",
                    "Answer Explanation": "Section 9(8)(d) states that for a medicine that is a composite pack or medicine kit, the information required under 9(6)(b) or 9(7) must be provided separately for each formulation in the pack or kit. Section 9(7) specifies requirements for medicines intended to be registered goods."
                },
                {
                    "Question": "For a medicine intended to be registered goods that contains four or more active ingredients, assuming subsection 8(2) applies, what labeling requirements are not required to be met according to the regulation?",
                    "Answer": "Compliance with paragraphs 9(1)(b) and 9(1)(c) is not required for a medicine intended to be registered goods that contains four or more active ingredients if subsection 8(2) applies.",
                    "Answer Explanation": "Section 9(7)(c) states that for a medicine intended to be registered goods containing four or more active ingredients, if subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. This is subject to the condition in 9(9)."
                },
                {
                    "Question": "Assuming a medicine is a composite pack or medicine kit containing multiple formulations that are all intended to be registered goods, and each formulation contains four or more active ingredients with subsection 8(2) applying, what labeling requirements can be omitted for each formulation?",
                    "Answer": "For each formulation in the composite pack or medicine kit, the information required under 9(7) can omit compliance with paragraphs 9(1)(b) and 9(1)(c), provided subsection 8(2) applies to each formulation containing four or more active ingredients. The information under 9(7) must still be provided separately for each formulation as per 9(8)(d).",
                    "Answer Explanation": "Combining 9(8)(d) and 9(7)(c), for a composite pack or kit, the labeling for each component formulation intended as registered goods with 4+ ingredients can omit 9(1)(b) and (c) if 8(2) applies, but the labeling required under 9(7) must still be provided separately for each formulation in the pack\/kit."
                },
                {
                    "Question": "In a composite pack or medicine kit containing multiple formulations, assuming one formulation is intended to be registered goods and contains five active ingredients with subsection 8(2) applying, while another formulation is not registered goods, what differing labeling requirements apply to each formulation?",
                    "Answer": "The formulation intended as registered goods with five active ingredients can omit information required in 9(1)(b) and (c) since 8(2) applies, but must provide the information required under 9(7). The non-registered goods formulation must provide information under 9(6)(b) instead of 9(7). Per 9(8)(d), the applicable information must be provided separately for each formulation.",
                    "Answer Explanation": "9(8)(d) requires relevant information to be separate for each formulation. For the registered goods, 9(7)(c) allows omitting 9(1)(b) and (c) as it has 5 ingredients and 8(2) applies, but other parts of 9(7) still apply. The non-registered formulation must follow 9(6)(b) instead of 9(7) per the distinction made in 9(8)(d)."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a medicine is a composite pack or medicine kit containing multiple formulations, and the medicine is intended to be registered goods, what information must be provided separately for each formulation according to the regulation?\",\n    \"Answer\": \"The information required under either paragraph 9(6)(b) or subsection 9(7) must be provided separately for each formulation of medicine in the composite pack or medicine kit.\",\n    \"Answer Explanation\": \"Section 9(8)(d) states that for a medicine that is a composite pack or medicine kit, the information required under 9(6)(b) or 9(7) must be provided separately for each formulation in the pack or kit. Section 9(7) specifies requirements for medicines intended to be registered goods.\"\n  },\n  {\n    \"Question\": \"For a medicine intended to be registered goods that contains four or more active ingredients, assuming subsection 8(2) applies, what labeling requirements are not required to be met according to the regulation?\",\n    \"Answer\": \"Compliance with paragraphs 9(1)(b) and 9(1)(c) is not required for a medicine intended to be registered goods that contains four or more active ingredients if subsection 8(2) applies.\",\n    \"Answer Explanation\": \"Section 9(7)(c) states that for a medicine intended to be registered goods containing four or more active ingredients, if subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. This is subject to the condition in 9(9).\"\n  },  \n  {\n    \"Question\": \"Assuming a medicine is a composite pack or medicine kit containing multiple formulations that are all intended to be registered goods, and each formulation contains four or more active ingredients with subsection 8(2) applying, what labeling requirements can be omitted for each formulation?\",\n    \"Answer\": \"For each formulation in the composite pack or medicine kit, the information required under 9(7) can omit compliance with paragraphs 9(1)(b) and 9(1)(c), provided subsection 8(2) applies to each formulation containing four or more active ingredients. The information under 9(7) must still be provided separately for each formulation as per 9(8)(d).\",\n    \"Answer Explanation\": \"Combining 9(8)(d) and 9(7)(c), for a composite pack or kit, the labeling for each component formulation intended as registered goods with 4+ ingredients can omit 9(1)(b) and (c) if 8(2) applies, but the labeling required under 9(7) must still be provided separately for each formulation in the pack\/kit.\"\n  },\n  {\n    \"Question\": \"In a composite pack or medicine kit containing multiple formulations, assuming one formulation is intended to be registered goods and contains five active ingredients with subsection 8(2) applying, while another formulation is not registered goods, what differing labeling requirements apply to each formulation?\",\n    \"Answer\": \"The formulation intended as registered goods with five active ingredients can omit information required in 9(1)(b) and (c) since 8(2) applies, but must provide the information required under 9(7). The non-registered goods formulation must provide information under 9(6)(b) instead of 9(7). Per 9(8)(d), the applicable information must be provided separately for each formulation.\",\n    \"Answer Explanation\": \"9(8)(d) requires relevant information to be separate for each formulation. For the registered goods, 9(7)(c) allows omitting 9(1)(b) and (c) as it has 5 ingredients and 8(2) applies, but other parts of 9(7) still apply. The non-registered formulation must follow 9(6)(b) instead of 9(7) per the distinction made in 9(8)(d).\"\n  }\n]}",
        "misc_info": {
            "guided_entity_path": []
        }
    }
]